[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fz0M34z_OoeCRsB_eeEreHyX8JqLklfgs2SvL9JbELdU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"ViiV Healthcare",[4],260,false,22,53,337538,49,9,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"HIV Infections",126,{"name":18,"count":19},"Infection, Human Immunodeficiency Virus",96,{"name":21,"count":22},"Infection, Human Immunodeficiency Virus I",17,{"name":24,"count":25},"HIV Infection",12,{"name":27,"count":28},"HIV",8,{"name":30,"count":31},"Infections, Human Immunodeficiency Virus and Herpesviridae",5,{"name":33,"count":31},"Healthy",{"name":35,"count":36},"AIDS",4,[38,43,48,52,57,62,67,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02362503","Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients","2016-08-18","BMS-663068",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT02951052","Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","2018-05-29","Cabotegravir (CAB)",{"nctId":49,"briefTitle":50,"date":51,"intervention":47},"NCT02938520","Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","2018-08-30",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT03299049","Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults","2019-06-06","Cabotegravir",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06970223","A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV","2025-07-15","Cabotegravir long-acting",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05979311","A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy","2026-03-24","Dolutegravir",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05996471","A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)","2026-05-22","VH3810109",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05674656","Pharmacokinetics, Safety, Tolerability of Dolutegravir\u002FRilpivirine in Pediatrics","2026-06-01","Dolutegravir\u002FRilpivirine FDC",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06012136","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults","2026-06-09","VH4004280",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT06694805","A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1","2026-08-19","CAB LA + RPV LA",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,193,288,334,367,393,443,644,679,831,862,888,910,928,946,964,982,1000,1099,1180,1234,1260,1318,1346,1364,1382,1400,1421,1439,1469,1506,1536,1571,1605,1623,1641,1659,1677,1695,1713,1735,1760,1778,1796,1814,1832,1850,1872,1890,1908,2035,2114,2158,2214,2249,2305,2333,2351,2373,2396,2419,2437,2455,2478,2496,2514,2532,2556,2676,2717,2778,2821,2847,2886,2924,2954,2980,3013,3035,3057,3091,3126,3151,3169,3187,3205,3227,3252,3270,3293,3319,3337,3361,3379,3397,3415,3433,3451,3469,3496,3514,3532,3557,3581,3599,3617,3635,3653,3678,3696,3714,3732,3757,3775,3800,3818,3836,3854,3872,3890,3908,3926,4032,4120,4160,4195,4226,4248,4270,4292,4319,4341,4368,4390,4408,4440,4458,4476,4494,4512,4530,4548,4566,4589,4615,4633,4651,4669,4687,4705,4731,4749,4767,4785,4803,4821,4839,4857,4875,4899,4917,4935,4953,4971,5001,5049,5075,5100,5122,5144,5166,5188,5210,5245,5273,5291,5309,5327,5345,5363,5387,5405,5423,5441,5467,5485,5503,5527,5545,5568,5586,5604,5622,5645,5663,5687,5705,5723,5741,5759,5783,5801,5819,5837,5855,5878,5896,5914,5932,5950,5968,5986,6004,6022,6040,6058,6079,6102,6128,6146,6164,6182,6200,6218,6236,6254,6272,6290,6308,6333,6351,6369,6387,6405,6428,6446,6464,6482,6503,6534,6552,6570,6588,6606,6624,6642,6660,6678,6696,6719,6737,6761,6779,6797,6815,6833,6851,6869,6887,6909,6937,6955,6973,6991,7009,7027,7051,7069,7087,7105,7130,7148,7166,7189,7207,7234,7252,7270,7288,7306,7324,7342,7365,7383,7401,7419,7437,7455,7473,7491,7509,7527,7545,7569,7587,7611,7629,7647,7665,7683,7701,7719,7744,7762,7780,7798,7816,7834,7852,7870,7888,7906,7924,7942,7960,7978,8009,8027,8045,8063,8081,8099,8117,8135,8153,8171,8193,8216,8234,8260,8278,8296,8314,8479,8503,8525,8550,8571,8592,8613,8636,8659,8684,8711,8729,8747,8765,8783,8807,8832],{"intervention":56,"totalTrials":28,"cells":96},{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":125,"PHASE3":138,"PHASE4":179,"NA":191},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[102,114],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":112},"NCT03149848","Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects","COMPLETED",[89],"2017-09-06","2017-09-07","2017-06-06",15,[18,15],[56,113],"Rifabutin",{"nctId":115,"briefTitle":116,"status":105,"phases":117,"primaryCompletion":118,"completion":118,"start":119,"enrollment":110,"conditions":120,"interventions":121},"NCT04371380","Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants",[89],"2021-12-26","2020-09-16",[15],[56,122,123,124],"Rilpivirine","Cabotegravir extended release suspension for","Rilpivirine extended release suspension for",{"trials":126,"activeCount":137,"soonestReadout":70},[127],{"nctId":68,"briefTitle":69,"status":128,"phases":129,"primaryCompletion":70,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":134},"ACTIVE_NOT_RECRUITING",[90],"2028-11-09","2023-08-17",185,[15],[71,56,135,136],"Standard of care","rHuPH20",1,{"trials":139,"activeCount":178,"soonestReadout":46},[140,149,160,171],{"nctId":53,"briefTitle":54,"status":128,"phases":141,"primaryCompletion":55,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":146},[91],"2029-12-31","2017-10-27",1049,[15],[56,122,147,148],"Cabotegravir Injectable Suspension","Rilpivirine Injectable Suspension",{"nctId":150,"briefTitle":151,"status":105,"phases":152,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":158},"NCT04542070","A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed",[91],"2022-07-13","2023-04-17","2020-11-09",687,[15],[56,147,122,148,159],"BIKTARVY",{"nctId":49,"briefTitle":50,"status":128,"phases":161,"primaryCompletion":51,"completion":142,"start":162,"enrollment":163,"conditions":164,"interventions":165},[91],"2016-10-27",631,[15],[47,166,167,168,169,170],"Rilpivirine (RPV)","Cabotegravir - Injectable Suspension","Rilpivirine - Injectable Suspension","ABC\u002FDTG\u002F3TC STR -","DTG",{"nctId":44,"briefTitle":45,"status":128,"phases":172,"primaryCompletion":46,"completion":142,"start":173,"enrollment":174,"conditions":175,"interventions":176},[91],"2016-10-28",618,[18,15],[47,166,167,168,177],"2 NRTIs plus an INI, NNRTI, or PI",3,{"trials":180,"activeCount":99},[181],{"nctId":182,"briefTitle":183,"status":105,"phases":184,"primaryCompletion":185,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":189},"NCT05514509","A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories",[92],"2025-09-02","2022-10-28",370,[15],[190,56],"APRETUDE",{"trials":192,"activeCount":99},[],{"intervention":194,"totalTrials":195,"cells":196},"CAB LA",7,{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":222,"PHASE3":260,"PHASE4":284,"NA":286},{"trials":198,"activeCount":99},[],{"trials":200,"activeCount":137,"soonestReadout":205},[201,212],{"nctId":202,"briefTitle":203,"status":128,"phases":204,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":210},"NCT06786520","A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults",[89],"2027-03-09","2027-11-08","2025-01-17",69,[15],[194,211],"CAB ULA",{"nctId":213,"briefTitle":214,"status":105,"phases":215,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":220},"NCT03422172","A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men",[89],"2020-04-20","2018-04-10",48,[15],[221,194],"Oral CAB",{"trials":223,"activeCount":137,"soonestReadout":253},[224,236,249],{"nctId":225,"briefTitle":226,"status":105,"phases":227,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":233},"NCT03639311","Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study",[90],"2019-12-11","2023-01-30","2018-09-24",97,[15],[194,234,235,170],"RPV LA","RPV",{"nctId":237,"briefTitle":238,"status":105,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":245},"NCT02120352","A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir\u002FLamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects",[90],"2015-08-13","2023-04-20","2014-04-28",309,[18,15],[246,194,247,248,235],"CAB Oral","ABC\u002F3TC Oral","RPV Oral",{"nctId":250,"briefTitle":251,"status":128,"phases":252,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":258},"NCT06741397","A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)",[90],"2026-09-09","2029-01-10","2024-12-20",229,[15],[194,259],"New formulation of CAB LA",{"trials":261,"activeCount":137,"soonestReadout":279},[262,274],{"nctId":263,"briefTitle":264,"status":105,"phases":265,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":271},"NCT04399551","A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries",[91],"2022-03-07","2023-03-13","2020-09-28",437,[15],[272,194,273,234],"CAB OLI","RPV OLI",{"nctId":275,"briefTitle":276,"status":277,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":283},"NCT06134362","Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)","RECRUITING",[91],"2029-01-01","2024-05-14",3508,[15],[194],{"trials":285,"activeCount":99},[],{"trials":287,"activeCount":99},[],{"intervention":122,"totalTrials":289,"cells":290},6,{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":299,"PHASE3":301,"PHASE4":319,"NA":321},{"trials":292,"activeCount":99},[],{"trials":294,"activeCount":99},[295],{"nctId":115,"briefTitle":116,"status":105,"phases":296,"primaryCompletion":118,"completion":118,"start":119,"enrollment":110,"conditions":297,"interventions":298},[89],[15],[56,122,123,124],{"trials":300,"activeCount":99},[],{"trials":302,"activeCount":178,"soonestReadout":46},[303,307,311,315],{"nctId":53,"briefTitle":54,"status":128,"phases":304,"primaryCompletion":55,"completion":142,"start":143,"enrollment":144,"conditions":305,"interventions":306},[91],[15],[56,122,147,148],{"nctId":150,"briefTitle":151,"status":105,"phases":308,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":309,"interventions":310},[91],[15],[56,147,122,148,159],{"nctId":49,"briefTitle":50,"status":128,"phases":312,"primaryCompletion":51,"completion":142,"start":162,"enrollment":163,"conditions":313,"interventions":314},[91],[15],[47,166,167,168,169,170],{"nctId":44,"briefTitle":45,"status":128,"phases":316,"primaryCompletion":46,"completion":142,"start":173,"enrollment":174,"conditions":317,"interventions":318},[91],[18,15],[47,166,167,168,177],{"trials":320,"activeCount":99},[],{"trials":322,"activeCount":99},[323],{"nctId":324,"briefTitle":325,"status":105,"phases":326,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":332},"NCT04019873","'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor",[],"2023-04-14","2023-12-05","2019-11-18",774,[15],[66,333,122],"Lamivudine",{"intervention":167,"totalTrials":178,"cells":335},{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":363,"NA":365},{"trials":337,"activeCount":99},[],{"trials":339,"activeCount":99},[],{"trials":341,"activeCount":99},[],{"trials":343,"activeCount":362,"soonestReadout":46},[344,354,358],{"nctId":345,"briefTitle":346,"status":105,"phases":347,"primaryCompletion":348,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":353},"NCT05896748","Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study",[91],"2023-09-14","2022-11-08",94,[352],"Human Immunodeficiency Virus Type 1 (HIV-1)",[167,168],{"nctId":49,"briefTitle":50,"status":128,"phases":355,"primaryCompletion":51,"completion":142,"start":162,"enrollment":163,"conditions":356,"interventions":357},[91],[15],[47,166,167,168,169,170],{"nctId":44,"briefTitle":45,"status":128,"phases":359,"primaryCompletion":46,"completion":142,"start":173,"enrollment":174,"conditions":360,"interventions":361},[91],[18,15],[47,166,167,168,177],2,{"trials":364,"activeCount":99},[],{"trials":366,"activeCount":99},[],{"intervention":168,"totalTrials":178,"cells":368},{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":389,"NA":391},{"trials":370,"activeCount":99},[],{"trials":372,"activeCount":99},[],{"trials":374,"activeCount":99},[],{"trials":376,"activeCount":362,"soonestReadout":46},[377,381,385],{"nctId":345,"briefTitle":346,"status":105,"phases":378,"primaryCompletion":348,"completion":348,"start":349,"enrollment":350,"conditions":379,"interventions":380},[91],[352],[167,168],{"nctId":49,"briefTitle":50,"status":128,"phases":382,"primaryCompletion":51,"completion":142,"start":162,"enrollment":163,"conditions":383,"interventions":384},[91],[15],[47,166,167,168,169,170],{"nctId":44,"briefTitle":45,"status":128,"phases":386,"primaryCompletion":46,"completion":142,"start":173,"enrollment":174,"conditions":387,"interventions":388},[91],[18,15],[47,166,167,168,177],{"trials":390,"activeCount":99},[],{"trials":392,"activeCount":99},[],{"intervention":394,"totalTrials":178,"cells":395},"Emtricitabine",{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":428,"PHASE4":439,"NA":441},{"trials":397,"activeCount":99},[],{"trials":399,"activeCount":99},[],{"trials":401,"activeCount":137,"soonestReadout":419},[402,415],{"nctId":403,"briefTitle":404,"status":105,"phases":405,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":410},"NCT01803074","Study to Evaluate a HIV Drug for the Treatment of HIV Infection",[90],"2014-11-29","2013-04-04",107,[18,15],[411,412,413,414,394],"BMS-955176","Atazanavir","Ritonavir","Tenofovir",{"nctId":416,"briefTitle":417,"status":277,"phases":418,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":424},"NCT07202546","A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)",[90],"2027-07-26","2028-07-24","2026-02-11",150,[15],[425,426,427],"VH4524184","Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC)","Dolutegravir \u002F Lamivudine",{"trials":429,"activeCount":137,"soonestReadout":65},[430],{"nctId":63,"briefTitle":64,"status":128,"phases":431,"primaryCompletion":65,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":436},[91],"2027-02-23","2024-02-09",473,[27,15],[66,333,437,394,438],"Bictegravir","Tenofovir alafenamide",{"trials":440,"activeCount":99},[],{"trials":442,"activeCount":99},[],{"intervention":66,"totalTrials":444,"cells":445},19,{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":510,"PHASE3":545,"PHASE4":618,"NA":620},{"trials":447,"activeCount":99},[],{"trials":449,"activeCount":99},[450,460,470,480,489,499],{"nctId":451,"briefTitle":452,"status":105,"phases":453,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":458},"NCT02715479","A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176",[89],"2016-05","2016-04",14,[18],[66,459],"BMS955176",{"nctId":461,"briefTitle":462,"status":105,"phases":463,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":467,"interventions":468},"NCT01498861","Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol",[89],"2012-03","2011-12",16,[18],[469,66],"Ortho-Cyclen",{"nctId":471,"briefTitle":472,"status":105,"phases":473,"primaryCompletion":474,"completion":474,"start":465,"enrollment":475,"conditions":476,"interventions":478},"NCT01467518","Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.",[89],"2012-02",11,[477],"Infections, Human Immunodeficiency Virus and Hepatitis",[66,479],"Methadone",{"nctId":481,"briefTitle":482,"status":105,"phases":483,"primaryCompletion":484,"completion":484,"start":485,"enrollment":25,"conditions":486,"interventions":487},"NCT01425099","Drug Interaction Study Between Dolutegravir and Prednisone",[89],"2011-10","2011-09",[18],[66,488],"Prednisone",{"nctId":490,"briefTitle":491,"status":105,"phases":492,"primaryCompletion":474,"completion":474,"start":493,"enrollment":494,"conditions":495,"interventions":496},"NCT01467531","A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects",[89],"2011-11",28,[477],[66,497,498],"Rlipivirine","GSK1265744",{"nctId":500,"briefTitle":501,"status":105,"phases":502,"primaryCompletion":503,"completion":503,"start":504,"enrollment":505,"conditions":506,"interventions":507},"NCT03078556","Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine",[89],"2017-08-18","2017-03-27",154,[18],[66,333,508,509],"Dolutegravir + Lamivudine FDC Formulation 1","Dolutegravir + Lamivudine FDC Formulation 2",{"trials":511,"activeCount":99},[512,526,535],{"nctId":513,"briefTitle":514,"status":515,"phases":516,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":521,"interventions":522},"NCT04493216","A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults","TERMINATED",[90],"2022-09-05","2023-05-29","2020-11-18",161,[15],[523,524,525,66],"GSK3640254","ABC\u002F3TC","FTC\u002FTAF",{"nctId":527,"briefTitle":528,"status":515,"phases":529,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":534},"NCT02386098","Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults",[90],"2017-06-07","2015-07-08",86,[15],[411,412,413,66,414],{"nctId":536,"briefTitle":537,"status":515,"phases":538,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":544},"NCT04900038","A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults",[90],"2022-11-22","2023-05-11","2021-08-18",85,[15],[523,66,333,333],{"trials":546,"activeCount":362,"soonestReadout":65},[547,558,562,577,587,598,608],{"nctId":548,"briefTitle":549,"status":550,"phases":551,"primaryCompletion":552,"completion":552,"start":553,"enrollment":554,"conditions":555,"interventions":556},"NCT07393659","A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment","NOT_YET_RECRUITING",[91],"2030-12-30","2026-05-08",183,[15],[557,66],"Fostemsavir",{"nctId":63,"briefTitle":64,"status":128,"phases":559,"primaryCompletion":65,"completion":432,"start":433,"enrollment":434,"conditions":560,"interventions":561},[91],[27,15],[66,333,437,394,438],{"nctId":563,"briefTitle":564,"status":105,"phases":565,"primaryCompletion":566,"completion":567,"start":568,"enrollment":569,"conditions":570,"interventions":571},"NCT01263015","A Trial Comparing GSK1349572 50mg Plus Abacavir\u002FLamivudine Once Daily to Atripla (Also Called The SINGLE Trial)",[91],"2012-05-14","2015-12-03","2011-02-01",844,[21],[66,572,573,574,575,576],"Atripla","Abacavir\u002FLamivudine","Abacavir\u002FLamivudine Placebo","Dolutegravir placebo","Atripla placebo",{"nctId":578,"briefTitle":579,"status":105,"phases":580,"primaryCompletion":581,"completion":582,"start":583,"enrollment":554,"conditions":584,"interventions":585},"NCT01328041","A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.",[91],"2012-05","2015-05","2011-05",[18],[586],"dolutegravir",{"nctId":588,"briefTitle":589,"status":105,"phases":590,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":596},"NCT02831764","An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir\u002FEmtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)",[91],"2018-04-04","2022-06-29","2016-07-18",722,[18,15],[66,333,597],"Tenofovir disoproxil fumarate\u002FEmtricitabine",{"nctId":599,"briefTitle":600,"status":105,"phases":601,"primaryCompletion":602,"completion":603,"start":604,"enrollment":605,"conditions":606,"interventions":607},"NCT01499199","A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects",[91],"2012-10","2014-05","2012-01",13,[18],[66],{"nctId":609,"briefTitle":610,"status":105,"phases":611,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":617},"NCT02831673","An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir\u002FEmtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)",[91],"2018-03-29","2022-08-15","2016-07-21",719,[18,15],[66,333,597],{"trials":619,"activeCount":99},[],{"trials":621,"activeCount":99},[622,631,635],{"nctId":623,"briefTitle":624,"status":105,"phases":625,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":630},"NCT01536873","Dolutegravir Expanded Access Study",[93],"2016-09-23","2012-06-14",200,[18,15],[66],{"nctId":324,"briefTitle":325,"status":105,"phases":632,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":633,"interventions":634},[],[15],[66,333,122],{"nctId":636,"briefTitle":637,"status":105,"phases":638,"primaryCompletion":639,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":643},"NCT02076386","A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany",[],"2017-07-05","2014-03-04",411,[18],[66],{"intervention":557,"totalTrials":178,"cells":645},{"EARLY_PHASE1":646,"PHASE1":648,"PHASE2":660,"PHASE3":662,"PHASE4":668,"NA":670},{"trials":647,"activeCount":99},[],{"trials":649,"activeCount":137,"soonestReadout":654},[650],{"nctId":651,"briefTitle":652,"status":128,"phases":653,"primaryCompletion":654,"completion":655,"start":656,"enrollment":408,"conditions":657,"interventions":658},"NCT07053384","A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV",[89],"2027-01-22","2028-09-06","2025-07-10",[15],[71,557,659],"SOC INSTI-based ART",{"trials":661,"activeCount":99},[],{"trials":663,"activeCount":137,"soonestReadout":552},[664],{"nctId":548,"briefTitle":549,"status":550,"phases":665,"primaryCompletion":552,"completion":552,"start":553,"enrollment":554,"conditions":666,"interventions":667},[91],[15],[557,66],{"trials":669,"activeCount":99},[],{"trials":671,"activeCount":99},[672],{"nctId":673,"briefTitle":674,"status":675,"phases":676,"conditions":677,"interventions":678},"NCT04233047","Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)","AVAILABLE",[],[15],[557],{"intervention":42,"totalTrials":110,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":808,"PHASE3":818,"PHASE4":827,"NA":829},{"trials":682,"activeCount":99},[],{"trials":684,"activeCount":99},[685,694,704,716,726,736,745,754,764,774,783,792,799],{"nctId":686,"briefTitle":687,"status":105,"phases":688,"primaryCompletion":689,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":693},"NCT02508064","Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet",[89],"2015-11-05","2015-08-03",27,[18],[42],{"nctId":695,"briefTitle":696,"status":105,"phases":697,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":702},"NCT02234882","Study on Pharmacokinetics",[89],"2014-10-31","2014-09-05",50,[15],[703,42],"Rosuvastatin",{"nctId":705,"briefTitle":706,"status":105,"phases":707,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":712,"interventions":713},"NCT02063360","DDI Study of BMS-663068 With Etravirine (ETR) and\u002For Darunavir (DVR) + Ritonavir (RTV)",[89],"2014-05-01","2014-05-13","2014-02-01",42,[18],[42,714,413,715],"Darunavir","Etravirine",{"nctId":717,"briefTitle":718,"status":105,"phases":719,"primaryCompletion":720,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":724},"NCT02805556","Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing",[89],"2016-05-05","2016-03-15",36,[18],[42,725],"BMS-626529",{"nctId":727,"briefTitle":728,"status":105,"phases":729,"primaryCompletion":730,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":734},"NCT02480894","A Open-label, Drug-Drug Interaction With Maraviroc (DDI)",[89],"2015-09-21","2015-07-07",112,[18],[42,735],"Maraviroc",{"nctId":737,"briefTitle":738,"status":105,"phases":739,"primaryCompletion":740,"completion":740,"start":741,"enrollment":742,"conditions":743,"interventions":744},"NCT02467335","Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects",[89],"2015-10-03","2015-01-29",52,[18],[42],{"nctId":746,"briefTitle":747,"status":105,"phases":748,"primaryCompletion":749,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":753},"NCT02666053","A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects",[89],"2016-02-22","2016-01-27",72,[18],[42],{"nctId":755,"briefTitle":756,"status":105,"phases":757,"primaryCompletion":758,"completion":758,"start":759,"enrollment":760,"conditions":761,"interventions":762},"NCT02666001","A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine\u002FNaloxone",[89],"2016-06-29","2016-01-12",32,[18],[42,479,763],"Buprenorphine and Norbuprenorphine",{"nctId":765,"briefTitle":766,"status":105,"phases":767,"primaryCompletion":768,"completion":768,"start":731,"enrollment":769,"conditions":770,"interventions":771},"NCT02480881","A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)",[89],"2016-01-11",26,[18],[42,772,773],"Oral Contraceptive","Loestrin 1.5\u002F30",{"nctId":775,"briefTitle":776,"status":105,"phases":777,"primaryCompletion":778,"completion":778,"start":779,"enrollment":780,"conditions":781,"interventions":782},"NCT02138084","Drug-drug Interaction (DDI) Rifabutin",[89],"2014-07-24","2014-05-14",102,[18],[42,113,413],{"nctId":784,"briefTitle":785,"status":105,"phases":786,"primaryCompletion":787,"completion":787,"start":788,"enrollment":760,"conditions":789,"interventions":790},"NCT02277600","A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)",[89],"2015-01-12","2014-11-05",[18],[42,714,791],"Cobicistat",{"nctId":793,"briefTitle":794,"status":105,"phases":795,"primaryCompletion":796,"completion":796,"start":796,"enrollment":456,"conditions":797,"interventions":798},"NCT02859259","A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects",[89],"2016-08-12",[18],[42,42],{"nctId":800,"briefTitle":801,"status":105,"phases":802,"primaryCompletion":803,"completion":803,"start":804,"enrollment":805,"conditions":806,"interventions":807},"NCT02164045","Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529",[89],"2014-07-25","2014-06-24",38,[18],[42],{"trials":809,"activeCount":99},[810],{"nctId":811,"briefTitle":812,"status":105,"phases":813,"primaryCompletion":814,"completion":814,"start":815,"enrollment":700,"conditions":816,"interventions":817},"NCT01009814","Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1",[90],"2010-06-25","2009-11-23",[15],[42,413],{"trials":819,"activeCount":137,"soonestReadout":41},[820],{"nctId":39,"briefTitle":40,"status":128,"phases":821,"primaryCompletion":41,"completion":822,"start":823,"enrollment":824,"conditions":825,"interventions":826},[91],"2026-09-30","2015-02-23",371,[15],[42],{"trials":828,"activeCount":99},[],{"trials":830,"activeCount":99},[],{"intervention":147,"totalTrials":178,"cells":832},{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":858,"NA":860},{"trials":834,"activeCount":99},[],{"trials":836,"activeCount":99},[],{"trials":838,"activeCount":99},[],{"trials":840,"activeCount":137,"soonestReadout":55},[841,850,854],{"nctId":842,"briefTitle":843,"status":105,"phases":844,"primaryCompletion":845,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":849},"NCT05896761","A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants",[91],"2022-08-23","2021-10-28",118,[352],[147,148],{"nctId":53,"briefTitle":54,"status":128,"phases":851,"primaryCompletion":55,"completion":142,"start":143,"enrollment":144,"conditions":852,"interventions":853},[91],[15],[56,122,147,148],{"nctId":150,"briefTitle":151,"status":105,"phases":855,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":856,"interventions":857},[91],[15],[56,147,122,148,159],{"trials":859,"activeCount":99},[],{"trials":861,"activeCount":99},[],{"intervention":148,"totalTrials":178,"cells":863},{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":884,"NA":886},{"trials":865,"activeCount":99},[],{"trials":867,"activeCount":99},[],{"trials":869,"activeCount":99},[],{"trials":871,"activeCount":137,"soonestReadout":55},[872,876,880],{"nctId":842,"briefTitle":843,"status":105,"phases":873,"primaryCompletion":845,"completion":845,"start":846,"enrollment":847,"conditions":874,"interventions":875},[91],[352],[147,148],{"nctId":53,"briefTitle":54,"status":128,"phases":877,"primaryCompletion":55,"completion":142,"start":143,"enrollment":144,"conditions":878,"interventions":879},[91],[15],[56,122,147,148],{"nctId":150,"briefTitle":151,"status":105,"phases":881,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":882,"interventions":883},[91],[15],[56,147,122,148,159],{"trials":885,"activeCount":99},[],{"trials":887,"activeCount":99},[],{"intervention":86,"totalTrials":137,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":906,"NA":908},{"trials":891,"activeCount":99},[],{"trials":893,"activeCount":99},[],{"trials":895,"activeCount":99},[],{"trials":897,"activeCount":137,"soonestReadout":85},[898],{"nctId":83,"briefTitle":84,"status":277,"phases":899,"primaryCompletion":85,"completion":900,"start":901,"enrollment":902,"conditions":903,"interventions":904},[91],"2028-08-18","2024-12-02",332,[15],[86,905],"Oral ART",{"trials":907,"activeCount":99},[],{"trials":909,"activeCount":99},[],{"intervention":905,"totalTrials":137,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":924,"NA":926},{"trials":913,"activeCount":99},[],{"trials":915,"activeCount":99},[],{"trials":917,"activeCount":99},[],{"trials":919,"activeCount":137,"soonestReadout":85},[920],{"nctId":83,"briefTitle":84,"status":277,"phases":921,"primaryCompletion":85,"completion":900,"start":901,"enrollment":902,"conditions":922,"interventions":923},[91],[15],[86,905],{"trials":925,"activeCount":99},[],{"trials":927,"activeCount":99},[],{"intervention":437,"totalTrials":137,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":936,"PHASE4":942,"NA":944},{"trials":931,"activeCount":99},[],{"trials":933,"activeCount":99},[],{"trials":935,"activeCount":99},[],{"trials":937,"activeCount":137,"soonestReadout":65},[938],{"nctId":63,"briefTitle":64,"status":128,"phases":939,"primaryCompletion":65,"completion":432,"start":433,"enrollment":434,"conditions":940,"interventions":941},[91],[27,15],[66,333,437,394,438],{"trials":943,"activeCount":99},[],{"trials":945,"activeCount":99},[],{"intervention":438,"totalTrials":137,"cells":947},{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":954,"PHASE4":960,"NA":962},{"trials":949,"activeCount":99},[],{"trials":951,"activeCount":99},[],{"trials":953,"activeCount":99},[],{"trials":955,"activeCount":137,"soonestReadout":65},[956],{"nctId":63,"briefTitle":64,"status":128,"phases":957,"primaryCompletion":65,"completion":432,"start":433,"enrollment":434,"conditions":958,"interventions":959},[91],[27,15],[66,333,437,394,438],{"trials":961,"activeCount":99},[],{"trials":963,"activeCount":99},[],{"intervention":169,"totalTrials":137,"cells":965},{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":972,"PHASE4":978,"NA":980},{"trials":967,"activeCount":99},[],{"trials":969,"activeCount":99},[],{"trials":971,"activeCount":99},[],{"trials":973,"activeCount":137,"soonestReadout":51},[974],{"nctId":49,"briefTitle":50,"status":128,"phases":975,"primaryCompletion":51,"completion":142,"start":162,"enrollment":163,"conditions":976,"interventions":977},[91],[15],[47,166,167,168,169,170],{"trials":979,"activeCount":99},[],{"trials":981,"activeCount":99},[],{"intervention":177,"totalTrials":137,"cells":983},{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":990,"PHASE4":996,"NA":998},{"trials":985,"activeCount":99},[],{"trials":987,"activeCount":99},[],{"trials":989,"activeCount":99},[],{"trials":991,"activeCount":137,"soonestReadout":46},[992],{"nctId":44,"briefTitle":45,"status":128,"phases":993,"primaryCompletion":46,"completion":142,"start":173,"enrollment":174,"conditions":994,"interventions":995},[91],[18,15],[47,166,167,168,177],{"trials":997,"activeCount":99},[],{"trials":999,"activeCount":99},[],{"intervention":170,"totalTrials":1001,"cells":1002},10,{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1062,"PHASE3":1068,"PHASE4":1086,"NA":1088},{"trials":1004,"activeCount":99},[],{"trials":1006,"activeCount":99},[1007,1015,1025,1034,1043,1053],{"nctId":1008,"briefTitle":1009,"status":105,"phases":1010,"primaryCompletion":603,"completion":603,"start":1011,"enrollment":25,"conditions":1012,"interventions":1013},"NCT02082808","Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects",[89],"2014-03",[18],[170,1014],"DCV",{"nctId":1016,"briefTitle":1017,"status":105,"phases":1018,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":760,"conditions":1021,"interventions":1022},"NCT01563328","A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).",[89],"2012-05-01","2012-03-01",[18],[170,1023,1024],"BCV","TVR",{"nctId":1026,"briefTitle":1027,"status":105,"phases":1028,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":466,"conditions":1032,"interventions":1033},"NCT03816696","Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)",[89],"2019-03-30","2019-04-10","2019-01-23",[15],[523,170],{"nctId":1035,"briefTitle":1036,"status":105,"phases":1037,"primaryCompletion":1038,"completion":1038,"start":1039,"enrollment":847,"conditions":1040,"interventions":1041},"NCT02741557","Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)",[89],"2016-10-24","2016-05-11",[18,15],[170,235,1042],"DTG\u002FRPV FDC",{"nctId":1044,"briefTitle":1045,"status":105,"phases":1046,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":1049,"conditions":1050,"interventions":1051},"NCT04857892","A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants",[89],"2021-09-10","2021-04-21",41,[15],[523,170,1052],"GSK3640254\u002FDTG",{"nctId":1054,"briefTitle":1055,"status":105,"phases":1056,"primaryCompletion":1057,"completion":1057,"start":1058,"enrollment":466,"conditions":1059,"interventions":1060},"NCT01967771","Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects",[89],"2014-01","2013-10",[18],[170,1061],"CBZ",{"trials":1063,"activeCount":99},[1064],{"nctId":225,"briefTitle":226,"status":105,"phases":1065,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":1066,"interventions":1067},[90],[15],[194,234,235,170],{"trials":1069,"activeCount":137,"soonestReadout":51},[1070,1074],{"nctId":49,"briefTitle":50,"status":128,"phases":1071,"primaryCompletion":51,"completion":142,"start":162,"enrollment":163,"conditions":1072,"interventions":1073},[91],[15],[47,166,167,168,169,170],{"nctId":1075,"briefTitle":1076,"status":105,"phases":1077,"primaryCompletion":1078,"completion":1079,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1083},"NCT02227238","Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir\u002FRitonavir in Second-line Treatment",[91],"2017-08-02","2022-02-14","2014-12-11",627,[15],[170,1084,1085],"LPV\u002FRTV","Two NRTIs",{"trials":1087,"activeCount":99},[],{"trials":1089,"activeCount":99},[1090],{"nctId":1091,"briefTitle":1092,"status":1093,"phases":1094,"primaryCompletion":1095,"completion":1095,"start":329,"enrollment":1096,"conditions":1097,"interventions":1098},"NCT03564613","Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women","UNKNOWN",[],"2024-10-30",250,[15],[170],{"intervention":333,"totalTrials":1001,"cells":1100},{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1109,"PHASE3":1115,"PHASE4":1151,"NA":1174},{"trials":1102,"activeCount":99},[],{"trials":1104,"activeCount":99},[1105],{"nctId":500,"briefTitle":501,"status":105,"phases":1106,"primaryCompletion":503,"completion":503,"start":504,"enrollment":505,"conditions":1107,"interventions":1108},[89],[18],[66,333,508,509],{"trials":1110,"activeCount":99},[1111],{"nctId":536,"briefTitle":537,"status":515,"phases":1112,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":1113,"interventions":1114},[90],[15],[523,66,333,333],{"trials":1116,"activeCount":137,"soonestReadout":65},[1117,1121,1134,1143,1147],{"nctId":63,"briefTitle":64,"status":128,"phases":1118,"primaryCompletion":65,"completion":432,"start":433,"enrollment":434,"conditions":1119,"interventions":1120},[91],[27,15],[66,333,437,394,438],{"nctId":1122,"briefTitle":1123,"status":105,"phases":1124,"primaryCompletion":1125,"completion":1125,"start":1126,"enrollment":1127,"conditions":1128,"interventions":1129},"NCT00044577","New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects",[91],"2004-05-25","2002-07-16",166,[21,24],[1130,1131,1132,1133],"abacavir\u002Flamivudine","abacavir","lamivudine","tenofovir",{"nctId":1135,"briefTitle":1136,"status":105,"phases":1137,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1142},"NCT00046176","A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients",[91],"2004-05-17","2002-08-26",240,[21,24],[1130,1131,1132],{"nctId":588,"briefTitle":589,"status":105,"phases":1144,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":1145,"interventions":1146},[91],[18,15],[66,333,597],{"nctId":609,"briefTitle":610,"status":105,"phases":1148,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":1149,"interventions":1150},[91],[18,15],[66,333,597],{"trials":1152,"activeCount":99},[1153,1164],{"nctId":1154,"briefTitle":1155,"status":105,"phases":1156,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":1159,"conditions":1160,"interventions":1162},"NCT00354653","A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone",[92],"2007-01-23","2002-02-09",100,[1161],"CHRONIC HEPATITIS B",[1163],"LAMIVUDINE",{"nctId":1165,"briefTitle":1166,"status":105,"phases":1167,"primaryCompletion":1168,"completion":1169,"start":1170,"enrollment":466,"conditions":1171,"interventions":1172},"NCT02634073","A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers",[92],"2016-03-01","2016-03-11","2016-01-01",[18],[333,1173],"Sorbitol",{"trials":1175,"activeCount":99},[1176],{"nctId":324,"briefTitle":325,"status":105,"phases":1177,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":1178,"interventions":1179},[],[15],[66,333,122],{"intervention":136,"totalTrials":36,"cells":1181},{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1222,"PHASE3":1228,"PHASE4":1230,"NA":1232},{"trials":1183,"activeCount":99},[],{"trials":1185,"activeCount":362,"soonestReadout":1204},[1186,1200,1213],{"nctId":1187,"briefTitle":1188,"status":277,"phases":1189,"primaryCompletion":1190,"completion":1190,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1194},"NCT06310551","First Time in Human Study of Long Acting VH4524184 Formulations",[89],"2028-01-21","2024-03-21",268,[15],[1195,1196,136,1197,1198,1199],"Oral VH4524184","VH4524184 Formulation A SC","VH4524184 Formulation B SC","VH4524184 Formulation A IM","VH4524184 Formulation B IM",{"nctId":1201,"briefTitle":1202,"status":277,"phases":1203,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":1207,"interventions":1208},"NCT05418868","A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants",[89],"2027-06-08","2022-06-14",214,[15],[1209,1210,1211,1212,136,235],"Cabotegravir 200 mg\u002FmL","Cabotegravir >=400 mg\u002FmL","Cabotegravir Formulation I","CAB Formulation J",{"nctId":1214,"briefTitle":1215,"status":105,"phases":1216,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":1219,"conditions":1220,"interventions":1221},"NCT05291520","A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants",[89],"2023-04-10","2022-02-23",24,[15],[71,136],{"trials":1223,"activeCount":137,"soonestReadout":70},[1224],{"nctId":68,"briefTitle":69,"status":128,"phases":1225,"primaryCompletion":70,"completion":130,"start":131,"enrollment":132,"conditions":1226,"interventions":1227},[90],[15],[71,56,135,136],{"trials":1229,"activeCount":99},[],{"trials":1231,"activeCount":99},[],{"trials":1233,"activeCount":99},[],{"intervention":71,"totalTrials":178,"cells":1235},{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1248,"PHASE3":1254,"PHASE4":1256,"NA":1258},{"trials":1237,"activeCount":99},[],{"trials":1239,"activeCount":137,"soonestReadout":654},[1240,1244],{"nctId":1214,"briefTitle":1215,"status":105,"phases":1241,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":1219,"conditions":1242,"interventions":1243},[89],[15],[71,136],{"nctId":651,"briefTitle":652,"status":128,"phases":1245,"primaryCompletion":654,"completion":655,"start":656,"enrollment":408,"conditions":1246,"interventions":1247},[89],[15],[71,557,659],{"trials":1249,"activeCount":137,"soonestReadout":70},[1250],{"nctId":68,"briefTitle":69,"status":128,"phases":1251,"primaryCompletion":70,"completion":130,"start":131,"enrollment":132,"conditions":1252,"interventions":1253},[90],[15],[71,56,135,136],{"trials":1255,"activeCount":99},[],{"trials":1257,"activeCount":99},[],{"trials":1259,"activeCount":99},[],{"intervention":425,"totalTrials":31,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1297,"PHASE3":1312,"PHASE4":1314,"NA":1316},{"trials":1263,"activeCount":99},[],{"trials":1265,"activeCount":99},[1266,1278,1287],{"nctId":1267,"briefTitle":1268,"status":105,"phases":1269,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":16,"conditions":1272,"interventions":1273},"NCT07066722","A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults",[89],"2025-12-17","2025-07-07",[15],[425,1274,113,1275,1276,1277],"Itraconazole","Phenytoin","Metformin","Digoxin",{"nctId":1279,"briefTitle":1280,"status":105,"phases":1281,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":769,"conditions":1284,"interventions":1285},"NCT06310616","A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants",[89],"2024-08-15","2024-03-06",[15],[425,1286],"Loestrin",{"nctId":1288,"briefTitle":1289,"status":105,"phases":1290,"primaryCompletion":1291,"completion":1291,"start":1292,"enrollment":1293,"conditions":1294,"interventions":1295},"NCT05631704","A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity",[89],"2023-07-27","2022-12-02",84,[15],[425,1296],"Midazolam",{"trials":1298,"activeCount":137,"soonestReadout":419},[1299,1303],{"nctId":416,"briefTitle":417,"status":277,"phases":1300,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":1301,"interventions":1302},[90],[15],[425,426,427],{"nctId":1304,"briefTitle":1305,"status":105,"phases":1306,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":8,"conditions":1309,"interventions":1310},"NCT06214052","VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1",[90],"2024-06-12","2024-02-07",[15],[425,1311],"Antiretroviral therapy",{"trials":1313,"activeCount":99},[],{"trials":1315,"activeCount":99},[],{"trials":1317,"activeCount":99},[],{"intervention":221,"totalTrials":362,"cells":1319},{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1328,"PHASE3":1340,"PHASE4":1342,"NA":1344},{"trials":1321,"activeCount":99},[],{"trials":1323,"activeCount":99},[1324],{"nctId":213,"briefTitle":214,"status":105,"phases":1325,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":1326,"interventions":1327},[89],[15],[221,194],{"trials":1329,"activeCount":137,"soonestReadout":1334},[1330],{"nctId":1331,"briefTitle":1332,"status":277,"phases":1333,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":1337,"interventions":1338},"NCT07275606","A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1",[89,90],"2029-10-10","2026-04-15",44,[15],[221,1339],"IM CAB LA",{"trials":1341,"activeCount":99},[],{"trials":1343,"activeCount":99},[],{"trials":1345,"activeCount":99},[],{"intervention":1339,"totalTrials":137,"cells":1347},{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1358,"PHASE4":1360,"NA":1362},{"trials":1349,"activeCount":99},[],{"trials":1351,"activeCount":99},[],{"trials":1353,"activeCount":137,"soonestReadout":1334},[1354],{"nctId":1331,"briefTitle":1332,"status":277,"phases":1355,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":1356,"interventions":1357},[89,90],[15],[221,1339],{"trials":1359,"activeCount":99},[],{"trials":1361,"activeCount":99},[],{"trials":1363,"activeCount":99},[],{"intervention":427,"totalTrials":137,"cells":1365},{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1376,"PHASE4":1378,"NA":1380},{"trials":1367,"activeCount":99},[],{"trials":1369,"activeCount":99},[],{"trials":1371,"activeCount":137,"soonestReadout":419},[1372],{"nctId":416,"briefTitle":417,"status":277,"phases":1373,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":1374,"interventions":1375},[90],[15],[425,426,427],{"trials":1377,"activeCount":99},[],{"trials":1379,"activeCount":99},[],{"trials":1381,"activeCount":99},[],{"intervention":135,"totalTrials":137,"cells":1383},{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1394,"PHASE4":1396,"NA":1398},{"trials":1385,"activeCount":99},[],{"trials":1387,"activeCount":99},[],{"trials":1389,"activeCount":137,"soonestReadout":70},[1390],{"nctId":68,"briefTitle":69,"status":128,"phases":1391,"primaryCompletion":70,"completion":130,"start":131,"enrollment":132,"conditions":1392,"interventions":1393},[90],[15],[71,56,135,136],{"trials":1395,"activeCount":99},[],{"trials":1397,"activeCount":99},[],{"trials":1399,"activeCount":99},[],{"intervention":76,"totalTrials":137,"cells":1401},{"EARLY_PHASE1":1402,"PHASE1":1404,"PHASE2":1406,"PHASE3":1415,"PHASE4":1417,"NA":1419},{"trials":1403,"activeCount":99},[],{"trials":1405,"activeCount":99},[],{"trials":1407,"activeCount":137,"soonestReadout":75},[1408],{"nctId":73,"briefTitle":74,"status":277,"phases":1409,"primaryCompletion":75,"completion":1410,"start":1411,"enrollment":1412,"conditions":1413,"interventions":1414},[89,90],"2028-05-03","2023-07-06",20,[15],[76],{"trials":1416,"activeCount":99},[],{"trials":1418,"activeCount":99},[],{"trials":1420,"activeCount":99},[],{"intervention":259,"totalTrials":137,"cells":1422},{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1433,"PHASE4":1435,"NA":1437},{"trials":1424,"activeCount":99},[],{"trials":1426,"activeCount":99},[],{"trials":1428,"activeCount":137,"soonestReadout":253},[1429],{"nctId":250,"briefTitle":251,"status":128,"phases":1430,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":1431,"interventions":1432},[90],[15],[194,259],{"trials":1434,"activeCount":99},[],{"trials":1436,"activeCount":99},[],{"trials":1438,"activeCount":99},[],{"intervention":235,"totalTrials":36,"cells":1440},{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1453,"PHASE3":1463,"PHASE4":1465,"NA":1467},{"trials":1442,"activeCount":99},[],{"trials":1444,"activeCount":137,"soonestReadout":1204},[1445,1449],{"nctId":1201,"briefTitle":1202,"status":277,"phases":1446,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":1447,"interventions":1448},[89],[15],[1209,1210,1211,1212,136,235],{"nctId":1035,"briefTitle":1036,"status":105,"phases":1450,"primaryCompletion":1038,"completion":1038,"start":1039,"enrollment":847,"conditions":1451,"interventions":1452},[89],[18,15],[170,235,1042],{"trials":1454,"activeCount":99},[1455,1459],{"nctId":225,"briefTitle":226,"status":105,"phases":1456,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":1457,"interventions":1458},[90],[15],[194,234,235,170],{"nctId":237,"briefTitle":238,"status":105,"phases":1460,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":1461,"interventions":1462},[90],[18,15],[246,194,247,248,235],{"trials":1464,"activeCount":99},[],{"trials":1466,"activeCount":99},[],{"trials":1468,"activeCount":99},[],{"intervention":1470,"totalTrials":178,"cells":1471},"VH4011499",{"EARLY_PHASE1":1472,"PHASE1":1474,"PHASE2":1490,"PHASE3":1500,"PHASE4":1502,"NA":1504},{"trials":1473,"activeCount":99},[],{"trials":1475,"activeCount":137,"soonestReadout":80},[1476,1485],{"nctId":1477,"briefTitle":1478,"status":105,"phases":1479,"primaryCompletion":1480,"completion":1480,"start":1481,"enrollment":1482,"conditions":1483,"interventions":1484},"NCT05393271","First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants",[89],"2023-04-24","2022-10-03",73,[15],[1470,1296],{"nctId":78,"briefTitle":79,"status":128,"phases":1486,"primaryCompletion":80,"completion":80,"start":1487,"enrollment":542,"conditions":1488,"interventions":1489},[89],"2023-08-24",[15],[81,1470],{"trials":1491,"activeCount":99},[1492],{"nctId":1493,"briefTitle":1494,"status":105,"phases":1495,"primaryCompletion":1496,"completion":1496,"start":1497,"enrollment":1336,"conditions":1498,"interventions":1499},"NCT06039579","Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults",[90],"2024-06-24","2023-10-25",[15],[81,1470,1311],{"trials":1501,"activeCount":99},[],{"trials":1503,"activeCount":99},[],{"trials":1505,"activeCount":99},[],{"intervention":81,"totalTrials":178,"cells":1507},{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1524,"PHASE3":1530,"PHASE4":1532,"NA":1534},{"trials":1509,"activeCount":99},[],{"trials":1511,"activeCount":137,"soonestReadout":80},[1512,1520],{"nctId":1513,"briefTitle":1514,"status":105,"phases":1515,"primaryCompletion":1516,"completion":1516,"start":1517,"enrollment":1482,"conditions":1518,"interventions":1519},"NCT05163522","First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants",[89],"2023-06-21","2021-12-13",[15],[81,1296],{"nctId":78,"briefTitle":79,"status":128,"phases":1521,"primaryCompletion":80,"completion":80,"start":1487,"enrollment":542,"conditions":1522,"interventions":1523},[89],[15],[81,1470],{"trials":1525,"activeCount":99},[1526],{"nctId":1493,"briefTitle":1494,"status":105,"phases":1527,"primaryCompletion":1496,"completion":1496,"start":1497,"enrollment":1336,"conditions":1528,"interventions":1529},[90],[15],[81,1470,1311],{"trials":1531,"activeCount":99},[],{"trials":1533,"activeCount":99},[],{"trials":1535,"activeCount":99},[],{"intervention":1296,"totalTrials":36,"cells":1537},{"EARLY_PHASE1":1538,"PHASE1":1540,"PHASE2":1563,"PHASE3":1565,"PHASE4":1567,"NA":1569},{"trials":1539,"activeCount":99},[],{"trials":1541,"activeCount":137,"soonestReadout":1558},[1542,1546,1550,1554],{"nctId":1477,"briefTitle":1478,"status":105,"phases":1543,"primaryCompletion":1480,"completion":1480,"start":1481,"enrollment":1482,"conditions":1544,"interventions":1545},[89],[15],[1470,1296],{"nctId":1513,"briefTitle":1514,"status":105,"phases":1547,"primaryCompletion":1516,"completion":1516,"start":1517,"enrollment":1482,"conditions":1548,"interventions":1549},[89],[15],[81,1296],{"nctId":1288,"briefTitle":1289,"status":105,"phases":1551,"primaryCompletion":1291,"completion":1291,"start":1292,"enrollment":1293,"conditions":1552,"interventions":1553},[89],[15],[425,1296],{"nctId":1555,"briefTitle":1556,"status":550,"phases":1557,"primaryCompletion":1558,"completion":1558,"start":1559,"enrollment":1206,"conditions":1560,"interventions":1561},"NCT07525544","A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants",[89],"2027-05-05","2026-04-07",[15],[1562,1296],"VH4770359",{"trials":1564,"activeCount":99},[],{"trials":1566,"activeCount":99},[],{"trials":1568,"activeCount":99},[],{"trials":1570,"activeCount":99},[],{"intervention":1209,"totalTrials":362,"cells":1572},{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1597,"PHASE3":1599,"PHASE4":1601,"NA":1603},{"trials":1574,"activeCount":99},[],{"trials":1576,"activeCount":137,"soonestReadout":1204},[1577,1593],{"nctId":1578,"briefTitle":1579,"status":105,"phases":1580,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":1584,"interventions":1585},"NCT04484337","Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg\u002FmL) Formulation in Healthy Adult Participants",[89],"2023-05-05","2020-07-31",138,[15],[1586,1587,1209,1588,1589,1590,1591,1592],"Cabotegravir sodium","Cabotegravir 400 mg\u002FmL","Topical Non-steroidal anti-inflammatory drug","Topical steroid","Topical NSAID placebo","Recombinant human hyaluronidase PH20","Topical steroid placebo",{"nctId":1201,"briefTitle":1202,"status":277,"phases":1594,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":1595,"interventions":1596},[89],[15],[1209,1210,1211,1212,136,235],{"trials":1598,"activeCount":99},[],{"trials":1600,"activeCount":99},[],{"trials":1602,"activeCount":99},[],{"trials":1604,"activeCount":99},[],{"intervention":1195,"totalTrials":137,"cells":1606},{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1615,"PHASE3":1617,"PHASE4":1619,"NA":1621},{"trials":1608,"activeCount":99},[],{"trials":1610,"activeCount":137,"soonestReadout":1190},[1611],{"nctId":1187,"briefTitle":1188,"status":277,"phases":1612,"primaryCompletion":1190,"completion":1190,"start":1191,"enrollment":1192,"conditions":1613,"interventions":1614},[89],[15],[1195,1196,136,1197,1198,1199],{"trials":1616,"activeCount":99},[],{"trials":1618,"activeCount":99},[],{"trials":1620,"activeCount":99},[],{"trials":1622,"activeCount":99},[],{"intervention":1196,"totalTrials":137,"cells":1624},{"EARLY_PHASE1":1625,"PHASE1":1627,"PHASE2":1633,"PHASE3":1635,"PHASE4":1637,"NA":1639},{"trials":1626,"activeCount":99},[],{"trials":1628,"activeCount":137,"soonestReadout":1190},[1629],{"nctId":1187,"briefTitle":1188,"status":277,"phases":1630,"primaryCompletion":1190,"completion":1190,"start":1191,"enrollment":1192,"conditions":1631,"interventions":1632},[89],[15],[1195,1196,136,1197,1198,1199],{"trials":1634,"activeCount":99},[],{"trials":1636,"activeCount":99},[],{"trials":1638,"activeCount":99},[],{"trials":1640,"activeCount":99},[],{"intervention":1197,"totalTrials":137,"cells":1642},{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1651,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1644,"activeCount":99},[],{"trials":1646,"activeCount":137,"soonestReadout":1190},[1647],{"nctId":1187,"briefTitle":1188,"status":277,"phases":1648,"primaryCompletion":1190,"completion":1190,"start":1191,"enrollment":1192,"conditions":1649,"interventions":1650},[89],[15],[1195,1196,136,1197,1198,1199],{"trials":1652,"activeCount":99},[],{"trials":1654,"activeCount":99},[],{"trials":1656,"activeCount":99},[],{"trials":1658,"activeCount":99},[],{"intervention":1198,"totalTrials":137,"cells":1660},{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1669,"PHASE3":1671,"PHASE4":1673,"NA":1675},{"trials":1662,"activeCount":99},[],{"trials":1664,"activeCount":137,"soonestReadout":1190},[1665],{"nctId":1187,"briefTitle":1188,"status":277,"phases":1666,"primaryCompletion":1190,"completion":1190,"start":1191,"enrollment":1192,"conditions":1667,"interventions":1668},[89],[15],[1195,1196,136,1197,1198,1199],{"trials":1670,"activeCount":99},[],{"trials":1672,"activeCount":99},[],{"trials":1674,"activeCount":99},[],{"trials":1676,"activeCount":99},[],{"intervention":1199,"totalTrials":137,"cells":1678},{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1687,"PHASE3":1689,"PHASE4":1691,"NA":1693},{"trials":1680,"activeCount":99},[],{"trials":1682,"activeCount":137,"soonestReadout":1190},[1683],{"nctId":1187,"briefTitle":1188,"status":277,"phases":1684,"primaryCompletion":1190,"completion":1190,"start":1191,"enrollment":1192,"conditions":1685,"interventions":1686},[89],[15],[1195,1196,136,1197,1198,1199],{"trials":1688,"activeCount":99},[],{"trials":1690,"activeCount":99},[],{"trials":1692,"activeCount":99},[],{"trials":1694,"activeCount":99},[],{"intervention":211,"totalTrials":137,"cells":1696},{"EARLY_PHASE1":1697,"PHASE1":1699,"PHASE2":1705,"PHASE3":1707,"PHASE4":1709,"NA":1711},{"trials":1698,"activeCount":99},[],{"trials":1700,"activeCount":137,"soonestReadout":205},[1701],{"nctId":202,"briefTitle":203,"status":128,"phases":1702,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":1703,"interventions":1704},[89],[15],[194,211],{"trials":1706,"activeCount":99},[],{"trials":1708,"activeCount":99},[],{"trials":1710,"activeCount":99},[],{"trials":1712,"activeCount":99},[],{"intervention":1714,"totalTrials":137,"cells":1715},"VH4527079",{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1727,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1717,"activeCount":99},[],{"trials":1719,"activeCount":137,"soonestReadout":253},[1720],{"nctId":1721,"briefTitle":1722,"status":128,"phases":1723,"primaryCompletion":253,"completion":253,"start":1724,"enrollment":780,"conditions":1725,"interventions":1726},"NCT06652958","A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV",[89],"2024-10-02",[15],[1714],{"trials":1728,"activeCount":99},[],{"trials":1730,"activeCount":99},[],{"trials":1732,"activeCount":99},[],{"trials":1734,"activeCount":99},[],{"intervention":1736,"totalTrials":137,"cells":1737},"VH4011499 low dose",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1752,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1739,"activeCount":99},[],{"trials":1741,"activeCount":137,"soonestReadout":1746},[1742],{"nctId":1743,"briefTitle":1744,"status":277,"phases":1745,"primaryCompletion":1746,"completion":1746,"start":1747,"enrollment":1748,"conditions":1749,"interventions":1750},"NCT06724640","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV",[89],"2028-08-16","2024-12-16",168,[15],[1736,1751],"VH4011499 high dose",{"trials":1753,"activeCount":99},[],{"trials":1755,"activeCount":99},[],{"trials":1757,"activeCount":99},[],{"trials":1759,"activeCount":99},[],{"intervention":1751,"totalTrials":137,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1770,"PHASE3":1772,"PHASE4":1774,"NA":1776},{"trials":1763,"activeCount":99},[],{"trials":1765,"activeCount":137,"soonestReadout":1746},[1766],{"nctId":1743,"briefTitle":1744,"status":277,"phases":1767,"primaryCompletion":1746,"completion":1746,"start":1747,"enrollment":1748,"conditions":1768,"interventions":1769},[89],[15],[1736,1751],{"trials":1771,"activeCount":99},[],{"trials":1773,"activeCount":99},[],{"trials":1775,"activeCount":99},[],{"trials":1777,"activeCount":99},[],{"intervention":1210,"totalTrials":137,"cells":1779},{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1788,"PHASE3":1790,"PHASE4":1792,"NA":1794},{"trials":1781,"activeCount":99},[],{"trials":1783,"activeCount":137,"soonestReadout":1204},[1784],{"nctId":1201,"briefTitle":1202,"status":277,"phases":1785,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":1786,"interventions":1787},[89],[15],[1209,1210,1211,1212,136,235],{"trials":1789,"activeCount":99},[],{"trials":1791,"activeCount":99},[],{"trials":1793,"activeCount":99},[],{"trials":1795,"activeCount":99},[],{"intervention":1211,"totalTrials":137,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1806,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1799,"activeCount":99},[],{"trials":1801,"activeCount":137,"soonestReadout":1204},[1802],{"nctId":1201,"briefTitle":1202,"status":277,"phases":1803,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":1804,"interventions":1805},[89],[15],[1209,1210,1211,1212,136,235],{"trials":1807,"activeCount":99},[],{"trials":1809,"activeCount":99},[],{"trials":1811,"activeCount":99},[],{"trials":1813,"activeCount":99},[],{"intervention":1212,"totalTrials":137,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1824,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1817,"activeCount":99},[],{"trials":1819,"activeCount":137,"soonestReadout":1204},[1820],{"nctId":1201,"briefTitle":1202,"status":277,"phases":1821,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":1206,"conditions":1822,"interventions":1823},[89],[15],[1209,1210,1211,1212,136,235],{"trials":1825,"activeCount":99},[],{"trials":1827,"activeCount":99},[],{"trials":1829,"activeCount":99},[],{"trials":1831,"activeCount":99},[],{"intervention":659,"totalTrials":137,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1842,"PHASE3":1844,"PHASE4":1846,"NA":1848},{"trials":1835,"activeCount":99},[],{"trials":1837,"activeCount":137,"soonestReadout":654},[1838],{"nctId":651,"briefTitle":652,"status":128,"phases":1839,"primaryCompletion":654,"completion":655,"start":656,"enrollment":408,"conditions":1840,"interventions":1841},[89],[15],[71,557,659],{"trials":1843,"activeCount":99},[],{"trials":1845,"activeCount":99},[],{"trials":1847,"activeCount":99},[],{"trials":1849,"activeCount":99},[],{"intervention":61,"totalTrials":137,"cells":1851},{"EARLY_PHASE1":1852,"PHASE1":1854,"PHASE2":1864,"PHASE3":1866,"PHASE4":1868,"NA":1870},{"trials":1853,"activeCount":99},[],{"trials":1855,"activeCount":137,"soonestReadout":60},[1856],{"nctId":58,"briefTitle":59,"status":128,"phases":1857,"primaryCompletion":60,"completion":1858,"start":1859,"enrollment":1860,"conditions":1861,"interventions":1862},[89],"2026-07-10","2025-04-22",65,[15],[61,1863],"Lenacapavir long-acting",{"trials":1865,"activeCount":99},[],{"trials":1867,"activeCount":99},[],{"trials":1869,"activeCount":99},[],{"trials":1871,"activeCount":99},[],{"intervention":1863,"totalTrials":137,"cells":1873},{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1882,"PHASE3":1884,"PHASE4":1886,"NA":1888},{"trials":1875,"activeCount":99},[],{"trials":1877,"activeCount":137,"soonestReadout":60},[1878],{"nctId":58,"briefTitle":59,"status":128,"phases":1879,"primaryCompletion":60,"completion":1858,"start":1859,"enrollment":1860,"conditions":1880,"interventions":1881},[89],[15],[61,1863],{"trials":1883,"activeCount":99},[],{"trials":1885,"activeCount":99},[],{"trials":1887,"activeCount":99},[],{"trials":1889,"activeCount":99},[],{"intervention":1562,"totalTrials":137,"cells":1891},{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1900,"PHASE3":1902,"PHASE4":1904,"NA":1906},{"trials":1893,"activeCount":99},[],{"trials":1895,"activeCount":137,"soonestReadout":1558},[1896],{"nctId":1555,"briefTitle":1556,"status":550,"phases":1897,"primaryCompletion":1558,"completion":1558,"start":1559,"enrollment":1206,"conditions":1898,"interventions":1899},[89],[15],[1562,1296],{"trials":1901,"activeCount":99},[],{"trials":1903,"activeCount":99},[],{"trials":1905,"activeCount":99},[],{"trials":1907,"activeCount":99},[],{"intervention":413,"totalTrials":456,"cells":1909},{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1942,"PHASE3":1998,"PHASE4":2021,"NA":2033},{"trials":1911,"activeCount":99},[],{"trials":1913,"activeCount":99},[1914,1924,1928,1932],{"nctId":1915,"briefTitle":1916,"status":105,"phases":1917,"primaryCompletion":1918,"completion":1918,"start":1919,"enrollment":691,"conditions":1920,"interventions":1921},"NCT01209065","GSK1349572 Drug Interaction Study With Fosamprenavir\u002FRitonavir",[89],"2010-11","2010-09",[30],[1922,1923,413],"GSK1349572","Fosamprenavir",{"nctId":705,"briefTitle":706,"status":105,"phases":1925,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":1926,"interventions":1927},[89],[18],[42,714,413,715],{"nctId":775,"briefTitle":776,"status":105,"phases":1929,"primaryCompletion":778,"completion":778,"start":779,"enrollment":780,"conditions":1930,"interventions":1931},[89],[18],[42,113,413],{"nctId":1933,"briefTitle":1934,"status":105,"phases":1935,"primaryCompletion":1936,"completion":1936,"start":1937,"enrollment":22,"conditions":1938,"interventions":1940},"NCT00867152","GSK1349572 Drug Interaction With Etravirine and Either Darunavir\u002FRitonavir or Lopinavir\u002FRitonavir",[89],"2009-05","2009-04",[1939],"Healthy Volunteer",[714,715,413,1941,1922],"Lopinavir\u002Fritonavir",{"trials":1943,"activeCount":99},[1944,1954,1958,1970,1981,1985,1989],{"nctId":1945,"briefTitle":1946,"status":105,"phases":1947,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":1950,"conditions":1951,"interventions":1952},"NCT00257621","GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults",[90],"2007-01","2004-10",30,[21,24],[1953,413],"GW640385",{"nctId":403,"briefTitle":404,"status":105,"phases":1955,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":1956,"interventions":1957},[90],[18,15],[411,412,413,414,394],{"nctId":1959,"briefTitle":1960,"status":105,"phases":1961,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":1966,"interventions":1967},"NCT00071760","Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects",[90],"2011-07-05","2022-03-29","2003-10-23",59,[18,15],[1968,1969],"GW433908","ritonavir",{"nctId":1971,"briefTitle":1972,"status":105,"phases":1973,"primaryCompletion":1974,"completion":1975,"start":1976,"enrollment":1977,"conditions":1978,"interventions":1979},"NCT00089583","48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection",[90],"2011-03","2013-07","2004-07",110,[21],[1980,413],"LEXIVA",{"nctId":811,"briefTitle":812,"status":105,"phases":1982,"primaryCompletion":814,"completion":814,"start":815,"enrollment":700,"conditions":1983,"interventions":1984},[90],[15],[42,413],{"nctId":527,"briefTitle":528,"status":515,"phases":1986,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":1987,"interventions":1988},[90],[15],[411,412,413,66,414],{"nctId":1990,"briefTitle":1991,"status":105,"phases":1992,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":208,"conditions":1995,"interventions":1996},"NCT00040664","A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years",[90],"2008-10","2002-07",[24],[1969,1997],"fosamprenavir",{"trials":1999,"activeCount":99},[2000,2009],{"nctId":2001,"briefTitle":2002,"status":105,"phases":2003,"primaryCompletion":2004,"completion":2004,"start":2005,"enrollment":2006,"conditions":2007,"interventions":2008},"NCT00296504","A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects",[91],"2010-10","2001-11",753,[18],[1997,1969],{"nctId":2010,"briefTitle":2011,"status":105,"phases":2012,"primaryCompletion":2013,"completion":2014,"start":2015,"enrollment":2016,"conditions":2017,"interventions":2018},"NCT01910402","A Study to Determine Safety and Efficacy of Dolutegravir\u002FAbacavir\u002FLamivudine (DTG\u002FABC\u002F3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)",[91],"2015-09-22","2022-08-18","2013-08-22",499,[18,15],[2019,412,413,2020],"Dolutegravir\u002Fabacavir\u002Flamivudine FDC","Tenofovir\u002Femtricitabine FDC",{"trials":2022,"activeCount":99},[2023],{"nctId":2024,"briefTitle":2025,"status":105,"phases":2026,"primaryCompletion":2027,"completion":2027,"start":2028,"enrollment":1950,"conditions":2029,"interventions":2031},"NCT00717067","Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function",[92],"2008-11","2008-07",[2030],"Human Immunodeficiency Virus (HIV) Infection",[735,735,413,2032,735,413,2032,735,413,2032,735,735,735],"Saquinavir",{"trials":2034,"activeCount":99},[],{"intervention":2036,"totalTrials":195,"cells":2037},"Dolutegravir 50 mg",{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2097,"PHASE3":2099,"PHASE4":2101,"NA":2112},{"trials":2039,"activeCount":99},[],{"trials":2041,"activeCount":99},[2042,2051,2062,2071,2080,2087],{"nctId":2043,"briefTitle":2044,"status":105,"phases":2045,"primaryCompletion":2046,"completion":2046,"start":2047,"enrollment":1412,"conditions":2048,"interventions":2049},"NCT01382238","Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir",[89],"2011-08","2011-06",[30],[2036,2050],"Dolutegravir 50 mg oral granules",{"nctId":2052,"briefTitle":2053,"status":105,"phases":2054,"primaryCompletion":2055,"completion":2055,"start":2047,"enrollment":2056,"conditions":2057,"interventions":2059},"NCT01366547","Relative Bioavailability Study of Two New Dolutegravir\u002FAbacavir\u002FLamivudine Fixed Dose Combination Tablets",[89],"2011-07",18,[2058,18],"Healthy Subjects",[2060,2036,2061],"Dolutegravir 50 mg\u002Fabacavir 600 mg\u002Flamivudine 300 mg","abacavir 600 mg\u002Flamivudine 300 mg",{"nctId":2063,"briefTitle":2064,"status":105,"phases":2065,"primaryCompletion":2066,"completion":2066,"start":2067,"enrollment":2068,"conditions":2069,"interventions":2070},"NCT01622790","Evaluation of the Bioequivalence of a Combined Formulated Tablet",[89],"2012-08","2012-06",66,[18],[2060,2036,2061],{"nctId":2072,"briefTitle":2073,"status":105,"phases":2074,"primaryCompletion":2075,"completion":2075,"start":454,"enrollment":1950,"conditions":2076,"interventions":2077},"NCT02738931","Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations",[89],"2016-06",[18],[2036,2078,2079,2079],"Lamivudine 300 mg","Dolutegravir\u002FLamivudine 50 mg\u002F300 mg",{"nctId":2081,"briefTitle":2082,"status":105,"phases":2083,"primaryCompletion":2084,"completion":2084,"start":2047,"enrollment":466,"conditions":2085,"interventions":2086},"NCT01353716","Dolutegravir Renal Impairment Study",[89],"2012-04",[18],[2036],{"nctId":2088,"briefTitle":2089,"status":105,"phases":2090,"primaryCompletion":2091,"completion":2091,"start":2092,"enrollment":1219,"conditions":2093,"interventions":2094},"NCT01762995","A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects",[89],"2013-03","2012-12",[18],[2036,2095,2096],"Calcium Carbonate 1200 mg","Ferrous Fumarate 324 mg",{"trials":2098,"activeCount":99},[],{"trials":2100,"activeCount":99},[],{"trials":2102,"activeCount":99},[2103],{"nctId":2104,"briefTitle":2105,"status":105,"phases":2106,"primaryCompletion":2107,"completion":2107,"start":2108,"enrollment":2109,"conditions":2110,"interventions":2111},"NCT03314064","Phase 4 Study of Dolutegravir (DTG) in Russian Federation",[92],"2018-10-01","2016-12-08",43,[18,15],[2036],{"trials":2113,"activeCount":99},[],{"intervention":1997,"totalTrials":31,"cells":2115},{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2124,"PHASE3":2130,"PHASE4":2145,"NA":2156},{"trials":2117,"activeCount":99},[],{"trials":2119,"activeCount":99},[2120],{"nctId":1915,"briefTitle":1916,"status":105,"phases":2121,"primaryCompletion":1918,"completion":1918,"start":1919,"enrollment":691,"conditions":2122,"interventions":2123},[89],[30],[1922,1923,413],{"trials":2125,"activeCount":99},[2126],{"nctId":1990,"briefTitle":1991,"status":105,"phases":2127,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":208,"conditions":2128,"interventions":2129},[90],[24],[1969,1997],{"trials":2131,"activeCount":99},[2132,2141],{"nctId":2133,"briefTitle":2134,"status":105,"phases":2135,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":2139,"interventions":2140},"NCT00094523","Fosamprenavir Versus Other Protease Inhibitors",[91],"2007-06-29","2004-12-14",314,[21],[1923],{"nctId":2001,"briefTitle":2002,"status":105,"phases":2142,"primaryCompletion":2004,"completion":2004,"start":2005,"enrollment":2006,"conditions":2143,"interventions":2144},[91],[18],[1997,1969],{"trials":2146,"activeCount":99},[2147],{"nctId":2148,"briefTitle":2149,"status":105,"phases":2150,"completion":2151,"start":2152,"enrollment":542,"conditions":2153,"interventions":2154},"NCT00240552","Fosamprenavir Expanded Access",[92],"2005-08","2003-07",[18],[1997,2155],"Telzir®",{"trials":2157,"activeCount":99},[],{"intervention":715,"totalTrials":31,"cells":2159},{"EARLY_PHASE1":2160,"PHASE1":2162,"PHASE2":2182,"PHASE3":2194,"PHASE4":2196,"NA":2212},{"trials":2161,"activeCount":99},[],{"trials":2163,"activeCount":99},[2164,2168,2172],{"nctId":705,"briefTitle":706,"status":105,"phases":2165,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":2166,"interventions":2167},[89],[18],[42,714,413,715],{"nctId":1933,"briefTitle":1934,"status":105,"phases":2169,"primaryCompletion":1936,"completion":1936,"start":1937,"enrollment":22,"conditions":2170,"interventions":2171},[89],[1939],[714,715,413,1941,1922],{"nctId":2173,"briefTitle":2174,"status":105,"phases":2175,"primaryCompletion":2176,"completion":2176,"start":2177,"enrollment":2178,"conditions":2179,"interventions":2180},"NCT04630002","Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir\u002FRitonavir (DRV\u002FRTV) and Etravirine (ETR)",[89],"2021-10-02","2020-10-28",54,[15],[523,2181,715],"Darunavir\u002FRitonavir",{"trials":2183,"activeCount":99},[2184],{"nctId":2185,"briefTitle":2186,"status":515,"phases":2187,"primaryCompletion":2188,"completion":2188,"start":2189,"enrollment":1950,"conditions":2190,"interventions":2191},"NCT01199731","Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection",[90],"2011-07-19","2010-10-05",[18],[2192,2193,715],"GSK2248761 100 mg once daily","GSK2248761 200 mg once daily",{"trials":2195,"activeCount":99},[],{"trials":2197,"activeCount":99},[2198],{"nctId":2199,"briefTitle":2200,"status":2201,"phases":2202,"primaryCompletion":2203,"completion":2203,"start":2204,"enrollment":99,"conditions":2205,"interventions":2209},"NCT00782301","Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients","WITHDRAWN",[92],"2010-02","2009-03",[2206,2207,2208],"Hepatitis B","Human Immunodeficiency Virus","Hepatitis C, Chronic",[2210,2211],"maraviroc","etravirine",{"trials":2213,"activeCount":99},[],{"intervention":1133,"totalTrials":36,"cells":2215},{"EARLY_PHASE1":2216,"PHASE1":2218,"PHASE2":2220,"PHASE3":2230,"PHASE4":2236,"NA":2247},{"trials":2217,"activeCount":99},[],{"trials":2219,"activeCount":99},[],{"trials":2221,"activeCount":99},[2222,2226],{"nctId":403,"briefTitle":404,"status":105,"phases":2223,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":2224,"interventions":2225},[90],[18,15],[411,412,413,414,394],{"nctId":527,"briefTitle":528,"status":515,"phases":2227,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":2228,"interventions":2229},[90],[15],[411,412,413,66,414],{"trials":2231,"activeCount":99},[2232],{"nctId":1122,"briefTitle":1123,"status":105,"phases":2233,"primaryCompletion":1125,"completion":1125,"start":1126,"enrollment":1127,"conditions":2234,"interventions":2235},[91],[21,24],[1130,1131,1132,1133],{"trials":2237,"activeCount":99},[2238],{"nctId":2239,"briefTitle":2240,"status":105,"phases":2241,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":1159,"conditions":2244,"interventions":2245},"NCT00038506","Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure",[92],"2004-08","2002-03",[24],[2246,1133],"abacavir\u002Flamivudine\u002Fzidovudine",{"trials":2248,"activeCount":99},[],{"intervention":2250,"totalTrials":36,"cells":2251},"Raltegravir",{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2266,"PHASE3":2268,"PHASE4":2293,"NA":2303},{"trials":2253,"activeCount":99},[],{"trials":2255,"activeCount":99},[2256],{"nctId":2257,"briefTitle":2258,"status":105,"phases":2259,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":110,"conditions":2262,"interventions":2263},"NCT01101893","A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects",[89],"2010-06","2010-04",[18],[2250,2264,2265],"GSK2248761","GSK2248761 + Raltegravir",{"trials":2267,"activeCount":99},[],{"trials":2269,"activeCount":99},[2270,2281],{"nctId":2271,"briefTitle":2272,"status":105,"phases":2273,"primaryCompletion":2274,"completion":2275,"start":2276,"enrollment":2277,"conditions":2278,"interventions":2279},"NCT01227824","A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily",[91],"2012-02-06","2016-12-27","2010-10-19",828,[21],[1922,2280],"raltegravir",{"nctId":2282,"briefTitle":2283,"status":105,"phases":2284,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":2289,"interventions":2290},"NCT01231516","A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults",[91],"2013-02-04","2021-02-02","2010-10-26",724,[18,15],[1922,2250,2291,2292],"GSK1349572 Placebo","Raltegravir Placebo",{"trials":2294,"activeCount":99},[2295],{"nctId":2296,"briefTitle":2297,"status":105,"phases":2298,"primaryCompletion":2299,"completion":2299,"start":2300,"enrollment":2056,"conditions":2301,"interventions":2302},"NCT00666705","A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects",[92],"2008-03","2008-02",[33],[735,735,2250,2250],{"trials":2304,"activeCount":99},[],{"intervention":190,"totalTrials":362,"cells":2306},{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2313,"PHASE4":2315,"NA":2331},{"trials":2308,"activeCount":99},[],{"trials":2310,"activeCount":99},[],{"trials":2312,"activeCount":99},[],{"trials":2314,"activeCount":99},[],{"trials":2316,"activeCount":99},[2317,2321],{"nctId":182,"briefTitle":183,"status":105,"phases":2318,"primaryCompletion":185,"completion":185,"start":186,"enrollment":187,"conditions":2319,"interventions":2320},[92],[15],[190,56],{"nctId":2322,"briefTitle":2323,"status":105,"phases":2324,"primaryCompletion":2325,"completion":2325,"start":2326,"enrollment":2327,"conditions":2328,"interventions":2329},"NCT05374525","A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States",[92],"2024-08-08","2022-05-18",287,[15],[190,2330],"Cabotegravir OLI",{"trials":2332,"activeCount":99},[],{"intervention":2246,"totalTrials":137,"cells":2334},{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2341,"PHASE4":2343,"NA":2349},{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":99},[],{"trials":2340,"activeCount":99},[],{"trials":2342,"activeCount":99},[],{"trials":2344,"activeCount":99},[2345],{"nctId":2239,"briefTitle":2240,"status":105,"phases":2346,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":1159,"conditions":2347,"interventions":2348},[92],[24],[2246,1133],{"trials":2350,"activeCount":99},[],{"intervention":2352,"totalTrials":137,"cells":2353},"HIV therapy",{"EARLY_PHASE1":2354,"PHASE1":2356,"PHASE2":2358,"PHASE3":2360,"PHASE4":2362,"NA":2371},{"trials":2355,"activeCount":99},[],{"trials":2357,"activeCount":99},[],{"trials":2359,"activeCount":99},[],{"trials":2361,"activeCount":99},[],{"trials":2363,"activeCount":99},[2364],{"nctId":2365,"briefTitle":2366,"status":105,"phases":2367,"primaryCompletion":602,"completion":1975,"start":2047,"enrollment":2368,"conditions":2369,"interventions":2370},"NCT01275625","Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia",[92],98,[27],[2352],{"trials":2372,"activeCount":99},[],{"intervention":2374,"totalTrials":137,"cells":2375},"CABENUVA",{"EARLY_PHASE1":2376,"PHASE1":2378,"PHASE2":2380,"PHASE3":2382,"PHASE4":2384,"NA":2394},{"trials":2377,"activeCount":99},[],{"trials":2379,"activeCount":99},[],{"trials":2381,"activeCount":99},[],{"trials":2383,"activeCount":99},[],{"trials":2385,"activeCount":99},[2386],{"nctId":2387,"briefTitle":2388,"status":105,"phases":2389,"primaryCompletion":2390,"completion":2390,"start":2391,"enrollment":1336,"conditions":2392,"interventions":2393},"NCT04982445","Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)",[92],"2024-01-31","2021-11-18",[15],[2374],{"trials":2395,"activeCount":99},[],{"intervention":2397,"totalTrials":137,"cells":2398},"Vardenafil",{"EARLY_PHASE1":2399,"PHASE1":2401,"PHASE2":2403,"PHASE3":2405,"PHASE4":2407,"NA":2417},{"trials":2400,"activeCount":99},[],{"trials":2402,"activeCount":99},[],{"trials":2404,"activeCount":99},[],{"trials":2406,"activeCount":99},[],{"trials":2408,"activeCount":99},[2409],{"nctId":2410,"briefTitle":2411,"status":105,"phases":2412,"primaryCompletion":2413,"completion":2413,"start":2414,"enrollment":2056,"conditions":2415,"interventions":2416},"NCT00853840","Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc",[92],"2008-05","2008-04",[35],[735,2397,735],{"trials":2418,"activeCount":99},[],{"intervention":2330,"totalTrials":137,"cells":2420},{"EARLY_PHASE1":2421,"PHASE1":2423,"PHASE2":2425,"PHASE3":2427,"PHASE4":2429,"NA":2435},{"trials":2422,"activeCount":99},[],{"trials":2424,"activeCount":99},[],{"trials":2426,"activeCount":99},[],{"trials":2428,"activeCount":99},[],{"trials":2430,"activeCount":99},[2431],{"nctId":2322,"briefTitle":2323,"status":105,"phases":2432,"primaryCompletion":2325,"completion":2325,"start":2326,"enrollment":2327,"conditions":2433,"interventions":2434},[92],[15],[190,2330],{"trials":2436,"activeCount":99},[],{"intervention":2032,"totalTrials":137,"cells":2438},{"EARLY_PHASE1":2439,"PHASE1":2441,"PHASE2":2443,"PHASE3":2445,"PHASE4":2447,"NA":2453},{"trials":2440,"activeCount":99},[],{"trials":2442,"activeCount":99},[],{"trials":2444,"activeCount":99},[],{"trials":2446,"activeCount":99},[],{"trials":2448,"activeCount":99},[2449],{"nctId":2024,"briefTitle":2025,"status":105,"phases":2450,"primaryCompletion":2027,"completion":2027,"start":2028,"enrollment":1950,"conditions":2451,"interventions":2452},[92],[2030],[735,735,413,2032,735,413,2032,735,413,2032,735,735,735],{"trials":2454,"activeCount":99},[],{"intervention":2456,"totalTrials":137,"cells":2457},"Reyataz + Norvir + Truvada",{"EARLY_PHASE1":2458,"PHASE1":2460,"PHASE2":2462,"PHASE3":2464,"PHASE4":2466,"NA":2476},{"trials":2459,"activeCount":99},[],{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[],{"trials":2465,"activeCount":99},[],{"trials":2467,"activeCount":99},[2468],{"nctId":2469,"briefTitle":2470,"status":105,"phases":2471,"primaryCompletion":2067,"completion":2092,"start":2261,"enrollment":2472,"conditions":2473,"interventions":2474},"NCT01102972","A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)",[92],297,[18],[2456,2475],"Reyataz + Epzicom",{"trials":2477,"activeCount":99},[],{"intervention":2475,"totalTrials":137,"cells":2479},{"EARLY_PHASE1":2480,"PHASE1":2482,"PHASE2":2484,"PHASE3":2486,"PHASE4":2488,"NA":2494},{"trials":2481,"activeCount":99},[],{"trials":2483,"activeCount":99},[],{"trials":2485,"activeCount":99},[],{"trials":2487,"activeCount":99},[],{"trials":2489,"activeCount":99},[2490],{"nctId":2469,"briefTitle":2470,"status":105,"phases":2491,"primaryCompletion":2067,"completion":2092,"start":2261,"enrollment":2472,"conditions":2492,"interventions":2493},[92],[18],[2456,2475],{"trials":2495,"activeCount":99},[],{"intervention":1173,"totalTrials":137,"cells":2497},{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2504,"PHASE4":2506,"NA":2512},{"trials":2499,"activeCount":99},[],{"trials":2501,"activeCount":99},[],{"trials":2503,"activeCount":99},[],{"trials":2505,"activeCount":99},[],{"trials":2507,"activeCount":99},[2508],{"nctId":1165,"briefTitle":1166,"status":105,"phases":2509,"primaryCompletion":1168,"completion":1169,"start":1170,"enrollment":466,"conditions":2510,"interventions":2511},[92],[18],[333,1173],{"trials":2513,"activeCount":99},[],{"intervention":2155,"totalTrials":137,"cells":2515},{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2520,"PHASE3":2522,"PHASE4":2524,"NA":2530},{"trials":2517,"activeCount":99},[],{"trials":2519,"activeCount":99},[],{"trials":2521,"activeCount":99},[],{"trials":2523,"activeCount":99},[],{"trials":2525,"activeCount":99},[2526],{"nctId":2148,"briefTitle":2149,"status":105,"phases":2527,"completion":2151,"start":2152,"enrollment":542,"conditions":2528,"interventions":2529},[92],[18],[1997,2155],{"trials":2531,"activeCount":99},[],{"intervention":2533,"totalTrials":137,"cells":2534},"GI265235",{"EARLY_PHASE1":2535,"PHASE1":2537,"PHASE2":2539,"PHASE3":2541,"PHASE4":2543,"NA":2554},{"trials":2536,"activeCount":99},[],{"trials":2538,"activeCount":99},[],{"trials":2540,"activeCount":99},[],{"trials":2542,"activeCount":99},[],{"trials":2544,"activeCount":99},[2545],{"nctId":2546,"briefTitle":2547,"status":105,"phases":2548,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":2551,"conditions":2552,"interventions":2553},"NCT00441688","Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients",[92],"2007-06-01","2007-03-15",974,[18],[2533],{"trials":2555,"activeCount":99},[],{"intervention":1922,"totalTrials":110,"cells":2557},{"EARLY_PHASE1":2558,"PHASE1":2560,"PHASE2":2632,"PHASE3":2662,"PHASE4":2672,"NA":2674},{"trials":2559,"activeCount":99},[],{"trials":2561,"activeCount":99},[2562,2566,2575,2581,2590,2599,2606,2613,2620,2624],{"nctId":1915,"briefTitle":1916,"status":105,"phases":2563,"primaryCompletion":1918,"completion":1918,"start":1919,"enrollment":691,"conditions":2564,"interventions":2565},[89],[30],[1922,1923,413],{"nctId":2567,"briefTitle":2568,"status":105,"phases":2569,"primaryCompletion":2570,"completion":2570,"start":2571,"enrollment":25,"conditions":2572,"interventions":2573},"NCT01098526","GSK1349572 Drug Interaction Study With Efavirenz",[89],"2010-05-26","2010-03-16",[30],[1922,2574],"Efavirenz",{"nctId":2576,"briefTitle":2577,"status":2201,"phases":2578,"primaryCompletion":1974,"completion":2047,"start":1974,"enrollment":99,"conditions":2579,"interventions":2580},"NCT01283100","A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.",[89],[21],[1922,2264],{"nctId":2582,"briefTitle":2583,"status":105,"phases":2584,"primaryCompletion":1918,"completion":1918,"start":2004,"enrollment":805,"conditions":2585,"interventions":2587},"NCT01214993","A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects",[89],[2586],"Infections, Human Immunodeficiency Virus and Tuberculosis",[1922,2588,2589],"Iohexol","Para-aminohippurate",{"nctId":2591,"briefTitle":2592,"status":105,"phases":2593,"primaryCompletion":2594,"completion":2594,"start":2595,"enrollment":466,"conditions":2596,"interventions":2598},"NCT01231529","GSK1349572 Hepatic Impairment Study",[89],"2011-06-04","2010-11-19",[2058,2597,18,15],"Hepatic Impairment",[1922],{"nctId":2600,"briefTitle":2601,"status":105,"phases":2602,"primaryCompletion":493,"completion":465,"start":583,"enrollment":691,"conditions":2603,"interventions":2604},"NCT01231542","Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers",[89],[18],[1922,2605,113],"Rifampin",{"nctId":2607,"briefTitle":2608,"status":105,"phases":2609,"primaryCompletion":2047,"completion":2047,"start":2610,"enrollment":1001,"conditions":2611,"interventions":2612},"NCT01332565","A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects",[89],"2011-04",[18],[1922],{"nctId":2614,"briefTitle":2615,"status":105,"phases":2616,"primaryCompletion":2617,"completion":2617,"start":2300,"enrollment":1336,"conditions":2618,"interventions":2619},"NCT00631592","GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study",[89],"2008-06",[2058],[1922],{"nctId":1933,"briefTitle":1934,"status":105,"phases":2621,"primaryCompletion":1936,"completion":1936,"start":1937,"enrollment":22,"conditions":2622,"interventions":2623},[89],[1939],[714,715,413,1941,1922],{"nctId":2625,"briefTitle":2626,"status":105,"phases":2627,"primaryCompletion":2628,"completion":2628,"start":2629,"enrollment":2056,"conditions":2630,"interventions":2631},"NCT01068925","Drug Interaction Study Between GSK1349572 and Tipranavir\u002FRitonavir in Healthy Volunteers",[89],"2010-04-05","2010-02-15",[18,15],[1922],{"trials":2633,"activeCount":99},[2634,2642,2651],{"nctId":2635,"briefTitle":2636,"status":105,"phases":2637,"primaryCompletion":2638,"completion":2638,"start":2617,"enrollment":2639,"conditions":2640,"interventions":2641},"NCT00708110","Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults",[90],"2008-08",35,[18],[1922],{"nctId":2643,"briefTitle":2644,"status":105,"phases":2645,"primaryCompletion":1918,"completion":2646,"start":2647,"enrollment":2648,"conditions":2649,"interventions":2650},"NCT00950859","A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir",[90],"2015-01","2009-08",51,[18],[1922,1922],{"nctId":2652,"briefTitle":2653,"status":105,"phases":2654,"primaryCompletion":2655,"completion":2656,"start":2657,"enrollment":2658,"conditions":2659,"interventions":2660},"NCT00951015","A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects",[90],"2010-02-26","2016-12-22","2009-07-30",208,[18],[1922,2661],"efavirenz",{"trials":2663,"activeCount":99},[2664,2668],{"nctId":2271,"briefTitle":2272,"status":105,"phases":2665,"primaryCompletion":2274,"completion":2275,"start":2276,"enrollment":2277,"conditions":2666,"interventions":2667},[91],[21],[1922,2280],{"nctId":2282,"briefTitle":2283,"status":105,"phases":2669,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":2670,"interventions":2671},[91],[18,15],[1922,2250,2291,2292],{"trials":2673,"activeCount":99},[],{"trials":2675,"activeCount":99},[],{"intervention":573,"totalTrials":36,"cells":2677},{"EARLY_PHASE1":2678,"PHASE1":2680,"PHASE2":2682,"PHASE3":2699,"PHASE4":2713,"NA":2715},{"trials":2679,"activeCount":99},[],{"trials":2681,"activeCount":99},[],{"trials":2683,"activeCount":99},[2684],{"nctId":2685,"briefTitle":2686,"status":105,"phases":2687,"primaryCompletion":2688,"completion":2689,"start":2690,"enrollment":2691,"conditions":2692,"interventions":2693},"NCT01641809","Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine",[90],"2013-10-10","2019-01-15","2012-08-06",244,[18,15],[2694,2695,2696,2697,2698,573],"GSK1265744 10 mg","GSK1265744 30 mg","GSK1265744 60 mg","Efavirenz 600 mg","Rilpivirine 25 mg",{"trials":2700,"activeCount":99},[2701,2705,2709],{"nctId":1122,"briefTitle":1123,"status":105,"phases":2702,"primaryCompletion":1125,"completion":1125,"start":1126,"enrollment":1127,"conditions":2703,"interventions":2704},[91],[21,24],[1130,1131,1132,1133],{"nctId":1135,"briefTitle":1136,"status":105,"phases":2706,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":2707,"interventions":2708},[91],[21,24],[1130,1131,1132],{"nctId":563,"briefTitle":564,"status":105,"phases":2710,"primaryCompletion":566,"completion":567,"start":568,"enrollment":569,"conditions":2711,"interventions":2712},[91],[21],[66,572,573,574,575,576],{"trials":2714,"activeCount":99},[],{"trials":2716,"activeCount":99},[],{"intervention":2718,"totalTrials":36,"cells":2719},"DTG 50 mg",{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2739,"PHASE3":2741,"PHASE4":2774,"NA":2776},{"trials":2721,"activeCount":99},[],{"trials":2723,"activeCount":99},[2724],{"nctId":2725,"briefTitle":2726,"status":105,"phases":2727,"primaryCompletion":2728,"completion":2728,"start":2729,"enrollment":2730,"conditions":2731,"interventions":2732},"NCT02373930","Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects",[89],"2015-09","2015-02",63,[18],[2718,2733,2734,2735,2736,2737,2738],"RPV 25 mg","DTG\u002FRPV 50 mg\u002F25 mg: Product Code AS","DTG\u002FRPV 50 mg\u002F25 mg: Product Code AM","DTG\u002FRPV 50 mg\u002F25 mg: Product Code AQ","DTG\u002FRPV 50 mg\u002F25 mg: Product Code AK","DTG\u002FRPV 50 mg\u002F25 mg: Product Code AR",{"trials":2740,"activeCount":99},[],{"trials":2742,"activeCount":99},[2743,2754,2765],{"nctId":2744,"briefTitle":2745,"status":105,"phases":2746,"primaryCompletion":2747,"completion":2748,"start":2749,"enrollment":2750,"conditions":2751,"interventions":2752},"NCT02178592","Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection",[91],"2017-11-02","2020-03-06","2015-01-23",113,[18,15],[2718,2753],"EFV 600 mg",{"nctId":2755,"briefTitle":2756,"status":105,"phases":2757,"primaryCompletion":2758,"completion":2759,"start":2760,"enrollment":2761,"conditions":2762,"interventions":2763},"NCT02422797","Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)",[91],"2016-09-16","2023-05-25","2015-04-21",518,[15],[2718,2733,2764],"CAR",{"nctId":2766,"briefTitle":2767,"status":105,"phases":2768,"primaryCompletion":2758,"completion":2769,"start":2770,"enrollment":2771,"conditions":2772,"interventions":2773},"NCT02429791","Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)",[91],"2023-05-30","2015-04-14",510,[15],[2718,2733,2764],{"trials":2775,"activeCount":99},[],{"trials":2777,"activeCount":99},[],{"intervention":2779,"totalTrials":178,"cells":2780},"GW873140",{"EARLY_PHASE1":2781,"PHASE1":2783,"PHASE2":2785,"PHASE3":2807,"PHASE4":2817,"NA":2819},{"trials":2782,"activeCount":99},[],{"trials":2784,"activeCount":99},[],{"trials":2786,"activeCount":99},[2787,2797],{"nctId":2788,"briefTitle":2789,"status":515,"phases":2790,"primaryCompletion":2791,"completion":2791,"start":2792,"enrollment":2793,"conditions":2794,"interventions":2795},"NCT00104429","GW873140 In Combination With Combivir In HIV Infected Subjects",[90],"2006-01","2005-01",125,[21,24],[2779,2796],"Combivir",{"nctId":2798,"briefTitle":2799,"status":515,"phases":2800,"primaryCompletion":2801,"completion":2801,"start":2802,"enrollment":2803,"conditions":2804,"interventions":2805},"NCT00102778","GW873140 In Combination With Kaletra In HIV Infected Subjects",[90],"2007-09","2004-12",175,[21,24],[2779,2806],"Kaletra",{"trials":2808,"activeCount":99},[2809],{"nctId":2810,"briefTitle":2811,"status":515,"phases":2812,"primaryCompletion":2813,"completion":2813,"start":2814,"enrollment":1219,"conditions":2815,"interventions":2816},"NCT00197145","Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects",[91],"2007-09-11","2005-07-21",[21],[2779],{"trials":2818,"activeCount":99},[],{"trials":2820,"activeCount":99},[],{"intervention":412,"totalTrials":178,"cells":2822},{"EARLY_PHASE1":2823,"PHASE1":2825,"PHASE2":2827,"PHASE3":2837,"PHASE4":2843,"NA":2845},{"trials":2824,"activeCount":99},[],{"trials":2826,"activeCount":99},[],{"trials":2828,"activeCount":99},[2829,2833],{"nctId":403,"briefTitle":404,"status":105,"phases":2830,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":2831,"interventions":2832},[90],[18,15],[411,412,413,414,394],{"nctId":527,"briefTitle":528,"status":515,"phases":2834,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":2835,"interventions":2836},[90],[15],[411,412,413,66,414],{"trials":2838,"activeCount":99},[2839],{"nctId":2010,"briefTitle":2011,"status":105,"phases":2840,"primaryCompletion":2013,"completion":2014,"start":2015,"enrollment":2016,"conditions":2841,"interventions":2842},[91],[18,15],[2019,412,413,2020],{"trials":2844,"activeCount":99},[],{"trials":2846,"activeCount":99},[],{"intervention":2848,"totalTrials":178,"cells":2849},"Optimized Background Therapy",{"EARLY_PHASE1":2850,"PHASE1":2852,"PHASE2":2854,"PHASE3":2856,"PHASE4":2882,"NA":2884},{"trials":2851,"activeCount":99},[],{"trials":2853,"activeCount":99},[],{"trials":2855,"activeCount":99},[],{"trials":2857,"activeCount":99},[2858,2867,2876],{"nctId":2859,"briefTitle":2860,"status":105,"phases":2861,"primaryCompletion":2862,"completion":1937,"start":2863,"enrollment":2864,"conditions":2865,"interventions":2866},"NCT00098748","Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects",[90,91],"2005-12","2004-11",190,[15],[2848,2210,2848,2210,2848],{"nctId":2868,"briefTitle":2869,"status":105,"phases":2870,"primaryCompletion":2871,"completion":2610,"start":2802,"enrollment":2872,"conditions":2873,"interventions":2874},"NCT00098722","Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",[90,91],"2007-04",474,[15],[735,2875,735,2875,2875],"optimized background therapy",{"nctId":2877,"briefTitle":2869,"status":105,"phases":2878,"primaryCompletion":2871,"completion":2610,"start":2863,"enrollment":2879,"conditions":2880,"interventions":2881},"NCT00098306",[90,91],601,[15],[735,2848,2848,2848],{"trials":2883,"activeCount":99},[],{"trials":2885,"activeCount":99},[],{"intervention":2887,"totalTrials":178,"cells":2888},"Fosamprenavir\u002Fritonavir",{"EARLY_PHASE1":2889,"PHASE1":2891,"PHASE2":2906,"PHASE3":2908,"PHASE4":2920,"NA":2922},{"trials":2890,"activeCount":99},[],{"trials":2892,"activeCount":99},[2893,2900],{"nctId":2894,"briefTitle":2895,"status":105,"phases":2896,"primaryCompletion":2047,"completion":2047,"start":2610,"enrollment":494,"conditions":2897,"interventions":2898},"NCT01290211","Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir\u002FRitonavir In Healthy Subjects",[89],[33],[735,2887,2899,735,2887,2899],"Maraviroc + Fosamprenavir\u002Fritonavir",{"nctId":2901,"briefTitle":2895,"status":515,"phases":2902,"primaryCompletion":2004,"completion":2004,"start":2903,"enrollment":456,"conditions":2904,"interventions":2905},"NCT01140412",[89],"2010-07",[33],[735,2887,2899,735,2887,2899],{"trials":2907,"activeCount":99},[],{"trials":2909,"activeCount":99},[2910],{"nctId":2911,"briefTitle":2912,"status":105,"phases":2913,"primaryCompletion":2638,"completion":2638,"start":2914,"enrollment":2915,"conditions":2916,"interventions":2918},"NCT00450580","HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults",[91],"2007-03",212,[21,2917],"HIV-1 Infection",[2919],"fosamprenavir\u002Fritonavir",{"trials":2921,"activeCount":99},[],{"trials":2923,"activeCount":99},[],{"intervention":1131,"totalTrials":178,"cells":2925},{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2930,"PHASE3":2932,"PHASE4":2950,"NA":2952},{"trials":2927,"activeCount":99},[],{"trials":2929,"activeCount":99},[],{"trials":2931,"activeCount":99},[],{"trials":2933,"activeCount":99},[2934,2938,2946],{"nctId":1122,"briefTitle":1123,"status":105,"phases":2935,"primaryCompletion":1125,"completion":1125,"start":1126,"enrollment":1127,"conditions":2936,"interventions":2937},[91],[21,24],[1130,1131,1132,1133],{"nctId":2939,"briefTitle":2940,"status":105,"phases":2941,"primaryCompletion":2903,"completion":2903,"start":2914,"enrollment":2942,"conditions":2943,"interventions":2944},"NCT00440947","Induction\u002FSimplification With Atazanavir + Ritonavir + Abacavir\u002FLamivudine Fixed-Dose Combination In HIV-1 Infection",[91],515,[21,24],[2945,2945],"Abacavir",{"nctId":1135,"briefTitle":1136,"status":105,"phases":2947,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":2948,"interventions":2949},[91],[21,24],[1130,1131,1132],{"trials":2951,"activeCount":99},[],{"trials":2953,"activeCount":99},[],{"intervention":2733,"totalTrials":178,"cells":2955},{"EARLY_PHASE1":2956,"PHASE1":2958,"PHASE2":2964,"PHASE3":2966,"PHASE4":2976,"NA":2978},{"trials":2957,"activeCount":99},[],{"trials":2959,"activeCount":99},[2960],{"nctId":2725,"briefTitle":2726,"status":105,"phases":2961,"primaryCompletion":2728,"completion":2728,"start":2729,"enrollment":2730,"conditions":2962,"interventions":2963},[89],[18],[2718,2733,2734,2735,2736,2737,2738],{"trials":2965,"activeCount":99},[],{"trials":2967,"activeCount":99},[2968,2972],{"nctId":2755,"briefTitle":2756,"status":105,"phases":2969,"primaryCompletion":2758,"completion":2759,"start":2760,"enrollment":2761,"conditions":2970,"interventions":2971},[91],[15],[2718,2733,2764],{"nctId":2766,"briefTitle":2767,"status":105,"phases":2973,"primaryCompletion":2758,"completion":2769,"start":2770,"enrollment":2771,"conditions":2974,"interventions":2975},[91],[15],[2718,2733,2764],{"trials":2977,"activeCount":99},[],{"trials":2979,"activeCount":99},[],{"intervention":2764,"totalTrials":178,"cells":2981},{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2986,"PHASE3":2988,"PHASE4":3009,"NA":3011},{"trials":2983,"activeCount":99},[],{"trials":2985,"activeCount":99},[],{"trials":2987,"activeCount":99},[],{"trials":2989,"activeCount":99},[2990,3001,3005],{"nctId":2991,"briefTitle":2992,"status":105,"phases":2993,"primaryCompletion":2994,"completion":2995,"start":2996,"enrollment":2997,"conditions":2998,"interventions":2999},"NCT04021290","Regimen Switch to Dolutegravir\u002FLamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)",[91],"2021-04-23","2022-09-09","2019-11-11",493,[15],[3000,2764],"DTG\u002F3TC FDC",{"nctId":2755,"briefTitle":2756,"status":105,"phases":3002,"primaryCompletion":2758,"completion":2759,"start":2760,"enrollment":2761,"conditions":3003,"interventions":3004},[91],[15],[2718,2733,2764],{"nctId":2766,"briefTitle":2767,"status":105,"phases":3006,"primaryCompletion":2758,"completion":2769,"start":2770,"enrollment":2771,"conditions":3007,"interventions":3008},[91],[15],[2718,2733,2764],{"trials":3010,"activeCount":99},[],{"trials":3012,"activeCount":99},[],{"intervention":234,"totalTrials":362,"cells":3014},{"EARLY_PHASE1":3015,"PHASE1":3017,"PHASE2":3019,"PHASE3":3025,"PHASE4":3031,"NA":3033},{"trials":3016,"activeCount":99},[],{"trials":3018,"activeCount":99},[],{"trials":3020,"activeCount":99},[3021],{"nctId":225,"briefTitle":226,"status":105,"phases":3022,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":3023,"interventions":3024},[90],[15],[194,234,235,170],{"trials":3026,"activeCount":99},[3027],{"nctId":263,"briefTitle":264,"status":105,"phases":3028,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":3029,"interventions":3030},[91],[15],[272,194,273,234],{"trials":3032,"activeCount":99},[],{"trials":3034,"activeCount":99},[],{"intervention":597,"totalTrials":362,"cells":3036},{"EARLY_PHASE1":3037,"PHASE1":3039,"PHASE2":3041,"PHASE3":3043,"PHASE4":3053,"NA":3055},{"trials":3038,"activeCount":99},[],{"trials":3040,"activeCount":99},[],{"trials":3042,"activeCount":99},[],{"trials":3044,"activeCount":99},[3045,3049],{"nctId":588,"briefTitle":589,"status":105,"phases":3046,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":3047,"interventions":3048},[91],[18,15],[66,333,597],{"nctId":609,"briefTitle":610,"status":105,"phases":3050,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":3051,"interventions":3052},[91],[18,15],[66,333,597],{"trials":3054,"activeCount":99},[],{"trials":3056,"activeCount":99},[],{"intervention":3058,"totalTrials":362,"cells":3059},"ABC\u002FDTG\u002F3TC FDC",{"EARLY_PHASE1":3060,"PHASE1":3062,"PHASE2":3072,"PHASE3":3074,"PHASE4":3087,"NA":3089},{"trials":3061,"activeCount":99},[],{"trials":3063,"activeCount":99},[3064],{"nctId":3065,"briefTitle":3066,"status":105,"phases":3067,"primaryCompletion":3068,"completion":3068,"start":3069,"enrollment":25,"conditions":3070,"interventions":3071},"NCT02539576","Pharmacokinetics, Safety and Tolerability Study of Abacavir\u002F Dolutegravir\u002F Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects",[89],"2015-11","2015-10",[18],[3058],{"trials":3073,"activeCount":99},[],{"trials":3075,"activeCount":99},[3076],{"nctId":3077,"briefTitle":3078,"status":105,"phases":3079,"primaryCompletion":3080,"completion":3081,"start":3082,"enrollment":3083,"conditions":3084,"interventions":3085},"NCT02105987","A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir\u002FDolutegravir\u002F Lamivudine From Current Antiretroviral Regimen",[91],"2015-04","2015-12","2014-04",555,[18],[3058,3086],"Ongoing cART regimen",{"trials":3088,"activeCount":99},[],{"trials":3090,"activeCount":99},[],{"intervention":3092,"totalTrials":362,"cells":3093},"DTG\u002F3TC",{"EARLY_PHASE1":3094,"PHASE1":3096,"PHASE2":3098,"PHASE3":3100,"PHASE4":3122,"NA":3124},{"trials":3095,"activeCount":99},[],{"trials":3097,"activeCount":99},[],{"trials":3099,"activeCount":99},[],{"trials":3101,"activeCount":99},[3102,3111],{"nctId":3103,"briefTitle":3104,"status":105,"phases":3105,"primaryCompletion":3106,"completion":3107,"start":1291,"enrollment":3108,"conditions":3109,"interventions":3110},"NCT05911360","A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG\u002F3TC FDC From BIC\u002FFTC\u002FTAF",[91],"2026-01-23","2026-02-09",203,[27,15],[3092],{"nctId":3112,"briefTitle":3113,"status":105,"phases":3114,"primaryCompletion":3115,"completion":3116,"start":1411,"enrollment":3117,"conditions":3118,"interventions":3119},"NCT05917509","A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy",[91],"2025-09-16","2026-04-20",171,[15],[3092,3120,3121],"Cabotegravir (CAB) LA","Rilpivirine (RPV) LA",{"trials":3123,"activeCount":99},[],{"trials":3125,"activeCount":99},[],{"intervention":3127,"totalTrials":137,"cells":3128},"Dolutegravir 50 mg twice daily",{"EARLY_PHASE1":3129,"PHASE1":3131,"PHASE2":3133,"PHASE3":3135,"PHASE4":3147,"NA":3149},{"trials":3130,"activeCount":99},[],{"trials":3132,"activeCount":99},[],{"trials":3134,"activeCount":99},[],{"trials":3136,"activeCount":99},[3137],{"nctId":3138,"briefTitle":3139,"status":105,"phases":3140,"primaryCompletion":3141,"completion":3142,"start":3143,"enrollment":1950,"conditions":3144,"interventions":3145},"NCT01568892","Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and\u002For Elivitegravir",[91],"2012-10-31","2013-12-16","2012-04-18",[15],[3127,3146],"Dolutegravir placebo twice daily",{"trials":3148,"activeCount":99},[],{"trials":3150,"activeCount":99},[],{"intervention":3146,"totalTrials":137,"cells":3152},{"EARLY_PHASE1":3153,"PHASE1":3155,"PHASE2":3157,"PHASE3":3159,"PHASE4":3165,"NA":3167},{"trials":3154,"activeCount":99},[],{"trials":3156,"activeCount":99},[],{"trials":3158,"activeCount":99},[],{"trials":3160,"activeCount":99},[3161],{"nctId":3138,"briefTitle":3139,"status":105,"phases":3162,"primaryCompletion":3141,"completion":3142,"start":3143,"enrollment":1950,"conditions":3163,"interventions":3164},[91],[15],[3127,3146],{"trials":3166,"activeCount":99},[],{"trials":3168,"activeCount":99},[],{"intervention":272,"totalTrials":137,"cells":3170},{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3175,"PHASE3":3177,"PHASE4":3183,"NA":3185},{"trials":3172,"activeCount":99},[],{"trials":3174,"activeCount":99},[],{"trials":3176,"activeCount":99},[],{"trials":3178,"activeCount":99},[3179],{"nctId":263,"briefTitle":264,"status":105,"phases":3180,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":3181,"interventions":3182},[91],[15],[272,194,273,234],{"trials":3184,"activeCount":99},[],{"trials":3186,"activeCount":99},[],{"intervention":273,"totalTrials":137,"cells":3188},{"EARLY_PHASE1":3189,"PHASE1":3191,"PHASE2":3193,"PHASE3":3195,"PHASE4":3201,"NA":3203},{"trials":3190,"activeCount":99},[],{"trials":3192,"activeCount":99},[],{"trials":3194,"activeCount":99},[],{"trials":3196,"activeCount":99},[3197],{"nctId":263,"briefTitle":264,"status":105,"phases":3198,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":3199,"interventions":3200},[91],[15],[272,194,273,234],{"trials":3202,"activeCount":99},[],{"trials":3204,"activeCount":99},[],{"intervention":3206,"totalTrials":137,"cells":3207},"No intervention; Observational study",{"EARLY_PHASE1":3208,"PHASE1":3210,"PHASE2":3212,"PHASE3":3214,"PHASE4":3223,"NA":3225},{"trials":3209,"activeCount":99},[],{"trials":3211,"activeCount":99},[],{"trials":3213,"activeCount":99},[],{"trials":3215,"activeCount":99},[3216],{"nctId":3217,"briefTitle":3218,"status":105,"phases":3219,"primaryCompletion":2791,"completion":2791,"start":3220,"enrollment":1412,"conditions":3221,"interventions":3222},"NCT00242840","Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)",[91],"2003-06",[21,24],[3206],{"trials":3224,"activeCount":99},[],{"trials":3226,"activeCount":99},[],{"intervention":3228,"totalTrials":137,"cells":3229},"Emtricitabine\u002Ftenofovir",{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3236,"PHASE4":3248,"NA":3250},{"trials":3231,"activeCount":99},[],{"trials":3233,"activeCount":99},[],{"trials":3235,"activeCount":99},[],{"trials":3237,"activeCount":99},[3238],{"nctId":3239,"briefTitle":3240,"status":515,"phases":3241,"primaryCompletion":3242,"completion":1057,"start":485,"enrollment":3243,"conditions":3244,"interventions":3246},"NCT01345630","Comparative Trial Of Maraviroc Versus Emtricitabine\u002FTenofovir Both With Darunavir\u002FRitonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1",[91],"2013-08",813,[3245],"HIV-1",[735,3228,3247],"darunavir\u002Fritonavir 800\u002F100 mg",{"trials":3249,"activeCount":99},[],{"trials":3251,"activeCount":99},[],{"intervention":3247,"totalTrials":137,"cells":3253},{"EARLY_PHASE1":3254,"PHASE1":3256,"PHASE2":3258,"PHASE3":3260,"PHASE4":3266,"NA":3268},{"trials":3255,"activeCount":99},[],{"trials":3257,"activeCount":99},[],{"trials":3259,"activeCount":99},[],{"trials":3261,"activeCount":99},[3262],{"nctId":3239,"briefTitle":3240,"status":515,"phases":3263,"primaryCompletion":3242,"completion":1057,"start":485,"enrollment":3243,"conditions":3264,"interventions":3265},[91],[3245],[735,3228,3247],{"trials":3267,"activeCount":99},[],{"trials":3269,"activeCount":99},[],{"intervention":3271,"totalTrials":137,"cells":3272},"Subjects do not receive study medication in this study 202094",{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3277,"PHASE3":3279,"PHASE4":3289,"NA":3291},{"trials":3274,"activeCount":99},[],{"trials":3276,"activeCount":99},[],{"trials":3278,"activeCount":99},[],{"trials":3280,"activeCount":99},[3281],{"nctId":3282,"briefTitle":3283,"status":105,"phases":3284,"primaryCompletion":2758,"completion":3285,"start":3286,"enrollment":780,"conditions":3287,"interventions":3288},"NCT02478632","Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen",[91],"2018-08-17","2015-06-12",[15],[3271],{"trials":3290,"activeCount":99},[],{"trials":3292,"activeCount":99},[],{"intervention":3294,"totalTrials":137,"cells":3295},"DTG + 3TC",{"EARLY_PHASE1":3296,"PHASE1":3298,"PHASE2":3300,"PHASE3":3302,"PHASE4":3315,"NA":3317},{"trials":3297,"activeCount":99},[],{"trials":3299,"activeCount":99},[],{"trials":3301,"activeCount":99},[],{"trials":3303,"activeCount":99},[3304],{"nctId":3305,"briefTitle":3306,"status":105,"phases":3307,"primaryCompletion":3308,"completion":3309,"start":3310,"enrollment":3311,"conditions":3312,"interventions":3313},"NCT03446573","Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)",[91],"2019-05-20","2022-05-03","2018-01-18",743,[15],[3294,3314],"TAF based regimen",{"trials":3316,"activeCount":99},[],{"trials":3318,"activeCount":99},[],{"intervention":3314,"totalTrials":137,"cells":3320},{"EARLY_PHASE1":3321,"PHASE1":3323,"PHASE2":3325,"PHASE3":3327,"PHASE4":3333,"NA":3335},{"trials":3322,"activeCount":99},[],{"trials":3324,"activeCount":99},[],{"trials":3326,"activeCount":99},[],{"trials":3328,"activeCount":99},[3329],{"nctId":3305,"briefTitle":3306,"status":105,"phases":3330,"primaryCompletion":3308,"completion":3309,"start":3310,"enrollment":3311,"conditions":3331,"interventions":3332},[91],[15],[3294,3314],{"trials":3334,"activeCount":99},[],{"trials":3336,"activeCount":99},[],{"intervention":3338,"totalTrials":137,"cells":3339},"Maraviroc + Zidovudine\u002FLamivudine",{"EARLY_PHASE1":3340,"PHASE1":3342,"PHASE2":3344,"PHASE3":3346,"PHASE4":3357,"NA":3359},{"trials":3341,"activeCount":99},[],{"trials":3343,"activeCount":99},[],{"trials":3345,"activeCount":99},[],{"trials":3347,"activeCount":99},[3348],{"nctId":3349,"briefTitle":3350,"status":105,"phases":3351,"primaryCompletion":2871,"completion":2092,"start":2863,"enrollment":3352,"conditions":3353,"interventions":3354},"NCT00098293","Trial of Maraviroc (UK-427,857) in Combination With Zidovudine\u002FLamivudine Versus Efavirenz in Combination With Zidovudine\u002FLamivudine",[91],916,[3245],[3338,3355,3356],"Efavirenz + Zidovudine\u002FLamivudine","Maraviroc (UK-427,857) + Zidovudine\u002FLamivudine",{"trials":3358,"activeCount":99},[],{"trials":3360,"activeCount":99},[],{"intervention":3355,"totalTrials":137,"cells":3362},{"EARLY_PHASE1":3363,"PHASE1":3365,"PHASE2":3367,"PHASE3":3369,"PHASE4":3375,"NA":3377},{"trials":3364,"activeCount":99},[],{"trials":3366,"activeCount":99},[],{"trials":3368,"activeCount":99},[],{"trials":3370,"activeCount":99},[3371],{"nctId":3349,"briefTitle":3350,"status":105,"phases":3372,"primaryCompletion":2871,"completion":2092,"start":2863,"enrollment":3352,"conditions":3373,"interventions":3374},[91],[3245],[3338,3355,3356],{"trials":3376,"activeCount":99},[],{"trials":3378,"activeCount":99},[],{"intervention":3356,"totalTrials":137,"cells":3380},{"EARLY_PHASE1":3381,"PHASE1":3383,"PHASE2":3385,"PHASE3":3387,"PHASE4":3393,"NA":3395},{"trials":3382,"activeCount":99},[],{"trials":3384,"activeCount":99},[],{"trials":3386,"activeCount":99},[],{"trials":3388,"activeCount":99},[3389],{"nctId":3349,"briefTitle":3350,"status":105,"phases":3390,"primaryCompletion":2871,"completion":2092,"start":2863,"enrollment":3352,"conditions":3391,"interventions":3392},[91],[3245],[3338,3355,3356],{"trials":3394,"activeCount":99},[],{"trials":3396,"activeCount":99},[],{"intervention":159,"totalTrials":137,"cells":3398},{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3403,"PHASE3":3405,"PHASE4":3411,"NA":3413},{"trials":3400,"activeCount":99},[],{"trials":3402,"activeCount":99},[],{"trials":3404,"activeCount":99},[],{"trials":3406,"activeCount":99},[3407],{"nctId":150,"briefTitle":151,"status":105,"phases":3408,"primaryCompletion":153,"completion":154,"start":155,"enrollment":156,"conditions":3409,"interventions":3410},[91],[15],[56,147,122,148,159],{"trials":3412,"activeCount":99},[],{"trials":3414,"activeCount":99},[],{"intervention":2291,"totalTrials":137,"cells":3416},{"EARLY_PHASE1":3417,"PHASE1":3419,"PHASE2":3421,"PHASE3":3423,"PHASE4":3429,"NA":3431},{"trials":3418,"activeCount":99},[],{"trials":3420,"activeCount":99},[],{"trials":3422,"activeCount":99},[],{"trials":3424,"activeCount":99},[3425],{"nctId":2282,"briefTitle":2283,"status":105,"phases":3426,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":3427,"interventions":3428},[91],[18,15],[1922,2250,2291,2292],{"trials":3430,"activeCount":99},[],{"trials":3432,"activeCount":99},[],{"intervention":2292,"totalTrials":137,"cells":3434},{"EARLY_PHASE1":3435,"PHASE1":3437,"PHASE2":3439,"PHASE3":3441,"PHASE4":3447,"NA":3449},{"trials":3436,"activeCount":99},[],{"trials":3438,"activeCount":99},[],{"trials":3440,"activeCount":99},[],{"trials":3442,"activeCount":99},[3443],{"nctId":2282,"briefTitle":2283,"status":105,"phases":3444,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":3445,"interventions":3446},[91],[18,15],[1922,2250,2291,2292],{"trials":3448,"activeCount":99},[],{"trials":3450,"activeCount":99},[],{"intervention":2753,"totalTrials":137,"cells":3452},{"EARLY_PHASE1":3453,"PHASE1":3455,"PHASE2":3457,"PHASE3":3459,"PHASE4":3465,"NA":3467},{"trials":3454,"activeCount":99},[],{"trials":3456,"activeCount":99},[],{"trials":3458,"activeCount":99},[],{"trials":3460,"activeCount":99},[3461],{"nctId":2744,"briefTitle":2745,"status":105,"phases":3462,"primaryCompletion":2747,"completion":2748,"start":2749,"enrollment":2750,"conditions":3463,"interventions":3464},[91],[18,15],[2718,2753],{"trials":3466,"activeCount":99},[],{"trials":3468,"activeCount":99},[],{"intervention":3470,"totalTrials":137,"cells":3471},"dolutegravir 50 mg OAD",{"EARLY_PHASE1":3472,"PHASE1":3474,"PHASE2":3476,"PHASE3":3478,"PHASE4":3492,"NA":3494},{"trials":3473,"activeCount":99},[],{"trials":3475,"activeCount":99},[],{"trials":3477,"activeCount":99},[],{"trials":3479,"activeCount":99},[3480],{"nctId":3481,"briefTitle":3482,"status":105,"phases":3483,"primaryCompletion":3484,"completion":3485,"start":3486,"enrollment":3487,"conditions":3488,"interventions":3489},"NCT01449929","Dolutegravir Compared to Darunavir\u002FRitonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects",[91],"2013-04-22","2016-12-26","2011-10-31",488,[18],[3470,3490,3491],"darunavir 800mg OAD","ritonavir 100mg OAD",{"trials":3493,"activeCount":99},[],{"trials":3495,"activeCount":99},[],{"intervention":3490,"totalTrials":137,"cells":3497},{"EARLY_PHASE1":3498,"PHASE1":3500,"PHASE2":3502,"PHASE3":3504,"PHASE4":3510,"NA":3512},{"trials":3499,"activeCount":99},[],{"trials":3501,"activeCount":99},[],{"trials":3503,"activeCount":99},[],{"trials":3505,"activeCount":99},[3506],{"nctId":3481,"briefTitle":3482,"status":105,"phases":3507,"primaryCompletion":3484,"completion":3485,"start":3486,"enrollment":3487,"conditions":3508,"interventions":3509},[91],[18],[3470,3490,3491],{"trials":3511,"activeCount":99},[],{"trials":3513,"activeCount":99},[],{"intervention":3491,"totalTrials":137,"cells":3515},{"EARLY_PHASE1":3516,"PHASE1":3518,"PHASE2":3520,"PHASE3":3522,"PHASE4":3528,"NA":3530},{"trials":3517,"activeCount":99},[],{"trials":3519,"activeCount":99},[],{"trials":3521,"activeCount":99},[],{"trials":3523,"activeCount":99},[3524],{"nctId":3481,"briefTitle":3482,"status":105,"phases":3525,"primaryCompletion":3484,"completion":3485,"start":3486,"enrollment":3487,"conditions":3526,"interventions":3527},[91],[18],[3470,3490,3491],{"trials":3529,"activeCount":99},[],{"trials":3531,"activeCount":99},[],{"intervention":3533,"totalTrials":137,"cells":3534},"CAB LA+RPV LA",{"EARLY_PHASE1":3535,"PHASE1":3537,"PHASE2":3539,"PHASE3":3541,"PHASE4":3553,"NA":3555},{"trials":3536,"activeCount":99},[],{"trials":3538,"activeCount":99},[],{"trials":3540,"activeCount":99},[],{"trials":3542,"activeCount":99},[3543],{"nctId":3544,"briefTitle":3545,"status":105,"phases":3546,"primaryCompletion":3547,"completion":3548,"start":3549,"enrollment":3550,"conditions":3551,"interventions":3552},"NCT04001803","Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)",[91],"2020-10-05","2022-03-18","2019-07-08",115,[15],[3533],{"trials":3554,"activeCount":99},[],{"trials":3556,"activeCount":99},[],{"intervention":3558,"totalTrials":137,"cells":3559},"DTG + 3TC FDC",{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3564,"PHASE3":3566,"PHASE4":3577,"NA":3579},{"trials":3561,"activeCount":99},[],{"trials":3563,"activeCount":99},[],{"trials":3565,"activeCount":99},[],{"trials":3567,"activeCount":99},[3568],{"nctId":3569,"briefTitle":3570,"status":105,"phases":3571,"primaryCompletion":3572,"completion":3573,"start":3574,"enrollment":760,"conditions":3575,"interventions":3576},"NCT03682848","Safety and Efficacy of Dolutegravir\u002FLamivudine (DTG\u002F3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents",[91],"2021-12-01","2025-05-22","2019-05-06",[15],[3558],{"trials":3578,"activeCount":99},[],{"trials":3580,"activeCount":99},[],{"intervention":572,"totalTrials":137,"cells":3582},{"EARLY_PHASE1":3583,"PHASE1":3585,"PHASE2":3587,"PHASE3":3589,"PHASE4":3595,"NA":3597},{"trials":3584,"activeCount":99},[],{"trials":3586,"activeCount":99},[],{"trials":3588,"activeCount":99},[],{"trials":3590,"activeCount":99},[3591],{"nctId":563,"briefTitle":564,"status":105,"phases":3592,"primaryCompletion":566,"completion":567,"start":568,"enrollment":569,"conditions":3593,"interventions":3594},[91],[21],[66,572,573,574,575,576],{"trials":3596,"activeCount":99},[],{"trials":3598,"activeCount":99},[],{"intervention":574,"totalTrials":137,"cells":3600},{"EARLY_PHASE1":3601,"PHASE1":3603,"PHASE2":3605,"PHASE3":3607,"PHASE4":3613,"NA":3615},{"trials":3602,"activeCount":99},[],{"trials":3604,"activeCount":99},[],{"trials":3606,"activeCount":99},[],{"trials":3608,"activeCount":99},[3609],{"nctId":563,"briefTitle":564,"status":105,"phases":3610,"primaryCompletion":566,"completion":567,"start":568,"enrollment":569,"conditions":3611,"interventions":3612},[91],[21],[66,572,573,574,575,576],{"trials":3614,"activeCount":99},[],{"trials":3616,"activeCount":99},[],{"intervention":575,"totalTrials":137,"cells":3618},{"EARLY_PHASE1":3619,"PHASE1":3621,"PHASE2":3623,"PHASE3":3625,"PHASE4":3631,"NA":3633},{"trials":3620,"activeCount":99},[],{"trials":3622,"activeCount":99},[],{"trials":3624,"activeCount":99},[],{"trials":3626,"activeCount":99},[3627],{"nctId":563,"briefTitle":564,"status":105,"phases":3628,"primaryCompletion":566,"completion":567,"start":568,"enrollment":569,"conditions":3629,"interventions":3630},[91],[21],[66,572,573,574,575,576],{"trials":3632,"activeCount":99},[],{"trials":3634,"activeCount":99},[],{"intervention":576,"totalTrials":137,"cells":3636},{"EARLY_PHASE1":3637,"PHASE1":3639,"PHASE2":3641,"PHASE3":3643,"PHASE4":3649,"NA":3651},{"trials":3638,"activeCount":99},[],{"trials":3640,"activeCount":99},[],{"trials":3642,"activeCount":99},[],{"trials":3644,"activeCount":99},[3645],{"nctId":563,"briefTitle":564,"status":105,"phases":3646,"primaryCompletion":566,"completion":567,"start":568,"enrollment":569,"conditions":3647,"interventions":3648},[91],[21],[66,572,573,574,575,576],{"trials":3650,"activeCount":99},[],{"trials":3652,"activeCount":99},[],{"intervention":3654,"totalTrials":137,"cells":3655},"Dolutegravir film-coated",{"EARLY_PHASE1":3656,"PHASE1":3658,"PHASE2":3660,"PHASE3":3662,"PHASE4":3674,"NA":3676},{"trials":3657,"activeCount":99},[],{"trials":3659,"activeCount":99},[],{"trials":3661,"activeCount":99},[],{"trials":3663,"activeCount":99},[3664],{"nctId":3665,"briefTitle":3666,"status":105,"phases":3667,"primaryCompletion":3668,"completion":3668,"start":109,"enrollment":1159,"conditions":3669,"interventions":3670},"NCT03016533","Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019",[91],"2024-12-24",[15],[3654,3671,3672,3673],"Dolutegravir film-coated dispersible","ABC\u002FDTG\u002F3TC immediate release","ABC\u002FDTG\u002F3TC film-coated dispersible",{"trials":3675,"activeCount":99},[],{"trials":3677,"activeCount":99},[],{"intervention":3671,"totalTrials":137,"cells":3679},{"EARLY_PHASE1":3680,"PHASE1":3682,"PHASE2":3684,"PHASE3":3686,"PHASE4":3692,"NA":3694},{"trials":3681,"activeCount":99},[],{"trials":3683,"activeCount":99},[],{"trials":3685,"activeCount":99},[],{"trials":3687,"activeCount":99},[3688],{"nctId":3665,"briefTitle":3666,"status":105,"phases":3689,"primaryCompletion":3668,"completion":3668,"start":109,"enrollment":1159,"conditions":3690,"interventions":3691},[91],[15],[3654,3671,3672,3673],{"trials":3693,"activeCount":99},[],{"trials":3695,"activeCount":99},[],{"intervention":3672,"totalTrials":137,"cells":3697},{"EARLY_PHASE1":3698,"PHASE1":3700,"PHASE2":3702,"PHASE3":3704,"PHASE4":3710,"NA":3712},{"trials":3699,"activeCount":99},[],{"trials":3701,"activeCount":99},[],{"trials":3703,"activeCount":99},[],{"trials":3705,"activeCount":99},[3706],{"nctId":3665,"briefTitle":3666,"status":105,"phases":3707,"primaryCompletion":3668,"completion":3668,"start":109,"enrollment":1159,"conditions":3708,"interventions":3709},[91],[15],[3654,3671,3672,3673],{"trials":3711,"activeCount":99},[],{"trials":3713,"activeCount":99},[],{"intervention":3673,"totalTrials":137,"cells":3715},{"EARLY_PHASE1":3716,"PHASE1":3718,"PHASE2":3720,"PHASE3":3722,"PHASE4":3728,"NA":3730},{"trials":3717,"activeCount":99},[],{"trials":3719,"activeCount":99},[],{"trials":3721,"activeCount":99},[],{"trials":3723,"activeCount":99},[3724],{"nctId":3665,"briefTitle":3666,"status":105,"phases":3725,"primaryCompletion":3668,"completion":3668,"start":109,"enrollment":1159,"conditions":3726,"interventions":3727},[91],[15],[3654,3671,3672,3673],{"trials":3729,"activeCount":99},[],{"trials":3731,"activeCount":99},[],{"intervention":3733,"totalTrials":137,"cells":3734},"DTG 50 mg \u002FABC 600 mg \u002F3TC 300 mg FDC",{"EARLY_PHASE1":3735,"PHASE1":3737,"PHASE2":3739,"PHASE3":3741,"PHASE4":3753,"NA":3755},{"trials":3736,"activeCount":99},[],{"trials":3738,"activeCount":99},[],{"trials":3740,"activeCount":99},[],{"trials":3742,"activeCount":99},[3743],{"nctId":3744,"briefTitle":3745,"status":105,"phases":3746,"primaryCompletion":3747,"completion":3748,"start":3749,"enrollment":36,"conditions":3750,"interventions":3752},"NCT02075593","ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection",[91],"2018-10-22","2021-09-15","2014-12-17",[18,15,3751],"Arthralgia",[3733],{"trials":3754,"activeCount":99},[],{"trials":3756,"activeCount":99},[],{"intervention":3086,"totalTrials":137,"cells":3758},{"EARLY_PHASE1":3759,"PHASE1":3761,"PHASE2":3763,"PHASE3":3765,"PHASE4":3771,"NA":3773},{"trials":3760,"activeCount":99},[],{"trials":3762,"activeCount":99},[],{"trials":3764,"activeCount":99},[],{"trials":3766,"activeCount":99},[3767],{"nctId":3077,"briefTitle":3078,"status":105,"phases":3768,"primaryCompletion":3080,"completion":3081,"start":3082,"enrollment":3083,"conditions":3769,"interventions":3770},[91],[18],[3058,3086],{"trials":3772,"activeCount":99},[],{"trials":3774,"activeCount":99},[],{"intervention":3776,"totalTrials":137,"cells":3777},"Dolutegravir + Lamivudine FDC",{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3782,"PHASE3":3784,"PHASE4":3796,"NA":3798},{"trials":3779,"activeCount":99},[],{"trials":3781,"activeCount":99},[],{"trials":3783,"activeCount":99},[],{"trials":3785,"activeCount":99},[3786],{"nctId":3787,"briefTitle":3788,"status":105,"phases":3789,"primaryCompletion":3790,"completion":3791,"start":3792,"enrollment":3793,"conditions":3794,"interventions":3795},"NCT03945981","Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults",[91],"2020-04-29","2020-10-20","2019-07-02",131,[15],[3776],{"trials":3797,"activeCount":99},[],{"trials":3799,"activeCount":99},[],{"intervention":2019,"totalTrials":137,"cells":3801},{"EARLY_PHASE1":3802,"PHASE1":3804,"PHASE2":3806,"PHASE3":3808,"PHASE4":3814,"NA":3816},{"trials":3803,"activeCount":99},[],{"trials":3805,"activeCount":99},[],{"trials":3807,"activeCount":99},[],{"trials":3809,"activeCount":99},[3810],{"nctId":2010,"briefTitle":2011,"status":105,"phases":3811,"primaryCompletion":2013,"completion":2014,"start":2015,"enrollment":2016,"conditions":3812,"interventions":3813},[91],[18,15],[2019,412,413,2020],{"trials":3815,"activeCount":99},[],{"trials":3817,"activeCount":99},[],{"intervention":2020,"totalTrials":137,"cells":3819},{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3826,"PHASE4":3832,"NA":3834},{"trials":3821,"activeCount":99},[],{"trials":3823,"activeCount":99},[],{"trials":3825,"activeCount":99},[],{"trials":3827,"activeCount":99},[3828],{"nctId":2010,"briefTitle":2011,"status":105,"phases":3829,"primaryCompletion":2013,"completion":2014,"start":2015,"enrollment":2016,"conditions":3830,"interventions":3831},[91],[18,15],[2019,412,413,2020],{"trials":3833,"activeCount":99},[],{"trials":3835,"activeCount":99},[],{"intervention":3000,"totalTrials":137,"cells":3837},{"EARLY_PHASE1":3838,"PHASE1":3840,"PHASE2":3842,"PHASE3":3844,"PHASE4":3850,"NA":3852},{"trials":3839,"activeCount":99},[],{"trials":3841,"activeCount":99},[],{"trials":3843,"activeCount":99},[],{"trials":3845,"activeCount":99},[3846],{"nctId":2991,"briefTitle":2992,"status":105,"phases":3847,"primaryCompletion":2994,"completion":2995,"start":2996,"enrollment":2997,"conditions":3848,"interventions":3849},[91],[15],[3000,2764],{"trials":3851,"activeCount":99},[],{"trials":3853,"activeCount":99},[],{"intervention":3120,"totalTrials":137,"cells":3855},{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3860,"PHASE3":3862,"PHASE4":3868,"NA":3870},{"trials":3857,"activeCount":99},[],{"trials":3859,"activeCount":99},[],{"trials":3861,"activeCount":99},[],{"trials":3863,"activeCount":99},[3864],{"nctId":3112,"briefTitle":3113,"status":105,"phases":3865,"primaryCompletion":3115,"completion":3116,"start":1411,"enrollment":3117,"conditions":3866,"interventions":3867},[91],[15],[3092,3120,3121],{"trials":3869,"activeCount":99},[],{"trials":3871,"activeCount":99},[],{"intervention":3121,"totalTrials":137,"cells":3873},{"EARLY_PHASE1":3874,"PHASE1":3876,"PHASE2":3878,"PHASE3":3880,"PHASE4":3886,"NA":3888},{"trials":3875,"activeCount":99},[],{"trials":3877,"activeCount":99},[],{"trials":3879,"activeCount":99},[],{"trials":3881,"activeCount":99},[3882],{"nctId":3112,"briefTitle":3113,"status":105,"phases":3883,"primaryCompletion":3115,"completion":3116,"start":1411,"enrollment":3117,"conditions":3884,"interventions":3885},[91],[15],[3092,3120,3121],{"trials":3887,"activeCount":99},[],{"trials":3889,"activeCount":99},[],{"intervention":1084,"totalTrials":137,"cells":3891},{"EARLY_PHASE1":3892,"PHASE1":3894,"PHASE2":3896,"PHASE3":3898,"PHASE4":3904,"NA":3906},{"trials":3893,"activeCount":99},[],{"trials":3895,"activeCount":99},[],{"trials":3897,"activeCount":99},[],{"trials":3899,"activeCount":99},[3900],{"nctId":1075,"briefTitle":1076,"status":105,"phases":3901,"primaryCompletion":1078,"completion":1079,"start":1080,"enrollment":1081,"conditions":3902,"interventions":3903},[91],[15],[170,1084,1085],{"trials":3905,"activeCount":99},[],{"trials":3907,"activeCount":99},[],{"intervention":1085,"totalTrials":137,"cells":3909},{"EARLY_PHASE1":3910,"PHASE1":3912,"PHASE2":3914,"PHASE3":3916,"PHASE4":3922,"NA":3924},{"trials":3911,"activeCount":99},[],{"trials":3913,"activeCount":99},[],{"trials":3915,"activeCount":99},[],{"trials":3917,"activeCount":99},[3918],{"nctId":1075,"briefTitle":1076,"status":105,"phases":3919,"primaryCompletion":1078,"completion":1079,"start":1080,"enrollment":1081,"conditions":3920,"interventions":3921},[91],[15],[170,1084,1085],{"trials":3923,"activeCount":99},[],{"trials":3925,"activeCount":99},[],{"intervention":523,"totalTrials":605,"cells":3927},{"EARLY_PHASE1":3928,"PHASE1":3930,"PHASE2":4007,"PHASE3":4026,"PHASE4":4028,"NA":4030},{"trials":3929,"activeCount":99},[],{"trials":3931,"activeCount":99},[3932,3942,3951,3955,3964,3975,3983,3991,3999,4003],{"nctId":3933,"briefTitle":3934,"status":105,"phases":3935,"primaryCompletion":3936,"completion":3936,"start":3937,"enrollment":3938,"conditions":3939,"interventions":3940},"NCT03984825","Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive",[89],"2019-08-16","2019-06-13",23,[15],[523,3941],"Portia",{"nctId":3943,"briefTitle":3944,"status":105,"phases":3945,"primaryCompletion":3946,"completion":3946,"start":3947,"enrollment":3948,"conditions":3949,"interventions":3950},"NCT03231943","GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers",[89],"2018-09-09","2017-09-19",78,[18,15],[523],{"nctId":1026,"briefTitle":1027,"status":105,"phases":3952,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":466,"conditions":3953,"interventions":3954},[89],[15],[523,170],{"nctId":3956,"briefTitle":3957,"status":105,"phases":3958,"primaryCompletion":1029,"completion":3959,"start":3960,"enrollment":466,"conditions":3961,"interventions":3962},"NCT03836729","Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide\u002FEmtricitabine",[89],"2019-04-30","2019-02-11",[15],[3963,523],"Tenofovir alafenamide\u002Femtricitabine",{"nctId":3965,"briefTitle":3966,"status":105,"phases":3967,"primaryCompletion":3968,"completion":3968,"start":3969,"enrollment":31,"conditions":3970,"interventions":3971},"NCT04507321","Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254",[89],"2020-11-23","2020-09-24",[15],[3972,3973,3974],"GSK3640254 Oral","[14C]-GSK3640254 intravenous","[14C]-GSK3640254 powder",{"nctId":3976,"briefTitle":3977,"status":105,"phases":3978,"primaryCompletion":3979,"completion":3979,"start":155,"enrollment":700,"conditions":3980,"interventions":3981},"NCT04563845","Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin",[89],"2021-10-30",[15],[523,3982],"Moxifloxacin",{"nctId":3984,"briefTitle":3985,"status":515,"phases":3986,"primaryCompletion":3987,"completion":3987,"start":3988,"enrollment":466,"conditions":3989,"interventions":3990},"NCT04128293","A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants",[89],"2019-11-15","2019-10-08",[15],[523,523],{"nctId":3992,"briefTitle":3985,"status":105,"phases":3993,"primaryCompletion":3994,"completion":3994,"start":3995,"enrollment":3996,"conditions":3997,"interventions":3998},"NCT04263142",[89],"2020-03-24","2020-01-27",39,[15],[523,523],{"nctId":1044,"briefTitle":1045,"status":105,"phases":4000,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":1049,"conditions":4001,"interventions":4002},[89],[15],[523,170,1052],{"nctId":2173,"briefTitle":2174,"status":105,"phases":4004,"primaryCompletion":2176,"completion":2176,"start":2177,"enrollment":2178,"conditions":4005,"interventions":4006},[89],[15],[523,2181,715],{"trials":4008,"activeCount":99},[4009,4013,4022],{"nctId":513,"briefTitle":514,"status":515,"phases":4010,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":4011,"interventions":4012},[90],[15],[523,524,525,66],{"nctId":4014,"briefTitle":4015,"status":105,"phases":4016,"primaryCompletion":4017,"completion":4017,"start":4018,"enrollment":4019,"conditions":4020,"interventions":4021},"NCT03784079","A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults",[90],"2020-02-06","2019-01-31",34,[15],[523],{"nctId":536,"briefTitle":537,"status":515,"phases":4023,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":4024,"interventions":4025},[90],[15],[523,66,333,333],{"trials":4027,"activeCount":99},[],{"trials":4029,"activeCount":99},[],{"trials":4031,"activeCount":99},[],{"intervention":411,"totalTrials":12,"cells":4033},{"EARLY_PHASE1":4034,"PHASE1":4036,"PHASE2":4092,"PHASE3":4114,"PHASE4":4116,"NA":4118},{"trials":4035,"activeCount":99},[],{"trials":4037,"activeCount":99},[4038,4048,4056,4065,4074,4082],{"nctId":4039,"briefTitle":4040,"status":105,"phases":4041,"primaryCompletion":4042,"completion":4042,"start":4043,"enrollment":1965,"conditions":4044,"interventions":4045},"NCT02578277","Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates",[89],"2015-12-23","2015-11-09",[15],[4046,411,4047],"CYP and transporter probe substrates","BMS-955176 plus CYP and transporter probe substrates",{"nctId":4049,"briefTitle":4050,"status":105,"phases":4051,"primaryCompletion":4052,"completion":4052,"start":4053,"enrollment":25,"conditions":4054,"interventions":4055},"NCT02273947","Food Effect Study With BMS-955176",[89],"2016-08-15","2014-10-23",[18],[411],{"nctId":4057,"briefTitle":4058,"status":105,"phases":4059,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":4062,"conditions":4063,"interventions":4064},"NCT02206711","Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.",[89],"2014-09-09","2014-08-08",21,[15],[411],{"nctId":4066,"briefTitle":4067,"status":105,"phases":4068,"primaryCompletion":4069,"completion":4069,"start":4070,"enrollment":4071,"conditions":4072,"interventions":4073},"NCT02095886","Relative Bioavailability Study With BMS-955176",[89],"2014-07-07","2014-03-25",47,[18],[411],{"nctId":4075,"briefTitle":4076,"status":105,"phases":4077,"primaryCompletion":4078,"completion":4078,"start":4079,"enrollment":28,"conditions":4080,"interventions":4081},"NCT02608918","Taste Properties of HIV Inhibitor",[89],"2016-05-24","2016-01-05",[15],[411],{"nctId":4083,"briefTitle":4084,"status":105,"phases":4085,"primaryCompletion":4086,"completion":4086,"start":4087,"enrollment":4088,"conditions":4089,"interventions":4090},"NCT02157467","Study of Combined Oral Contraceptive Effects in Female Subjects",[89],"2014-08-25","2014-06-02",46,[18],[411,4091],"Ortho Cyclen",{"trials":4093,"activeCount":99},[4094,4098,4102],{"nctId":403,"briefTitle":404,"status":105,"phases":4095,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":4096,"interventions":4097},[90],[18,15],[411,412,413,414,394],{"nctId":527,"briefTitle":528,"status":515,"phases":4099,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":4100,"interventions":4101},[90],[15],[411,412,413,66,414],{"nctId":4103,"briefTitle":4104,"status":515,"phases":4105,"primaryCompletion":4106,"completion":4107,"start":4108,"enrollment":4109,"conditions":4110,"interventions":4111},"NCT02415595","Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults",[90],"2016-05-26","2017-08-21","2015-05-12",210,[18],[411,4112,4113],"EFV","TDF\u002FFTC",{"trials":4115,"activeCount":99},[],{"trials":4117,"activeCount":99},[],{"trials":4119,"activeCount":99},[],{"intervention":2264,"totalTrials":36,"cells":4121},{"EARLY_PHASE1":4122,"PHASE1":4124,"PHASE2":4143,"PHASE3":4154,"PHASE4":4156,"NA":4158},{"trials":4123,"activeCount":99},[],{"trials":4125,"activeCount":99},[4126,4130,4139],{"nctId":2576,"briefTitle":2577,"status":2201,"phases":4127,"primaryCompletion":1974,"completion":2047,"start":1974,"enrollment":99,"conditions":4128,"interventions":4129},[89],[21],[1922,2264],{"nctId":4131,"briefTitle":4132,"status":515,"phases":4133,"primaryCompletion":4134,"completion":4134,"start":4135,"enrollment":605,"conditions":4136,"interventions":4137},"NCT01195974","A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.",[89],"2011-02-09","2010-09-14",[18,15],[4138,2264],"YASMIN",{"nctId":2257,"briefTitle":2258,"status":105,"phases":4140,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":110,"conditions":4141,"interventions":4142},[89],[18],[2250,2264,2265],{"trials":4144,"activeCount":99},[4145],{"nctId":4146,"briefTitle":4147,"status":105,"phases":4148,"primaryCompletion":4149,"completion":4149,"start":4150,"enrollment":28,"conditions":4151,"interventions":4152},"NCT00945282","Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.",[90],"2009-11-28","2009-10-20",[18],[2264,1941,4153,2264],"HAART",{"trials":4155,"activeCount":99},[],{"trials":4157,"activeCount":99},[],{"trials":4159,"activeCount":99},[],{"intervention":2695,"totalTrials":178,"cells":4161},{"EARLY_PHASE1":4162,"PHASE1":4164,"PHASE2":4183,"PHASE3":4189,"PHASE4":4191,"NA":4193},{"trials":4163,"activeCount":99},[],{"trials":4165,"activeCount":99},[4166,4175],{"nctId":4167,"briefTitle":4168,"status":105,"phases":4169,"primaryCompletion":3082,"completion":3082,"start":4170,"enrollment":2109,"conditions":4171,"interventions":4172},"NCT01754116","A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects",[89],"2013-01",[18],[2695,4173,4174,4174,4174],"Midazolam 3 mg oral + GSK1265744 30mg","GSK1265744 400 mg",{"nctId":4176,"briefTitle":4177,"status":105,"phases":4178,"primaryCompletion":4179,"completion":4179,"start":4180,"enrollment":466,"conditions":4181,"interventions":4182},"NCT02354937","Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment",[89],"2016-11-01","2015-07-13",[18,15],[2695],{"trials":4184,"activeCount":99},[4185],{"nctId":2685,"briefTitle":2686,"status":105,"phases":4186,"primaryCompletion":2688,"completion":2689,"start":2690,"enrollment":2691,"conditions":4187,"interventions":4188},[90],[18,15],[2694,2695,2696,2697,2698,573],{"trials":4190,"activeCount":99},[],{"trials":4192,"activeCount":99},[],{"trials":4194,"activeCount":99},[],{"intervention":4196,"totalTrials":362,"cells":4197},"GSK1265744 30mg",{"EARLY_PHASE1":4198,"PHASE1":4200,"PHASE2":4209,"PHASE3":4220,"PHASE4":4222,"NA":4224},{"trials":4199,"activeCount":99},[],{"trials":4201,"activeCount":99},[4202],{"nctId":4203,"briefTitle":4204,"status":105,"phases":4205,"primaryCompletion":2758,"completion":2758,"start":4206,"enrollment":466,"conditions":4207,"interventions":4208},"NCT02354950","A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers",[89],"2015-06-22",[15],[4196],{"trials":4210,"activeCount":99},[4211],{"nctId":4212,"briefTitle":4213,"status":105,"phases":4214,"primaryCompletion":4215,"completion":4215,"start":4216,"enrollment":12,"conditions":4217,"interventions":4218},"NCT00920426","Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)",[90],"2009-08-13","2009-06-09",[18],[4196,4219],"GSK1265744 5mg",{"trials":4221,"activeCount":99},[],{"trials":4223,"activeCount":99},[],{"trials":4225,"activeCount":99},[],{"intervention":2574,"totalTrials":362,"cells":4227},{"EARLY_PHASE1":4228,"PHASE1":4230,"PHASE2":4236,"PHASE3":4242,"PHASE4":4244,"NA":4246},{"trials":4229,"activeCount":99},[],{"trials":4231,"activeCount":99},[4232],{"nctId":2567,"briefTitle":2568,"status":105,"phases":4233,"primaryCompletion":2570,"completion":2570,"start":2571,"enrollment":25,"conditions":4234,"interventions":4235},[89],[30],[1922,2574],{"trials":4237,"activeCount":99},[4238],{"nctId":2652,"briefTitle":2653,"status":105,"phases":4239,"primaryCompletion":2655,"completion":2656,"start":2657,"enrollment":2658,"conditions":4240,"interventions":4241},[90],[18],[1922,2661],{"trials":4243,"activeCount":99},[],{"trials":4245,"activeCount":99},[],{"trials":4247,"activeCount":99},[],{"intervention":1941,"totalTrials":362,"cells":4249},{"EARLY_PHASE1":4250,"PHASE1":4252,"PHASE2":4258,"PHASE3":4264,"PHASE4":4266,"NA":4268},{"trials":4251,"activeCount":99},[],{"trials":4253,"activeCount":99},[4254],{"nctId":1933,"briefTitle":1934,"status":105,"phases":4255,"primaryCompletion":1936,"completion":1936,"start":1937,"enrollment":22,"conditions":4256,"interventions":4257},[89],[1939],[714,715,413,1941,1922],{"trials":4259,"activeCount":99},[4260],{"nctId":4146,"briefTitle":4147,"status":105,"phases":4261,"primaryCompletion":4149,"completion":4149,"start":4150,"enrollment":28,"conditions":4262,"interventions":4263},[90],[18],[2264,1941,4153,2264],{"trials":4265,"activeCount":99},[],{"trials":4267,"activeCount":99},[],{"trials":4269,"activeCount":99},[],{"intervention":524,"totalTrials":362,"cells":4271},{"EARLY_PHASE1":4272,"PHASE1":4274,"PHASE2":4276,"PHASE3":4286,"PHASE4":4288,"NA":4290},{"trials":4273,"activeCount":99},[],{"trials":4275,"activeCount":99},[],{"trials":4277,"activeCount":99},[4278,4282],{"nctId":513,"briefTitle":514,"status":515,"phases":4279,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":4280,"interventions":4281},[90],[15],[523,524,525,66],{"nctId":237,"briefTitle":238,"status":105,"phases":4283,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":4284,"interventions":4285},[90],[18,15],[246,194,247,248,235],{"trials":4287,"activeCount":99},[],{"trials":4289,"activeCount":99},[],{"trials":4291,"activeCount":99},[],{"intervention":4293,"totalTrials":362,"cells":4294},"CAB",{"EARLY_PHASE1":4295,"PHASE1":4297,"PHASE2":4307,"PHASE3":4313,"PHASE4":4315,"NA":4317},{"trials":4296,"activeCount":99},[],{"trials":4298,"activeCount":99},[4299],{"nctId":4300,"briefTitle":4301,"status":105,"phases":4302,"primaryCompletion":2728,"completion":2728,"start":4303,"enrollment":110,"conditions":4304,"interventions":4305},"NCT02411435","Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects",[89],"2015-07",[18],[4293,4306],"RIF",{"trials":4308,"activeCount":99},[4309],{"nctId":237,"briefTitle":238,"status":105,"phases":4310,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":4311,"interventions":4312},[90],[18,15],[246,194,247,248,235],{"trials":4314,"activeCount":99},[],{"trials":4316,"activeCount":99},[],{"trials":4318,"activeCount":99},[],{"intervention":1311,"totalTrials":362,"cells":4320},{"EARLY_PHASE1":4321,"PHASE1":4323,"PHASE2":4325,"PHASE3":4335,"PHASE4":4337,"NA":4339},{"trials":4322,"activeCount":99},[],{"trials":4324,"activeCount":99},[],{"trials":4326,"activeCount":99},[4327,4331],{"nctId":1304,"briefTitle":1305,"status":105,"phases":4328,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":8,"conditions":4329,"interventions":4330},[90],[15],[425,1311],{"nctId":1493,"briefTitle":1494,"status":105,"phases":4332,"primaryCompletion":1496,"completion":1496,"start":1497,"enrollment":1336,"conditions":4333,"interventions":4334},[90],[15],[81,1470,1311],{"trials":4336,"activeCount":99},[],{"trials":4338,"activeCount":99},[],{"trials":4340,"activeCount":99},[],{"intervention":2192,"totalTrials":362,"cells":4342},{"EARLY_PHASE1":4343,"PHASE1":4345,"PHASE2":4347,"PHASE3":4362,"PHASE4":4364,"NA":4366},{"trials":4344,"activeCount":99},[],{"trials":4346,"activeCount":99},[],{"trials":4348,"activeCount":99},[4349,4358],{"nctId":4350,"briefTitle":4351,"status":515,"phases":4352,"primaryCompletion":4353,"completion":4353,"start":4354,"enrollment":3938,"conditions":4355,"interventions":4356},"NCT01231555","Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)",[90],"2011-07-04","2010-11-18",[18],[2192,2193,4357],"Efavirenz 600 mg once daily",{"nctId":2185,"briefTitle":2186,"status":515,"phases":4359,"primaryCompletion":2188,"completion":2188,"start":2189,"enrollment":1950,"conditions":4360,"interventions":4361},[90],[18],[2192,2193,715],{"trials":4363,"activeCount":99},[],{"trials":4365,"activeCount":99},[],{"trials":4367,"activeCount":99},[],{"intervention":2193,"totalTrials":362,"cells":4369},{"EARLY_PHASE1":4370,"PHASE1":4372,"PHASE2":4374,"PHASE3":4384,"PHASE4":4386,"NA":4388},{"trials":4371,"activeCount":99},[],{"trials":4373,"activeCount":99},[],{"trials":4375,"activeCount":99},[4376,4380],{"nctId":4350,"briefTitle":4351,"status":515,"phases":4377,"primaryCompletion":4353,"completion":4353,"start":4354,"enrollment":3938,"conditions":4378,"interventions":4379},[90],[18],[2192,2193,4357],{"nctId":2185,"briefTitle":2186,"status":515,"phases":4381,"primaryCompletion":2188,"completion":2188,"start":2189,"enrollment":1950,"conditions":4382,"interventions":4383},[90],[18],[2192,2193,715],{"trials":4385,"activeCount":99},[],{"trials":4387,"activeCount":99},[],{"trials":4389,"activeCount":99},[],{"intervention":4219,"totalTrials":137,"cells":4391},{"EARLY_PHASE1":4392,"PHASE1":4394,"PHASE2":4396,"PHASE3":4402,"PHASE4":4404,"NA":4406},{"trials":4393,"activeCount":99},[],{"trials":4395,"activeCount":99},[],{"trials":4397,"activeCount":99},[4398],{"nctId":4212,"briefTitle":4213,"status":105,"phases":4399,"primaryCompletion":4215,"completion":4215,"start":4216,"enrollment":12,"conditions":4400,"interventions":4401},[90],[18],[4196,4219],{"trials":4403,"activeCount":99},[],{"trials":4405,"activeCount":99},[],{"trials":4407,"activeCount":99},[],{"intervention":4409,"totalTrials":137,"cells":4410},"BMS-663068 400 mg",{"EARLY_PHASE1":4411,"PHASE1":4413,"PHASE2":4415,"PHASE3":4434,"PHASE4":4436,"NA":4438},{"trials":4412,"activeCount":99},[],{"trials":4414,"activeCount":99},[],{"trials":4416,"activeCount":99},[4417],{"nctId":4418,"briefTitle":4419,"status":105,"phases":4420,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":4424,"conditions":4425,"interventions":4426},"NCT01384734","HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections",[90],"2013-02-18","2017-05-12","2011-07-26",254,[18],[4409,4427,4428,4429,4430,4431,4432,4433],"BMS-663068 800 mg","BMS-663068 600 mg","BMS-663068 1200 mg","Raltegravir 400 mg","Tenofovir 300 mg","Ritonavir 100 mg","Atazanavir 300 mg",{"trials":4435,"activeCount":99},[],{"trials":4437,"activeCount":99},[],{"trials":4439,"activeCount":99},[],{"intervention":4427,"totalTrials":137,"cells":4441},{"EARLY_PHASE1":4442,"PHASE1":4444,"PHASE2":4446,"PHASE3":4452,"PHASE4":4454,"NA":4456},{"trials":4443,"activeCount":99},[],{"trials":4445,"activeCount":99},[],{"trials":4447,"activeCount":99},[4448],{"nctId":4418,"briefTitle":4419,"status":105,"phases":4449,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":4424,"conditions":4450,"interventions":4451},[90],[18],[4409,4427,4428,4429,4430,4431,4432,4433],{"trials":4453,"activeCount":99},[],{"trials":4455,"activeCount":99},[],{"trials":4457,"activeCount":99},[],{"intervention":4428,"totalTrials":137,"cells":4459},{"EARLY_PHASE1":4460,"PHASE1":4462,"PHASE2":4464,"PHASE3":4470,"PHASE4":4472,"NA":4474},{"trials":4461,"activeCount":99},[],{"trials":4463,"activeCount":99},[],{"trials":4465,"activeCount":99},[4466],{"nctId":4418,"briefTitle":4419,"status":105,"phases":4467,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":4424,"conditions":4468,"interventions":4469},[90],[18],[4409,4427,4428,4429,4430,4431,4432,4433],{"trials":4471,"activeCount":99},[],{"trials":4473,"activeCount":99},[],{"trials":4475,"activeCount":99},[],{"intervention":4429,"totalTrials":137,"cells":4477},{"EARLY_PHASE1":4478,"PHASE1":4480,"PHASE2":4482,"PHASE3":4488,"PHASE4":4490,"NA":4492},{"trials":4479,"activeCount":99},[],{"trials":4481,"activeCount":99},[],{"trials":4483,"activeCount":99},[4484],{"nctId":4418,"briefTitle":4419,"status":105,"phases":4485,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":4424,"conditions":4486,"interventions":4487},[90],[18],[4409,4427,4428,4429,4430,4431,4432,4433],{"trials":4489,"activeCount":99},[],{"trials":4491,"activeCount":99},[],{"trials":4493,"activeCount":99},[],{"intervention":4430,"totalTrials":137,"cells":4495},{"EARLY_PHASE1":4496,"PHASE1":4498,"PHASE2":4500,"PHASE3":4506,"PHASE4":4508,"NA":4510},{"trials":4497,"activeCount":99},[],{"trials":4499,"activeCount":99},[],{"trials":4501,"activeCount":99},[4502],{"nctId":4418,"briefTitle":4419,"status":105,"phases":4503,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":4424,"conditions":4504,"interventions":4505},[90],[18],[4409,4427,4428,4429,4430,4431,4432,4433],{"trials":4507,"activeCount":99},[],{"trials":4509,"activeCount":99},[],{"trials":4511,"activeCount":99},[],{"intervention":4431,"totalTrials":137,"cells":4513},{"EARLY_PHASE1":4514,"PHASE1":4516,"PHASE2":4518,"PHASE3":4524,"PHASE4":4526,"NA":4528},{"trials":4515,"activeCount":99},[],{"trials":4517,"activeCount":99},[],{"trials":4519,"activeCount":99},[4520],{"nctId":4418,"briefTitle":4419,"status":105,"phases":4521,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":4424,"conditions":4522,"interventions":4523},[90],[18],[4409,4427,4428,4429,4430,4431,4432,4433],{"trials":4525,"activeCount":99},[],{"trials":4527,"activeCount":99},[],{"trials":4529,"activeCount":99},[],{"intervention":4432,"totalTrials":137,"cells":4531},{"EARLY_PHASE1":4532,"PHASE1":4534,"PHASE2":4536,"PHASE3":4542,"PHASE4":4544,"NA":4546},{"trials":4533,"activeCount":99},[],{"trials":4535,"activeCount":99},[],{"trials":4537,"activeCount":99},[4538],{"nctId":4418,"briefTitle":4419,"status":105,"phases":4539,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":4424,"conditions":4540,"interventions":4541},[90],[18],[4409,4427,4428,4429,4430,4431,4432,4433],{"trials":4543,"activeCount":99},[],{"trials":4545,"activeCount":99},[],{"trials":4547,"activeCount":99},[],{"intervention":4433,"totalTrials":137,"cells":4549},{"EARLY_PHASE1":4550,"PHASE1":4552,"PHASE2":4554,"PHASE3":4560,"PHASE4":4562,"NA":4564},{"trials":4551,"activeCount":99},[],{"trials":4553,"activeCount":99},[],{"trials":4555,"activeCount":99},[4556],{"nctId":4418,"briefTitle":4419,"status":105,"phases":4557,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":4424,"conditions":4558,"interventions":4559},[90],[18],[4409,4427,4428,4429,4430,4431,4432,4433],{"trials":4561,"activeCount":99},[],{"trials":4563,"activeCount":99},[],{"trials":4565,"activeCount":99},[],{"intervention":4567,"totalTrials":137,"cells":4568},"VH3739937",{"EARLY_PHASE1":4569,"PHASE1":4571,"PHASE2":4573,"PHASE3":4583,"PHASE4":4585,"NA":4587},{"trials":4570,"activeCount":99},[],{"trials":4572,"activeCount":99},[],{"trials":4574,"activeCount":99},[4575],{"nctId":4576,"briefTitle":4577,"status":515,"phases":4578,"primaryCompletion":4579,"completion":4579,"start":4580,"enrollment":4062,"conditions":4581,"interventions":4582},"NCT06061081","A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1",[90],"2024-08-27","2023-12-21",[15],[4567],{"trials":4584,"activeCount":99},[],{"trials":4586,"activeCount":99},[],{"trials":4588,"activeCount":99},[],{"intervention":4590,"totalTrials":137,"cells":4591},"GSK3810109A",{"EARLY_PHASE1":4592,"PHASE1":4594,"PHASE2":4596,"PHASE3":4609,"PHASE4":4611,"NA":4613},{"trials":4593,"activeCount":99},[],{"trials":4595,"activeCount":99},[],{"trials":4597,"activeCount":99},[4598],{"nctId":4599,"briefTitle":4600,"status":105,"phases":4601,"primaryCompletion":4602,"completion":4603,"start":4604,"enrollment":4605,"conditions":4606,"interventions":4607},"NCT04871113","A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults",[90],"2022-10-27","2023-09-21","2021-06-22",62,[15],[4590,4608],"Dolutegravir+lamivudine SOC regimen",{"trials":4610,"activeCount":99},[],{"trials":4612,"activeCount":99},[],{"trials":4614,"activeCount":99},[],{"intervention":4608,"totalTrials":137,"cells":4616},{"EARLY_PHASE1":4617,"PHASE1":4619,"PHASE2":4621,"PHASE3":4627,"PHASE4":4629,"NA":4631},{"trials":4618,"activeCount":99},[],{"trials":4620,"activeCount":99},[],{"trials":4622,"activeCount":99},[4623],{"nctId":4599,"briefTitle":4600,"status":105,"phases":4624,"primaryCompletion":4602,"completion":4603,"start":4604,"enrollment":4605,"conditions":4625,"interventions":4626},[90],[15],[4590,4608],{"trials":4628,"activeCount":99},[],{"trials":4630,"activeCount":99},[],{"trials":4632,"activeCount":99},[],{"intervention":1953,"totalTrials":137,"cells":4634},{"EARLY_PHASE1":4635,"PHASE1":4637,"PHASE2":4639,"PHASE3":4645,"PHASE4":4647,"NA":4649},{"trials":4636,"activeCount":99},[],{"trials":4638,"activeCount":99},[],{"trials":4640,"activeCount":99},[4641],{"nctId":1945,"briefTitle":1946,"status":105,"phases":4642,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":1950,"conditions":4643,"interventions":4644},[90],[21,24],[1953,413],{"trials":4646,"activeCount":99},[],{"trials":4648,"activeCount":99},[],{"trials":4650,"activeCount":99},[],{"intervention":2796,"totalTrials":137,"cells":4652},{"EARLY_PHASE1":4653,"PHASE1":4655,"PHASE2":4657,"PHASE3":4663,"PHASE4":4665,"NA":4667},{"trials":4654,"activeCount":99},[],{"trials":4656,"activeCount":99},[],{"trials":4658,"activeCount":99},[4659],{"nctId":2788,"briefTitle":2789,"status":515,"phases":4660,"primaryCompletion":2791,"completion":2791,"start":2792,"enrollment":2793,"conditions":4661,"interventions":4662},[90],[21,24],[2779,2796],{"trials":4664,"activeCount":99},[],{"trials":4666,"activeCount":99},[],{"trials":4668,"activeCount":99},[],{"intervention":4153,"totalTrials":137,"cells":4670},{"EARLY_PHASE1":4671,"PHASE1":4673,"PHASE2":4675,"PHASE3":4681,"PHASE4":4683,"NA":4685},{"trials":4672,"activeCount":99},[],{"trials":4674,"activeCount":99},[],{"trials":4676,"activeCount":99},[4677],{"nctId":4146,"briefTitle":4147,"status":105,"phases":4678,"primaryCompletion":4149,"completion":4149,"start":4150,"enrollment":28,"conditions":4679,"interventions":4680},[90],[18],[2264,1941,4153,2264],{"trials":4682,"activeCount":99},[],{"trials":4684,"activeCount":99},[],{"trials":4686,"activeCount":99},[],{"intervention":525,"totalTrials":137,"cells":4688},{"EARLY_PHASE1":4689,"PHASE1":4691,"PHASE2":4693,"PHASE3":4699,"PHASE4":4701,"NA":4703},{"trials":4690,"activeCount":99},[],{"trials":4692,"activeCount":99},[],{"trials":4694,"activeCount":99},[4695],{"nctId":513,"briefTitle":514,"status":515,"phases":4696,"primaryCompletion":517,"completion":518,"start":519,"enrollment":520,"conditions":4697,"interventions":4698},[90],[15],[523,524,525,66],{"trials":4700,"activeCount":99},[],{"trials":4702,"activeCount":99},[],{"trials":4704,"activeCount":99},[],{"intervention":4706,"totalTrials":137,"cells":4707},"744",{"EARLY_PHASE1":4708,"PHASE1":4710,"PHASE2":4712,"PHASE3":4725,"PHASE4":4727,"NA":4729},{"trials":4709,"activeCount":99},[],{"trials":4711,"activeCount":99},[],{"trials":4713,"activeCount":99},[4714],{"nctId":4715,"briefTitle":4716,"status":105,"phases":4717,"primaryCompletion":4718,"completion":4719,"start":4720,"enrollment":4721,"conditions":4722,"interventions":4723},"NCT02076178","Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)",[90],"2015-05-15","2016-02-23","2014-03-27",127,[18],[4706,4724],"744 LA",{"trials":4726,"activeCount":99},[],{"trials":4728,"activeCount":99},[],{"trials":4730,"activeCount":99},[],{"intervention":4724,"totalTrials":137,"cells":4732},{"EARLY_PHASE1":4733,"PHASE1":4735,"PHASE2":4737,"PHASE3":4743,"PHASE4":4745,"NA":4747},{"trials":4734,"activeCount":99},[],{"trials":4736,"activeCount":99},[],{"trials":4738,"activeCount":99},[4739],{"nctId":4715,"briefTitle":4716,"status":105,"phases":4740,"primaryCompletion":4718,"completion":4719,"start":4720,"enrollment":4721,"conditions":4741,"interventions":4742},[90],[18],[4706,4724],{"trials":4744,"activeCount":99},[],{"trials":4746,"activeCount":99},[],{"trials":4748,"activeCount":99},[],{"intervention":2694,"totalTrials":137,"cells":4750},{"EARLY_PHASE1":4751,"PHASE1":4753,"PHASE2":4755,"PHASE3":4761,"PHASE4":4763,"NA":4765},{"trials":4752,"activeCount":99},[],{"trials":4754,"activeCount":99},[],{"trials":4756,"activeCount":99},[4757],{"nctId":2685,"briefTitle":2686,"status":105,"phases":4758,"primaryCompletion":2688,"completion":2689,"start":2690,"enrollment":2691,"conditions":4759,"interventions":4760},[90],[18,15],[2694,2695,2696,2697,2698,573],{"trials":4762,"activeCount":99},[],{"trials":4764,"activeCount":99},[],{"trials":4766,"activeCount":99},[],{"intervention":2696,"totalTrials":137,"cells":4768},{"EARLY_PHASE1":4769,"PHASE1":4771,"PHASE2":4773,"PHASE3":4779,"PHASE4":4781,"NA":4783},{"trials":4770,"activeCount":99},[],{"trials":4772,"activeCount":99},[],{"trials":4774,"activeCount":99},[4775],{"nctId":2685,"briefTitle":2686,"status":105,"phases":4776,"primaryCompletion":2688,"completion":2689,"start":2690,"enrollment":2691,"conditions":4777,"interventions":4778},[90],[18,15],[2694,2695,2696,2697,2698,573],{"trials":4780,"activeCount":99},[],{"trials":4782,"activeCount":99},[],{"trials":4784,"activeCount":99},[],{"intervention":2697,"totalTrials":137,"cells":4786},{"EARLY_PHASE1":4787,"PHASE1":4789,"PHASE2":4791,"PHASE3":4797,"PHASE4":4799,"NA":4801},{"trials":4788,"activeCount":99},[],{"trials":4790,"activeCount":99},[],{"trials":4792,"activeCount":99},[4793],{"nctId":2685,"briefTitle":2686,"status":105,"phases":4794,"primaryCompletion":2688,"completion":2689,"start":2690,"enrollment":2691,"conditions":4795,"interventions":4796},[90],[18,15],[2694,2695,2696,2697,2698,573],{"trials":4798,"activeCount":99},[],{"trials":4800,"activeCount":99},[],{"trials":4802,"activeCount":99},[],{"intervention":2698,"totalTrials":137,"cells":4804},{"EARLY_PHASE1":4805,"PHASE1":4807,"PHASE2":4809,"PHASE3":4815,"PHASE4":4817,"NA":4819},{"trials":4806,"activeCount":99},[],{"trials":4808,"activeCount":99},[],{"trials":4810,"activeCount":99},[4811],{"nctId":2685,"briefTitle":2686,"status":105,"phases":4812,"primaryCompletion":2688,"completion":2689,"start":2690,"enrollment":2691,"conditions":4813,"interventions":4814},[90],[18,15],[2694,2695,2696,2697,2698,573],{"trials":4816,"activeCount":99},[],{"trials":4818,"activeCount":99},[],{"trials":4820,"activeCount":99},[],{"intervention":1968,"totalTrials":137,"cells":4822},{"EARLY_PHASE1":4823,"PHASE1":4825,"PHASE2":4827,"PHASE3":4833,"PHASE4":4835,"NA":4837},{"trials":4824,"activeCount":99},[],{"trials":4826,"activeCount":99},[],{"trials":4828,"activeCount":99},[4829],{"nctId":1959,"briefTitle":1960,"status":105,"phases":4830,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":4831,"interventions":4832},[90],[18,15],[1968,1969],{"trials":4834,"activeCount":99},[],{"trials":4836,"activeCount":99},[],{"trials":4838,"activeCount":99},[],{"intervention":2806,"totalTrials":137,"cells":4840},{"EARLY_PHASE1":4841,"PHASE1":4843,"PHASE2":4845,"PHASE3":4851,"PHASE4":4853,"NA":4855},{"trials":4842,"activeCount":99},[],{"trials":4844,"activeCount":99},[],{"trials":4846,"activeCount":99},[4847],{"nctId":2798,"briefTitle":2799,"status":515,"phases":4848,"primaryCompletion":2801,"completion":2801,"start":2802,"enrollment":2803,"conditions":4849,"interventions":4850},[90],[21,24],[2779,2806],{"trials":4852,"activeCount":99},[],{"trials":4854,"activeCount":99},[],{"trials":4856,"activeCount":99},[],{"intervention":1980,"totalTrials":137,"cells":4858},{"EARLY_PHASE1":4859,"PHASE1":4861,"PHASE2":4863,"PHASE3":4869,"PHASE4":4871,"NA":4873},{"trials":4860,"activeCount":99},[],{"trials":4862,"activeCount":99},[],{"trials":4864,"activeCount":99},[4865],{"nctId":1971,"briefTitle":1972,"status":105,"phases":4866,"primaryCompletion":1974,"completion":1975,"start":1976,"enrollment":1977,"conditions":4867,"interventions":4868},[90],[21],[1980,413],{"trials":4870,"activeCount":99},[],{"trials":4872,"activeCount":99},[],{"trials":4874,"activeCount":99},[],{"intervention":4876,"totalTrials":137,"cells":4877},"Physician determined comparator PI + ritonavir",{"EARLY_PHASE1":4878,"PHASE1":4880,"PHASE2":4882,"PHASE3":4893,"PHASE4":4895,"NA":4897},{"trials":4879,"activeCount":99},[],{"trials":4881,"activeCount":99},[],{"trials":4883,"activeCount":99},[4884],{"nctId":4885,"briefTitle":4886,"status":515,"phases":4887,"primaryCompletion":4888,"completion":4888,"start":2151,"enrollment":4889,"conditions":4890,"interventions":4891},"NCT00242879","A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults",[90],"2007-06",130,[21,2917],[4876,4892],"GW640385 + ritonavir",{"trials":4894,"activeCount":99},[],{"trials":4896,"activeCount":99},[],{"trials":4898,"activeCount":99},[],{"intervention":4892,"totalTrials":137,"cells":4900},{"EARLY_PHASE1":4901,"PHASE1":4903,"PHASE2":4905,"PHASE3":4911,"PHASE4":4913,"NA":4915},{"trials":4902,"activeCount":99},[],{"trials":4904,"activeCount":99},[],{"trials":4906,"activeCount":99},[4907],{"nctId":4885,"briefTitle":4886,"status":515,"phases":4908,"primaryCompletion":4888,"completion":4888,"start":2151,"enrollment":4889,"conditions":4909,"interventions":4910},[90],[21,2917],[4876,4892],{"trials":4912,"activeCount":99},[],{"trials":4914,"activeCount":99},[],{"trials":4916,"activeCount":99},[],{"intervention":4112,"totalTrials":137,"cells":4918},{"EARLY_PHASE1":4919,"PHASE1":4921,"PHASE2":4923,"PHASE3":4929,"PHASE4":4931,"NA":4933},{"trials":4920,"activeCount":99},[],{"trials":4922,"activeCount":99},[],{"trials":4924,"activeCount":99},[4925],{"nctId":4103,"briefTitle":4104,"status":515,"phases":4926,"primaryCompletion":4106,"completion":4107,"start":4108,"enrollment":4109,"conditions":4927,"interventions":4928},[90],[18],[411,4112,4113],{"trials":4930,"activeCount":99},[],{"trials":4932,"activeCount":99},[],{"trials":4934,"activeCount":99},[],{"intervention":4113,"totalTrials":137,"cells":4936},{"EARLY_PHASE1":4937,"PHASE1":4939,"PHASE2":4941,"PHASE3":4947,"PHASE4":4949,"NA":4951},{"trials":4938,"activeCount":99},[],{"trials":4940,"activeCount":99},[],{"trials":4942,"activeCount":99},[4943],{"nctId":4103,"briefTitle":4104,"status":515,"phases":4944,"primaryCompletion":4106,"completion":4107,"start":4108,"enrollment":4109,"conditions":4945,"interventions":4946},[90],[18],[411,4112,4113],{"trials":4948,"activeCount":99},[],{"trials":4950,"activeCount":99},[],{"trials":4952,"activeCount":99},[],{"intervention":4357,"totalTrials":137,"cells":4954},{"EARLY_PHASE1":4955,"PHASE1":4957,"PHASE2":4959,"PHASE3":4965,"PHASE4":4967,"NA":4969},{"trials":4956,"activeCount":99},[],{"trials":4958,"activeCount":99},[],{"trials":4960,"activeCount":99},[4961],{"nctId":4350,"briefTitle":4351,"status":515,"phases":4962,"primaryCompletion":4353,"completion":4353,"start":4354,"enrollment":3938,"conditions":4963,"interventions":4964},[90],[18],[2192,2193,4357],{"trials":4966,"activeCount":99},[],{"trials":4968,"activeCount":99},[],{"trials":4970,"activeCount":99},[],{"intervention":113,"totalTrials":36,"cells":4972},{"EARLY_PHASE1":4973,"PHASE1":4975,"PHASE2":4993,"PHASE3":4995,"PHASE4":4997,"NA":4999},{"trials":4974,"activeCount":99},[],{"trials":4976,"activeCount":99},[4977,4981,4985,4989],{"nctId":1267,"briefTitle":1268,"status":105,"phases":4978,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":16,"conditions":4979,"interventions":4980},[89],[15],[425,1274,113,1275,1276,1277],{"nctId":2600,"briefTitle":2601,"status":105,"phases":4982,"primaryCompletion":493,"completion":465,"start":583,"enrollment":691,"conditions":4983,"interventions":4984},[89],[18],[1922,2605,113],{"nctId":103,"briefTitle":104,"status":105,"phases":4986,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":4987,"interventions":4988},[89],[18,15],[56,113],{"nctId":775,"briefTitle":776,"status":105,"phases":4990,"primaryCompletion":778,"completion":778,"start":779,"enrollment":780,"conditions":4991,"interventions":4992},[89],[18],[42,113,413],{"trials":4994,"activeCount":99},[],{"trials":4996,"activeCount":99},[],{"trials":4998,"activeCount":99},[],{"trials":5000,"activeCount":99},[],{"intervention":498,"totalTrials":36,"cells":5002},{"EARLY_PHASE1":5003,"PHASE1":5005,"PHASE2":5041,"PHASE3":5043,"PHASE4":5045,"NA":5047},{"trials":5004,"activeCount":99},[],{"trials":5006,"activeCount":99},[5007,5020,5030,5037],{"nctId":5008,"briefTitle":5009,"status":105,"phases":5010,"primaryCompletion":5011,"completion":5011,"start":581,"enrollment":2109,"conditions":5012,"interventions":5013},"NCT01593046","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects",[89],"2013-11",[18],[498,5014,5015,5016,5017,5018,5019,5014],"GSK1265744 LAP 800mg intramuscular","GSK1265744 LAP 200mg subcutaneous","GSK1265744 LAP 200mg intramuscular","GSK1265744 LAP 400mg intramuscular","TMC278 LA 1200mg intramuscular","TMC278 LA 600mg intramuscular",{"nctId":5021,"briefTitle":5022,"status":105,"phases":5023,"primaryCompletion":5024,"completion":5024,"start":5025,"enrollment":1412,"conditions":5026,"interventions":5027},"NCT02159131","Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects",[89],"2014-12","2014-08",[477],[5028,5029,498],"Ethinyl Estadiol","Levonorgestrel",{"nctId":5031,"briefTitle":5032,"status":105,"phases":5033,"primaryCompletion":5034,"completion":5034,"start":1057,"enrollment":711,"conditions":5035,"interventions":5036},"NCT02027454","Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction",[89],"2014-06",[18],[498,3982],{"nctId":490,"briefTitle":491,"status":105,"phases":5038,"primaryCompletion":474,"completion":474,"start":493,"enrollment":494,"conditions":5039,"interventions":5040},[89],[477],[66,497,498],{"trials":5042,"activeCount":99},[],{"trials":5044,"activeCount":99},[],{"trials":5046,"activeCount":99},[],{"trials":5048,"activeCount":99},[],{"intervention":714,"totalTrials":178,"cells":5050},{"EARLY_PHASE1":5051,"PHASE1":5053,"PHASE2":5067,"PHASE3":5069,"PHASE4":5071,"NA":5073},{"trials":5052,"activeCount":99},[],{"trials":5054,"activeCount":99},[5055,5059,5063],{"nctId":705,"briefTitle":706,"status":105,"phases":5056,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":5057,"interventions":5058},[89],[18],[42,714,413,715],{"nctId":784,"briefTitle":785,"status":105,"phases":5060,"primaryCompletion":787,"completion":787,"start":788,"enrollment":760,"conditions":5061,"interventions":5062},[89],[18],[42,714,791],{"nctId":1933,"briefTitle":1934,"status":105,"phases":5064,"primaryCompletion":1936,"completion":1936,"start":1937,"enrollment":22,"conditions":5065,"interventions":5066},[89],[1939],[714,715,413,1941,1922],{"trials":5068,"activeCount":99},[],{"trials":5070,"activeCount":99},[],{"trials":5072,"activeCount":99},[],{"trials":5074,"activeCount":99},[],{"intervention":1277,"totalTrials":362,"cells":5076},{"EARLY_PHASE1":5077,"PHASE1":5079,"PHASE2":5092,"PHASE3":5094,"PHASE4":5096,"NA":5098},{"trials":5078,"activeCount":99},[],{"trials":5080,"activeCount":99},[5081,5085],{"nctId":1267,"briefTitle":1268,"status":105,"phases":5082,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":16,"conditions":5083,"interventions":5084},[89],[15],[425,1274,113,1275,1276,1277],{"nctId":5086,"briefTitle":5087,"status":105,"phases":5088,"primaryCompletion":2261,"completion":2261,"start":5089,"enrollment":25,"conditions":5090,"interventions":5091},"NCT01056874","Effect Of Maraviroc On The Pharmacokinetics Of Digoxin",[89],"2010-03",[33,15],[1277,1277,735],{"trials":5093,"activeCount":99},[],{"trials":5095,"activeCount":99},[],{"trials":5097,"activeCount":99},[],{"trials":5099,"activeCount":99},[],{"intervention":2060,"totalTrials":362,"cells":5101},{"EARLY_PHASE1":5102,"PHASE1":5104,"PHASE2":5114,"PHASE3":5116,"PHASE4":5118,"NA":5120},{"trials":5103,"activeCount":99},[],{"trials":5105,"activeCount":99},[5106,5110],{"nctId":2052,"briefTitle":2053,"status":105,"phases":5107,"primaryCompletion":2055,"completion":2055,"start":2047,"enrollment":2056,"conditions":5108,"interventions":5109},[89],[2058,18],[2060,2036,2061],{"nctId":2063,"briefTitle":2064,"status":105,"phases":5111,"primaryCompletion":2066,"completion":2066,"start":2067,"enrollment":2068,"conditions":5112,"interventions":5113},[89],[18],[2060,2036,2061],{"trials":5115,"activeCount":99},[],{"trials":5117,"activeCount":99},[],{"trials":5119,"activeCount":99},[],{"trials":5121,"activeCount":99},[],{"intervention":2061,"totalTrials":362,"cells":5123},{"EARLY_PHASE1":5124,"PHASE1":5126,"PHASE2":5136,"PHASE3":5138,"PHASE4":5140,"NA":5142},{"trials":5125,"activeCount":99},[],{"trials":5127,"activeCount":99},[5128,5132],{"nctId":2052,"briefTitle":2053,"status":105,"phases":5129,"primaryCompletion":2055,"completion":2055,"start":2047,"enrollment":2056,"conditions":5130,"interventions":5131},[89],[2058,18],[2060,2036,2061],{"nctId":2063,"briefTitle":2064,"status":105,"phases":5133,"primaryCompletion":2066,"completion":2066,"start":2067,"enrollment":2068,"conditions":5134,"interventions":5135},[89],[18],[2060,2036,2061],{"trials":5137,"activeCount":99},[],{"trials":5139,"activeCount":99},[],{"trials":5141,"activeCount":99},[],{"trials":5143,"activeCount":99},[],{"intervention":2899,"totalTrials":362,"cells":5145},{"EARLY_PHASE1":5146,"PHASE1":5148,"PHASE2":5158,"PHASE3":5160,"PHASE4":5162,"NA":5164},{"trials":5147,"activeCount":99},[],{"trials":5149,"activeCount":99},[5150,5154],{"nctId":2894,"briefTitle":2895,"status":105,"phases":5151,"primaryCompletion":2047,"completion":2047,"start":2610,"enrollment":494,"conditions":5152,"interventions":5153},[89],[33],[735,2887,2899,735,2887,2899],{"nctId":2901,"briefTitle":2895,"status":515,"phases":5155,"primaryCompletion":2004,"completion":2004,"start":2903,"enrollment":456,"conditions":5156,"interventions":5157},[89],[33],[735,2887,2899,735,2887,2899],{"trials":5159,"activeCount":99},[],{"trials":5161,"activeCount":99},[],{"trials":5163,"activeCount":99},[],{"trials":5165,"activeCount":99},[],{"intervention":479,"totalTrials":362,"cells":5167},{"EARLY_PHASE1":5168,"PHASE1":5170,"PHASE2":5180,"PHASE3":5182,"PHASE4":5184,"NA":5186},{"trials":5169,"activeCount":99},[],{"trials":5171,"activeCount":99},[5172,5176],{"nctId":755,"briefTitle":756,"status":105,"phases":5173,"primaryCompletion":758,"completion":758,"start":759,"enrollment":760,"conditions":5174,"interventions":5175},[89],[18],[42,479,763],{"nctId":471,"briefTitle":472,"status":105,"phases":5177,"primaryCompletion":474,"completion":474,"start":465,"enrollment":475,"conditions":5178,"interventions":5179},[89],[477],[66,479],{"trials":5181,"activeCount":99},[],{"trials":5183,"activeCount":99},[],{"trials":5185,"activeCount":99},[],{"trials":5187,"activeCount":99},[],{"intervention":3982,"totalTrials":362,"cells":5189},{"EARLY_PHASE1":5190,"PHASE1":5192,"PHASE2":5202,"PHASE3":5204,"PHASE4":5206,"NA":5208},{"trials":5191,"activeCount":99},[],{"trials":5193,"activeCount":99},[5194,5198],{"nctId":3976,"briefTitle":3977,"status":105,"phases":5195,"primaryCompletion":3979,"completion":3979,"start":155,"enrollment":700,"conditions":5196,"interventions":5197},[89],[15],[523,3982],{"nctId":5031,"briefTitle":5032,"status":105,"phases":5199,"primaryCompletion":5034,"completion":5034,"start":1057,"enrollment":711,"conditions":5200,"interventions":5201},[89],[18],[498,3982],{"trials":5203,"activeCount":99},[],{"trials":5205,"activeCount":99},[],{"trials":5207,"activeCount":99},[],{"trials":5209,"activeCount":99},[],{"intervention":5211,"totalTrials":362,"cells":5212},"Dolutegravir Dispersible",{"EARLY_PHASE1":5213,"PHASE1":5215,"PHASE2":5237,"PHASE3":5239,"PHASE4":5241,"NA":5243},{"trials":5214,"activeCount":99},[],{"trials":5216,"activeCount":99},[5217,5226],{"nctId":5218,"briefTitle":5219,"status":105,"phases":5220,"primaryCompletion":5221,"completion":5221,"start":5222,"enrollment":110,"conditions":5223,"interventions":5224},"NCT02185300","Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers",[89],"2014-09","2014-07",[18],[5225,5211],"Dolutegravir Pediatric Granules",{"nctId":5227,"briefTitle":5228,"status":105,"phases":5229,"primaryCompletion":5230,"completion":5230,"start":5231,"enrollment":8,"conditions":5232,"interventions":5233},"NCT03921723","Dolutegravir Pediatric Liquid Formulation Study",[89],"2019-07-25","2019-05-07",[15],[5234,5235,5236],"Dolutegravir dispersible","Dolutegravir oral suspension","Dolutegravir oral solution",{"trials":5238,"activeCount":99},[],{"trials":5240,"activeCount":99},[],{"trials":5242,"activeCount":99},[],{"trials":5244,"activeCount":99},[],{"intervention":5246,"totalTrials":137,"cells":5247},"Cabotegravir 30 mg current formulation",{"EARLY_PHASE1":5248,"PHASE1":5250,"PHASE2":5265,"PHASE3":5267,"PHASE4":5269,"NA":5271},{"trials":5249,"activeCount":99},[],{"trials":5251,"activeCount":99},[5252],{"nctId":5253,"briefTitle":5254,"status":105,"phases":5255,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":5259,"interventions":5260},"NCT02345707","Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir",[89],"2015-06","2015-03",37,[18],[5246,5261,5262,5263,5264],"Cabotegravir 30 mg micronized new formulation 500 M","Cabotegravir 30 mg unmicronized new formulation 500 U","Cabotegravir 30 mg micronized new formulation 650 M","Cabotegravir 30 mg unmicronized new formulation 650 U",{"trials":5266,"activeCount":99},[],{"trials":5268,"activeCount":99},[],{"trials":5270,"activeCount":99},[],{"trials":5272,"activeCount":99},[],{"intervention":5261,"totalTrials":137,"cells":5274},{"EARLY_PHASE1":5275,"PHASE1":5277,"PHASE2":5283,"PHASE3":5285,"PHASE4":5287,"NA":5289},{"trials":5276,"activeCount":99},[],{"trials":5278,"activeCount":99},[5279],{"nctId":5253,"briefTitle":5254,"status":105,"phases":5280,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":5281,"interventions":5282},[89],[18],[5246,5261,5262,5263,5264],{"trials":5284,"activeCount":99},[],{"trials":5286,"activeCount":99},[],{"trials":5288,"activeCount":99},[],{"trials":5290,"activeCount":99},[],{"intervention":5262,"totalTrials":137,"cells":5292},{"EARLY_PHASE1":5293,"PHASE1":5295,"PHASE2":5301,"PHASE3":5303,"PHASE4":5305,"NA":5307},{"trials":5294,"activeCount":99},[],{"trials":5296,"activeCount":99},[5297],{"nctId":5253,"briefTitle":5254,"status":105,"phases":5298,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":5299,"interventions":5300},[89],[18],[5246,5261,5262,5263,5264],{"trials":5302,"activeCount":99},[],{"trials":5304,"activeCount":99},[],{"trials":5306,"activeCount":99},[],{"trials":5308,"activeCount":99},[],{"intervention":5263,"totalTrials":137,"cells":5310},{"EARLY_PHASE1":5311,"PHASE1":5313,"PHASE2":5319,"PHASE3":5321,"PHASE4":5323,"NA":5325},{"trials":5312,"activeCount":99},[],{"trials":5314,"activeCount":99},[5315],{"nctId":5253,"briefTitle":5254,"status":105,"phases":5316,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":5317,"interventions":5318},[89],[18],[5246,5261,5262,5263,5264],{"trials":5320,"activeCount":99},[],{"trials":5322,"activeCount":99},[],{"trials":5324,"activeCount":99},[],{"trials":5326,"activeCount":99},[],{"intervention":5264,"totalTrials":137,"cells":5328},{"EARLY_PHASE1":5329,"PHASE1":5331,"PHASE2":5337,"PHASE3":5339,"PHASE4":5341,"NA":5343},{"trials":5330,"activeCount":99},[],{"trials":5332,"activeCount":99},[5333],{"nctId":5253,"briefTitle":5254,"status":105,"phases":5334,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":5335,"interventions":5336},[89],[18],[5246,5261,5262,5263,5264],{"trials":5338,"activeCount":99},[],{"trials":5340,"activeCount":99},[],{"trials":5342,"activeCount":99},[],{"trials":5344,"activeCount":99},[],{"intervention":2050,"totalTrials":137,"cells":5346},{"EARLY_PHASE1":5347,"PHASE1":5349,"PHASE2":5355,"PHASE3":5357,"PHASE4":5359,"NA":5361},{"trials":5348,"activeCount":99},[],{"trials":5350,"activeCount":99},[5351],{"nctId":2043,"briefTitle":2044,"status":105,"phases":5352,"primaryCompletion":2046,"completion":2046,"start":2047,"enrollment":1412,"conditions":5353,"interventions":5354},[89],[30],[2036,2050],{"trials":5356,"activeCount":99},[],{"trials":5358,"activeCount":99},[],{"trials":5360,"activeCount":99},[],{"trials":5362,"activeCount":99},[],{"intervention":5364,"totalTrials":137,"cells":5365},"VH4011499 Dose A",{"EARLY_PHASE1":5366,"PHASE1":5368,"PHASE2":5379,"PHASE3":5381,"PHASE4":5383,"NA":5385},{"trials":5367,"activeCount":99},[],{"trials":5369,"activeCount":99},[5370],{"nctId":5371,"briefTitle":5372,"status":105,"phases":5373,"primaryCompletion":1724,"completion":1724,"start":5374,"enrollment":5375,"conditions":5376,"interventions":5377},"NCT06368986","A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants",[89],"2024-04-17",60,[15],[5364,5378],"VH4011499 Dose B",{"trials":5380,"activeCount":99},[],{"trials":5382,"activeCount":99},[],{"trials":5384,"activeCount":99},[],{"trials":5386,"activeCount":99},[],{"intervention":5378,"totalTrials":137,"cells":5388},{"EARLY_PHASE1":5389,"PHASE1":5391,"PHASE2":5397,"PHASE3":5399,"PHASE4":5401,"NA":5403},{"trials":5390,"activeCount":99},[],{"trials":5392,"activeCount":99},[5393],{"nctId":5371,"briefTitle":5372,"status":105,"phases":5394,"primaryCompletion":1724,"completion":1724,"start":5374,"enrollment":5375,"conditions":5395,"interventions":5396},[89],[15],[5364,5378],{"trials":5398,"activeCount":99},[],{"trials":5400,"activeCount":99},[],{"trials":5402,"activeCount":99},[],{"trials":5404,"activeCount":99},[],{"intervention":703,"totalTrials":137,"cells":5406},{"EARLY_PHASE1":5407,"PHASE1":5409,"PHASE2":5415,"PHASE3":5417,"PHASE4":5419,"NA":5421},{"trials":5408,"activeCount":99},[],{"trials":5410,"activeCount":99},[5411],{"nctId":695,"briefTitle":696,"status":105,"phases":5412,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":5413,"interventions":5414},[89],[15],[703,42],{"trials":5416,"activeCount":99},[],{"trials":5418,"activeCount":99},[],{"trials":5420,"activeCount":99},[],{"trials":5422,"activeCount":99},[],{"intervention":459,"totalTrials":137,"cells":5424},{"EARLY_PHASE1":5425,"PHASE1":5427,"PHASE2":5433,"PHASE3":5435,"PHASE4":5437,"NA":5439},{"trials":5426,"activeCount":99},[],{"trials":5428,"activeCount":99},[5429],{"nctId":451,"briefTitle":452,"status":105,"phases":5430,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":5431,"interventions":5432},[89],[18],[66,459],{"trials":5434,"activeCount":99},[],{"trials":5436,"activeCount":99},[],{"trials":5438,"activeCount":99},[],{"trials":5440,"activeCount":99},[],{"intervention":5442,"totalTrials":137,"cells":5443},"BMS-955176, Placebo",{"EARLY_PHASE1":5444,"PHASE1":5446,"PHASE2":5459,"PHASE3":5461,"PHASE4":5463,"NA":5465},{"trials":5445,"activeCount":99},[],{"trials":5447,"activeCount":99},[5448],{"nctId":5449,"briefTitle":5450,"status":515,"phases":5451,"primaryCompletion":5452,"completion":5453,"start":5454,"enrollment":5455,"conditions":5456,"interventions":5457},"NCT02576119","A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects",[89],"2016-02-26","2016-10-14","2015-10-19",315,[18],[5442,5458],"BMS-955176, Moxifloxacin, Placebo",{"trials":5460,"activeCount":99},[],{"trials":5462,"activeCount":99},[],{"trials":5464,"activeCount":99},[],{"trials":5466,"activeCount":99},[],{"intervention":5458,"totalTrials":137,"cells":5468},{"EARLY_PHASE1":5469,"PHASE1":5471,"PHASE2":5477,"PHASE3":5479,"PHASE4":5481,"NA":5483},{"trials":5470,"activeCount":99},[],{"trials":5472,"activeCount":99},[5473],{"nctId":5449,"briefTitle":5450,"status":515,"phases":5474,"primaryCompletion":5452,"completion":5453,"start":5454,"enrollment":5455,"conditions":5475,"interventions":5476},[89],[18],[5442,5458],{"trials":5478,"activeCount":99},[],{"trials":5480,"activeCount":99},[],{"trials":5482,"activeCount":99},[],{"trials":5484,"activeCount":99},[],{"intervention":3941,"totalTrials":137,"cells":5486},{"EARLY_PHASE1":5487,"PHASE1":5489,"PHASE2":5495,"PHASE3":5497,"PHASE4":5499,"NA":5501},{"trials":5488,"activeCount":99},[],{"trials":5490,"activeCount":99},[5491],{"nctId":3933,"briefTitle":3934,"status":105,"phases":5492,"primaryCompletion":3936,"completion":3936,"start":3937,"enrollment":3938,"conditions":5493,"interventions":5494},[89],[15],[523,3941],{"trials":5496,"activeCount":99},[],{"trials":5498,"activeCount":99},[],{"trials":5500,"activeCount":99},[],{"trials":5502,"activeCount":99},[],{"intervention":5504,"totalTrials":137,"cells":5505},"GSK1265744B (sodium salt) containing 14C-GSK1265744B",{"EARLY_PHASE1":5506,"PHASE1":5508,"PHASE2":5519,"PHASE3":5521,"PHASE4":5523,"NA":5525},{"trials":5507,"activeCount":99},[],{"trials":5509,"activeCount":99},[5510],{"nctId":5511,"briefTitle":5512,"status":105,"phases":5513,"primaryCompletion":1975,"completion":1975,"start":5514,"enrollment":466,"conditions":5515,"interventions":5517},"NCT01848340","An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects",[89],"2013-05",[5516],"HIV-associated Lipodystrophy Syndrome",[5504,5518],"150 mg GSK1265744B",{"trials":5520,"activeCount":99},[],{"trials":5522,"activeCount":99},[],{"trials":5524,"activeCount":99},[],{"trials":5526,"activeCount":99},[],{"intervention":5518,"totalTrials":137,"cells":5528},{"EARLY_PHASE1":5529,"PHASE1":5531,"PHASE2":5537,"PHASE3":5539,"PHASE4":5541,"NA":5543},{"trials":5530,"activeCount":99},[],{"trials":5532,"activeCount":99},[5533],{"nctId":5511,"briefTitle":5512,"status":105,"phases":5534,"primaryCompletion":1975,"completion":1975,"start":5514,"enrollment":466,"conditions":5535,"interventions":5536},[89],[5516],[5504,5518],{"trials":5538,"activeCount":99},[],{"trials":5540,"activeCount":99},[],{"trials":5542,"activeCount":99},[],{"trials":5544,"activeCount":99},[],{"intervention":5546,"totalTrials":137,"cells":5547},"GSK3732394",{"EARLY_PHASE1":5548,"PHASE1":5550,"PHASE2":5560,"PHASE3":5562,"PHASE4":5564,"NA":5566},{"trials":5549,"activeCount":99},[],{"trials":5551,"activeCount":99},[5552],{"nctId":5553,"briefTitle":5554,"status":515,"phases":5555,"primaryCompletion":5556,"completion":5556,"start":5557,"enrollment":1219,"conditions":5558,"interventions":5559},"NCT03984812","Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study",[89],"2020-03-23","2019-06-17",[15],[5546],{"trials":5561,"activeCount":99},[],{"trials":5563,"activeCount":99},[],{"trials":5565,"activeCount":99},[],{"trials":5567,"activeCount":99},[],{"intervention":1274,"totalTrials":137,"cells":5569},{"EARLY_PHASE1":5570,"PHASE1":5572,"PHASE2":5578,"PHASE3":5580,"PHASE4":5582,"NA":5584},{"trials":5571,"activeCount":99},[],{"trials":5573,"activeCount":99},[5574],{"nctId":1267,"briefTitle":1268,"status":105,"phases":5575,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":16,"conditions":5576,"interventions":5577},[89],[15],[425,1274,113,1275,1276,1277],{"trials":5579,"activeCount":99},[],{"trials":5581,"activeCount":99},[],{"trials":5583,"activeCount":99},[],{"trials":5585,"activeCount":99},[],{"intervention":1275,"totalTrials":137,"cells":5587},{"EARLY_PHASE1":5588,"PHASE1":5590,"PHASE2":5596,"PHASE3":5598,"PHASE4":5600,"NA":5602},{"trials":5589,"activeCount":99},[],{"trials":5591,"activeCount":99},[5592],{"nctId":1267,"briefTitle":1268,"status":105,"phases":5593,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":16,"conditions":5594,"interventions":5595},[89],[15],[425,1274,113,1275,1276,1277],{"trials":5597,"activeCount":99},[],{"trials":5599,"activeCount":99},[],{"trials":5601,"activeCount":99},[],{"trials":5603,"activeCount":99},[],{"intervention":1276,"totalTrials":137,"cells":5605},{"EARLY_PHASE1":5606,"PHASE1":5608,"PHASE2":5614,"PHASE3":5616,"PHASE4":5618,"NA":5620},{"trials":5607,"activeCount":99},[],{"trials":5609,"activeCount":99},[5610],{"nctId":1267,"briefTitle":1268,"status":105,"phases":5611,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":16,"conditions":5612,"interventions":5613},[89],[15],[425,1274,113,1275,1276,1277],{"trials":5615,"activeCount":99},[],{"trials":5617,"activeCount":99},[],{"trials":5619,"activeCount":99},[],{"trials":5621,"activeCount":99},[],{"intervention":5623,"totalTrials":137,"cells":5624},"Maraviroc + Boceprevir",{"EARLY_PHASE1":5625,"PHASE1":5627,"PHASE2":5637,"PHASE3":5639,"PHASE4":5641,"NA":5643},{"trials":5626,"activeCount":99},[],{"trials":5628,"activeCount":99},[5629],{"nctId":5630,"briefTitle":5631,"status":105,"phases":5632,"primaryCompletion":2066,"completion":2066,"start":5633,"enrollment":456,"conditions":5634,"interventions":5635},"NCT01597895","Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects",[89],"2012-07",[33],[735,5623,5636],"Maraviroc + Telaprevir",{"trials":5638,"activeCount":99},[],{"trials":5640,"activeCount":99},[],{"trials":5642,"activeCount":99},[],{"trials":5644,"activeCount":99},[],{"intervention":5636,"totalTrials":137,"cells":5646},{"EARLY_PHASE1":5647,"PHASE1":5649,"PHASE2":5655,"PHASE3":5657,"PHASE4":5659,"NA":5661},{"trials":5648,"activeCount":99},[],{"trials":5650,"activeCount":99},[5651],{"nctId":5630,"briefTitle":5631,"status":105,"phases":5652,"primaryCompletion":2066,"completion":2066,"start":5633,"enrollment":456,"conditions":5653,"interventions":5654},[89],[33],[735,5623,5636],{"trials":5656,"activeCount":99},[],{"trials":5658,"activeCount":99},[],{"trials":5660,"activeCount":99},[],{"trials":5662,"activeCount":99},[],{"intervention":5664,"totalTrials":137,"cells":5665},"GSK1265744 Na Salt",{"EARLY_PHASE1":5666,"PHASE1":5668,"PHASE2":5679,"PHASE3":5681,"PHASE4":5683,"NA":5685},{"trials":5667,"activeCount":99},[],{"trials":5669,"activeCount":99},[5670],{"nctId":5671,"briefTitle":5672,"status":105,"phases":5673,"primaryCompletion":5674,"completion":5674,"start":2066,"enrollment":2056,"conditions":5675,"interventions":5676},"NCT01648257","Relative Bioavailability Study of GSK1265744 Formulations",[89],"2012-11",[477],[5664,5677,5678],"GSK1265744 Free Acid Nanomilled","GSK1265744 Free Acid Micronized",{"trials":5680,"activeCount":99},[],{"trials":5682,"activeCount":99},[],{"trials":5684,"activeCount":99},[],{"trials":5686,"activeCount":99},[],{"intervention":5677,"totalTrials":137,"cells":5688},{"EARLY_PHASE1":5689,"PHASE1":5691,"PHASE2":5697,"PHASE3":5699,"PHASE4":5701,"NA":5703},{"trials":5690,"activeCount":99},[],{"trials":5692,"activeCount":99},[5693],{"nctId":5671,"briefTitle":5672,"status":105,"phases":5694,"primaryCompletion":5674,"completion":5674,"start":2066,"enrollment":2056,"conditions":5695,"interventions":5696},[89],[477],[5664,5677,5678],{"trials":5698,"activeCount":99},[],{"trials":5700,"activeCount":99},[],{"trials":5702,"activeCount":99},[],{"trials":5704,"activeCount":99},[],{"intervention":5678,"totalTrials":137,"cells":5706},{"EARLY_PHASE1":5707,"PHASE1":5709,"PHASE2":5715,"PHASE3":5717,"PHASE4":5719,"NA":5721},{"trials":5708,"activeCount":99},[],{"trials":5710,"activeCount":99},[5711],{"nctId":5671,"briefTitle":5672,"status":105,"phases":5712,"primaryCompletion":5674,"completion":5674,"start":2066,"enrollment":2056,"conditions":5713,"interventions":5714},[89],[477],[5664,5677,5678],{"trials":5716,"activeCount":99},[],{"trials":5718,"activeCount":99},[],{"trials":5720,"activeCount":99},[],{"trials":5722,"activeCount":99},[],{"intervention":4046,"totalTrials":137,"cells":5724},{"EARLY_PHASE1":5725,"PHASE1":5727,"PHASE2":5733,"PHASE3":5735,"PHASE4":5737,"NA":5739},{"trials":5726,"activeCount":99},[],{"trials":5728,"activeCount":99},[5729],{"nctId":4039,"briefTitle":4040,"status":105,"phases":5730,"primaryCompletion":4042,"completion":4042,"start":4043,"enrollment":1965,"conditions":5731,"interventions":5732},[89],[15],[4046,411,4047],{"trials":5734,"activeCount":99},[],{"trials":5736,"activeCount":99},[],{"trials":5738,"activeCount":99},[],{"trials":5740,"activeCount":99},[],{"intervention":4047,"totalTrials":137,"cells":5742},{"EARLY_PHASE1":5743,"PHASE1":5745,"PHASE2":5751,"PHASE3":5753,"PHASE4":5755,"NA":5757},{"trials":5744,"activeCount":99},[],{"trials":5746,"activeCount":99},[5747],{"nctId":4039,"briefTitle":4040,"status":105,"phases":5748,"primaryCompletion":4042,"completion":4042,"start":4043,"enrollment":1965,"conditions":5749,"interventions":5750},[89],[15],[4046,411,4047],{"trials":5752,"activeCount":99},[],{"trials":5754,"activeCount":99},[],{"trials":5756,"activeCount":99},[],{"trials":5758,"activeCount":99},[],{"intervention":5760,"totalTrials":137,"cells":5761},"GSK1265744 Reference formulation",{"EARLY_PHASE1":5762,"PHASE1":5764,"PHASE2":5775,"PHASE3":5777,"PHASE4":5779,"NA":5781},{"trials":5763,"activeCount":99},[],{"trials":5765,"activeCount":99},[5766],{"nctId":5767,"briefTitle":5768,"status":105,"phases":5769,"primaryCompletion":5034,"completion":5034,"start":5770,"enrollment":1219,"conditions":5771,"interventions":5772},"NCT02059031","A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects",[89],"2014-02",[18],[5760,5773,5774],"GSK1265744 New formulation 1","GSK1265744 New formulation 2",{"trials":5776,"activeCount":99},[],{"trials":5778,"activeCount":99},[],{"trials":5780,"activeCount":99},[],{"trials":5782,"activeCount":99},[],{"intervention":5773,"totalTrials":137,"cells":5784},{"EARLY_PHASE1":5785,"PHASE1":5787,"PHASE2":5793,"PHASE3":5795,"PHASE4":5797,"NA":5799},{"trials":5786,"activeCount":99},[],{"trials":5788,"activeCount":99},[5789],{"nctId":5767,"briefTitle":5768,"status":105,"phases":5790,"primaryCompletion":5034,"completion":5034,"start":5770,"enrollment":1219,"conditions":5791,"interventions":5792},[89],[18],[5760,5773,5774],{"trials":5794,"activeCount":99},[],{"trials":5796,"activeCount":99},[],{"trials":5798,"activeCount":99},[],{"trials":5800,"activeCount":99},[],{"intervention":5774,"totalTrials":137,"cells":5802},{"EARLY_PHASE1":5803,"PHASE1":5805,"PHASE2":5811,"PHASE3":5813,"PHASE4":5815,"NA":5817},{"trials":5804,"activeCount":99},[],{"trials":5806,"activeCount":99},[5807],{"nctId":5767,"briefTitle":5768,"status":105,"phases":5808,"primaryCompletion":5034,"completion":5034,"start":5770,"enrollment":1219,"conditions":5809,"interventions":5810},[89],[18],[5760,5773,5774],{"trials":5812,"activeCount":99},[],{"trials":5814,"activeCount":99},[],{"trials":5816,"activeCount":99},[],{"trials":5818,"activeCount":99},[],{"intervention":2588,"totalTrials":137,"cells":5820},{"EARLY_PHASE1":5821,"PHASE1":5823,"PHASE2":5829,"PHASE3":5831,"PHASE4":5833,"NA":5835},{"trials":5822,"activeCount":99},[],{"trials":5824,"activeCount":99},[5825],{"nctId":2582,"briefTitle":2583,"status":105,"phases":5826,"primaryCompletion":1918,"completion":1918,"start":2004,"enrollment":805,"conditions":5827,"interventions":5828},[89],[2586],[1922,2588,2589],{"trials":5830,"activeCount":99},[],{"trials":5832,"activeCount":99},[],{"trials":5834,"activeCount":99},[],{"trials":5836,"activeCount":99},[],{"intervention":2589,"totalTrials":137,"cells":5838},{"EARLY_PHASE1":5839,"PHASE1":5841,"PHASE2":5847,"PHASE3":5849,"PHASE4":5851,"NA":5853},{"trials":5840,"activeCount":99},[],{"trials":5842,"activeCount":99},[5843],{"nctId":2582,"briefTitle":2583,"status":105,"phases":5844,"primaryCompletion":1918,"completion":1918,"start":2004,"enrollment":805,"conditions":5845,"interventions":5846},[89],[2586],[1922,2588,2589],{"trials":5848,"activeCount":99},[],{"trials":5850,"activeCount":99},[],{"trials":5852,"activeCount":99},[],{"trials":5854,"activeCount":99},[],{"intervention":5856,"totalTrials":137,"cells":5857},"Metformin 500 mg q12h",{"EARLY_PHASE1":5858,"PHASE1":5860,"PHASE2":5870,"PHASE3":5872,"PHASE4":5874,"NA":5876},{"trials":5859,"activeCount":99},[],{"trials":5861,"activeCount":99},[5862],{"nctId":5863,"briefTitle":5864,"status":105,"phases":5865,"primaryCompletion":603,"completion":603,"start":5770,"enrollment":1950,"conditions":5866,"interventions":5867},"NCT02064374","Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects",[89],[18],[5856,5868,5869],"Dolutegravir 50 mg q24h","Dolutegravir 50 mg q12h",{"trials":5871,"activeCount":99},[],{"trials":5873,"activeCount":99},[],{"trials":5875,"activeCount":99},[],{"trials":5877,"activeCount":99},[],{"intervention":5868,"totalTrials":137,"cells":5879},{"EARLY_PHASE1":5880,"PHASE1":5882,"PHASE2":5888,"PHASE3":5890,"PHASE4":5892,"NA":5894},{"trials":5881,"activeCount":99},[],{"trials":5883,"activeCount":99},[5884],{"nctId":5863,"briefTitle":5864,"status":105,"phases":5885,"primaryCompletion":603,"completion":603,"start":5770,"enrollment":1950,"conditions":5886,"interventions":5887},[89],[18],[5856,5868,5869],{"trials":5889,"activeCount":99},[],{"trials":5891,"activeCount":99},[],{"trials":5893,"activeCount":99},[],{"trials":5895,"activeCount":99},[],{"intervention":5869,"totalTrials":137,"cells":5897},{"EARLY_PHASE1":5898,"PHASE1":5900,"PHASE2":5906,"PHASE3":5908,"PHASE4":5910,"NA":5912},{"trials":5899,"activeCount":99},[],{"trials":5901,"activeCount":99},[5902],{"nctId":5863,"briefTitle":5864,"status":105,"phases":5903,"primaryCompletion":603,"completion":603,"start":5770,"enrollment":1950,"conditions":5904,"interventions":5905},[89],[18],[5856,5868,5869],{"trials":5907,"activeCount":99},[],{"trials":5909,"activeCount":99},[],{"trials":5911,"activeCount":99},[],{"trials":5913,"activeCount":99},[],{"intervention":725,"totalTrials":137,"cells":5915},{"EARLY_PHASE1":5916,"PHASE1":5918,"PHASE2":5924,"PHASE3":5926,"PHASE4":5928,"NA":5930},{"trials":5917,"activeCount":99},[],{"trials":5919,"activeCount":99},[5920],{"nctId":717,"briefTitle":718,"status":105,"phases":5921,"primaryCompletion":720,"completion":720,"start":721,"enrollment":722,"conditions":5922,"interventions":5923},[89],[18],[42,725],{"trials":5925,"activeCount":99},[],{"trials":5927,"activeCount":99},[],{"trials":5929,"activeCount":99},[],{"trials":5931,"activeCount":99},[],{"intervention":1586,"totalTrials":137,"cells":5933},{"EARLY_PHASE1":5934,"PHASE1":5936,"PHASE2":5942,"PHASE3":5944,"PHASE4":5946,"NA":5948},{"trials":5935,"activeCount":99},[],{"trials":5937,"activeCount":99},[5938],{"nctId":1578,"briefTitle":1579,"status":105,"phases":5939,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":5940,"interventions":5941},[89],[15],[1586,1587,1209,1588,1589,1590,1591,1592],{"trials":5943,"activeCount":99},[],{"trials":5945,"activeCount":99},[],{"trials":5947,"activeCount":99},[],{"trials":5949,"activeCount":99},[],{"intervention":1587,"totalTrials":137,"cells":5951},{"EARLY_PHASE1":5952,"PHASE1":5954,"PHASE2":5960,"PHASE3":5962,"PHASE4":5964,"NA":5966},{"trials":5953,"activeCount":99},[],{"trials":5955,"activeCount":99},[5956],{"nctId":1578,"briefTitle":1579,"status":105,"phases":5957,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":5958,"interventions":5959},[89],[15],[1586,1587,1209,1588,1589,1590,1591,1592],{"trials":5961,"activeCount":99},[],{"trials":5963,"activeCount":99},[],{"trials":5965,"activeCount":99},[],{"trials":5967,"activeCount":99},[],{"intervention":1588,"totalTrials":137,"cells":5969},{"EARLY_PHASE1":5970,"PHASE1":5972,"PHASE2":5978,"PHASE3":5980,"PHASE4":5982,"NA":5984},{"trials":5971,"activeCount":99},[],{"trials":5973,"activeCount":99},[5974],{"nctId":1578,"briefTitle":1579,"status":105,"phases":5975,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":5976,"interventions":5977},[89],[15],[1586,1587,1209,1588,1589,1590,1591,1592],{"trials":5979,"activeCount":99},[],{"trials":5981,"activeCount":99},[],{"trials":5983,"activeCount":99},[],{"trials":5985,"activeCount":99},[],{"intervention":1589,"totalTrials":137,"cells":5987},{"EARLY_PHASE1":5988,"PHASE1":5990,"PHASE2":5996,"PHASE3":5998,"PHASE4":6000,"NA":6002},{"trials":5989,"activeCount":99},[],{"trials":5991,"activeCount":99},[5992],{"nctId":1578,"briefTitle":1579,"status":105,"phases":5993,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":5994,"interventions":5995},[89],[15],[1586,1587,1209,1588,1589,1590,1591,1592],{"trials":5997,"activeCount":99},[],{"trials":5999,"activeCount":99},[],{"trials":6001,"activeCount":99},[],{"trials":6003,"activeCount":99},[],{"intervention":1590,"totalTrials":137,"cells":6005},{"EARLY_PHASE1":6006,"PHASE1":6008,"PHASE2":6014,"PHASE3":6016,"PHASE4":6018,"NA":6020},{"trials":6007,"activeCount":99},[],{"trials":6009,"activeCount":99},[6010],{"nctId":1578,"briefTitle":1579,"status":105,"phases":6011,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":6012,"interventions":6013},[89],[15],[1586,1587,1209,1588,1589,1590,1591,1592],{"trials":6015,"activeCount":99},[],{"trials":6017,"activeCount":99},[],{"trials":6019,"activeCount":99},[],{"trials":6021,"activeCount":99},[],{"intervention":1591,"totalTrials":137,"cells":6023},{"EARLY_PHASE1":6024,"PHASE1":6026,"PHASE2":6032,"PHASE3":6034,"PHASE4":6036,"NA":6038},{"trials":6025,"activeCount":99},[],{"trials":6027,"activeCount":99},[6028],{"nctId":1578,"briefTitle":1579,"status":105,"phases":6029,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":6030,"interventions":6031},[89],[15],[1586,1587,1209,1588,1589,1590,1591,1592],{"trials":6033,"activeCount":99},[],{"trials":6035,"activeCount":99},[],{"trials":6037,"activeCount":99},[],{"trials":6039,"activeCount":99},[],{"intervention":1592,"totalTrials":137,"cells":6041},{"EARLY_PHASE1":6042,"PHASE1":6044,"PHASE2":6050,"PHASE3":6052,"PHASE4":6054,"NA":6056},{"trials":6043,"activeCount":99},[],{"trials":6045,"activeCount":99},[6046],{"nctId":1578,"briefTitle":1579,"status":105,"phases":6047,"primaryCompletion":1581,"completion":1581,"start":1582,"enrollment":1583,"conditions":6048,"interventions":6049},[89],[15],[1586,1587,1209,1588,1589,1590,1591,1592],{"trials":6051,"activeCount":99},[],{"trials":6053,"activeCount":99},[],{"trials":6055,"activeCount":99},[],{"trials":6057,"activeCount":99},[],{"intervention":6059,"totalTrials":137,"cells":6060},"Oral BMS-663068",{"EARLY_PHASE1":6061,"PHASE1":6063,"PHASE2":6071,"PHASE3":6073,"PHASE4":6075,"NA":6077},{"trials":6062,"activeCount":99},[],{"trials":6064,"activeCount":99},[6065],{"nctId":6066,"briefTitle":6067,"status":105,"phases":6068,"primaryCompletion":4078,"completion":4078,"start":5452,"enrollment":1950,"conditions":6069,"interventions":6070},"NCT02674581","A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)",[89],[15],[6059],{"trials":6072,"activeCount":99},[],{"trials":6074,"activeCount":99},[],{"trials":6076,"activeCount":99},[],{"trials":6078,"activeCount":99},[],{"intervention":6080,"totalTrials":137,"cells":6081},"Darunavir\u002Fcobicistat",{"EARLY_PHASE1":6082,"PHASE1":6084,"PHASE2":6094,"PHASE3":6096,"PHASE4":6098,"NA":6100},{"trials":6083,"activeCount":99},[],{"trials":6085,"activeCount":99},[6086],{"nctId":6087,"briefTitle":6088,"status":105,"phases":6089,"primaryCompletion":6090,"completion":6090,"start":6091,"enrollment":4071,"conditions":6092,"interventions":6093},"NCT02625207","THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC",[89],"2016-03-26","2015-11-06",[2058],[735,735,6080],{"trials":6095,"activeCount":99},[],{"trials":6097,"activeCount":99},[],{"trials":6099,"activeCount":99},[],{"trials":6101,"activeCount":99},[],{"intervention":6103,"totalTrials":137,"cells":6104},"GSK2248761 formulation 1",{"EARLY_PHASE1":6105,"PHASE1":6107,"PHASE2":6120,"PHASE3":6122,"PHASE4":6124,"NA":6126},{"trials":6106,"activeCount":99},[],{"trials":6108,"activeCount":99},[6109],{"nctId":6110,"briefTitle":6111,"status":105,"phases":6112,"primaryCompletion":6113,"completion":6113,"start":6114,"enrollment":1219,"conditions":6115,"interventions":6116},"NCT01031472","A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761",[89],"2010-03-11","2009-12-21",[18,15],[6103,6117,6118,6119],"GSK2248761 reference formulation","GSK2248761 formulation 3","GSK2248761 formulation 2 or 4",{"trials":6121,"activeCount":99},[],{"trials":6123,"activeCount":99},[],{"trials":6125,"activeCount":99},[],{"trials":6127,"activeCount":99},[],{"intervention":6117,"totalTrials":137,"cells":6129},{"EARLY_PHASE1":6130,"PHASE1":6132,"PHASE2":6138,"PHASE3":6140,"PHASE4":6142,"NA":6144},{"trials":6131,"activeCount":99},[],{"trials":6133,"activeCount":99},[6134],{"nctId":6110,"briefTitle":6111,"status":105,"phases":6135,"primaryCompletion":6113,"completion":6113,"start":6114,"enrollment":1219,"conditions":6136,"interventions":6137},[89],[18,15],[6103,6117,6118,6119],{"trials":6139,"activeCount":99},[],{"trials":6141,"activeCount":99},[],{"trials":6143,"activeCount":99},[],{"trials":6145,"activeCount":99},[],{"intervention":6118,"totalTrials":137,"cells":6147},{"EARLY_PHASE1":6148,"PHASE1":6150,"PHASE2":6156,"PHASE3":6158,"PHASE4":6160,"NA":6162},{"trials":6149,"activeCount":99},[],{"trials":6151,"activeCount":99},[6152],{"nctId":6110,"briefTitle":6111,"status":105,"phases":6153,"primaryCompletion":6113,"completion":6113,"start":6114,"enrollment":1219,"conditions":6154,"interventions":6155},[89],[18,15],[6103,6117,6118,6119],{"trials":6157,"activeCount":99},[],{"trials":6159,"activeCount":99},[],{"trials":6161,"activeCount":99},[],{"trials":6163,"activeCount":99},[],{"intervention":6119,"totalTrials":137,"cells":6165},{"EARLY_PHASE1":6166,"PHASE1":6168,"PHASE2":6174,"PHASE3":6176,"PHASE4":6178,"NA":6180},{"trials":6167,"activeCount":99},[],{"trials":6169,"activeCount":99},[6170],{"nctId":6110,"briefTitle":6111,"status":105,"phases":6171,"primaryCompletion":6113,"completion":6113,"start":6114,"enrollment":1219,"conditions":6172,"interventions":6173},[89],[18,15],[6103,6117,6118,6119],{"trials":6175,"activeCount":99},[],{"trials":6177,"activeCount":99},[],{"trials":6179,"activeCount":99},[],{"trials":6181,"activeCount":99},[],{"intervention":5014,"totalTrials":137,"cells":6183},{"EARLY_PHASE1":6184,"PHASE1":6186,"PHASE2":6192,"PHASE3":6194,"PHASE4":6196,"NA":6198},{"trials":6185,"activeCount":99},[],{"trials":6187,"activeCount":99},[6188],{"nctId":5008,"briefTitle":5009,"status":105,"phases":6189,"primaryCompletion":5011,"completion":5011,"start":581,"enrollment":2109,"conditions":6190,"interventions":6191},[89],[18],[498,5014,5015,5016,5017,5018,5019,5014],{"trials":6193,"activeCount":99},[],{"trials":6195,"activeCount":99},[],{"trials":6197,"activeCount":99},[],{"trials":6199,"activeCount":99},[],{"intervention":5015,"totalTrials":137,"cells":6201},{"EARLY_PHASE1":6202,"PHASE1":6204,"PHASE2":6210,"PHASE3":6212,"PHASE4":6214,"NA":6216},{"trials":6203,"activeCount":99},[],{"trials":6205,"activeCount":99},[6206],{"nctId":5008,"briefTitle":5009,"status":105,"phases":6207,"primaryCompletion":5011,"completion":5011,"start":581,"enrollment":2109,"conditions":6208,"interventions":6209},[89],[18],[498,5014,5015,5016,5017,5018,5019,5014],{"trials":6211,"activeCount":99},[],{"trials":6213,"activeCount":99},[],{"trials":6215,"activeCount":99},[],{"trials":6217,"activeCount":99},[],{"intervention":5016,"totalTrials":137,"cells":6219},{"EARLY_PHASE1":6220,"PHASE1":6222,"PHASE2":6228,"PHASE3":6230,"PHASE4":6232,"NA":6234},{"trials":6221,"activeCount":99},[],{"trials":6223,"activeCount":99},[6224],{"nctId":5008,"briefTitle":5009,"status":105,"phases":6225,"primaryCompletion":5011,"completion":5011,"start":581,"enrollment":2109,"conditions":6226,"interventions":6227},[89],[18],[498,5014,5015,5016,5017,5018,5019,5014],{"trials":6229,"activeCount":99},[],{"trials":6231,"activeCount":99},[],{"trials":6233,"activeCount":99},[],{"trials":6235,"activeCount":99},[],{"intervention":5017,"totalTrials":137,"cells":6237},{"EARLY_PHASE1":6238,"PHASE1":6240,"PHASE2":6246,"PHASE3":6248,"PHASE4":6250,"NA":6252},{"trials":6239,"activeCount":99},[],{"trials":6241,"activeCount":99},[6242],{"nctId":5008,"briefTitle":5009,"status":105,"phases":6243,"primaryCompletion":5011,"completion":5011,"start":581,"enrollment":2109,"conditions":6244,"interventions":6245},[89],[18],[498,5014,5015,5016,5017,5018,5019,5014],{"trials":6247,"activeCount":99},[],{"trials":6249,"activeCount":99},[],{"trials":6251,"activeCount":99},[],{"trials":6253,"activeCount":99},[],{"intervention":5018,"totalTrials":137,"cells":6255},{"EARLY_PHASE1":6256,"PHASE1":6258,"PHASE2":6264,"PHASE3":6266,"PHASE4":6268,"NA":6270},{"trials":6257,"activeCount":99},[],{"trials":6259,"activeCount":99},[6260],{"nctId":5008,"briefTitle":5009,"status":105,"phases":6261,"primaryCompletion":5011,"completion":5011,"start":581,"enrollment":2109,"conditions":6262,"interventions":6263},[89],[18],[498,5014,5015,5016,5017,5018,5019,5014],{"trials":6265,"activeCount":99},[],{"trials":6267,"activeCount":99},[],{"trials":6269,"activeCount":99},[],{"trials":6271,"activeCount":99},[],{"intervention":5019,"totalTrials":137,"cells":6273},{"EARLY_PHASE1":6274,"PHASE1":6276,"PHASE2":6282,"PHASE3":6284,"PHASE4":6286,"NA":6288},{"trials":6275,"activeCount":99},[],{"trials":6277,"activeCount":99},[6278],{"nctId":5008,"briefTitle":5009,"status":105,"phases":6279,"primaryCompletion":5011,"completion":5011,"start":581,"enrollment":2109,"conditions":6280,"interventions":6281},[89],[18],[498,5014,5015,5016,5017,5018,5019,5014],{"trials":6283,"activeCount":99},[],{"trials":6285,"activeCount":99},[],{"trials":6287,"activeCount":99},[],{"trials":6289,"activeCount":99},[],{"intervention":1014,"totalTrials":137,"cells":6291},{"EARLY_PHASE1":6292,"PHASE1":6294,"PHASE2":6300,"PHASE3":6302,"PHASE4":6304,"NA":6306},{"trials":6293,"activeCount":99},[],{"trials":6295,"activeCount":99},[6296],{"nctId":1008,"briefTitle":1009,"status":105,"phases":6297,"primaryCompletion":603,"completion":603,"start":1011,"enrollment":25,"conditions":6298,"interventions":6299},[89],[18],[170,1014],{"trials":6301,"activeCount":99},[],{"trials":6303,"activeCount":99},[],{"trials":6305,"activeCount":99},[],{"trials":6307,"activeCount":99},[],{"intervention":6309,"totalTrials":137,"cells":6310},"Cabotegravir Formulation F",{"EARLY_PHASE1":6311,"PHASE1":6313,"PHASE2":6325,"PHASE3":6327,"PHASE4":6329,"NA":6331},{"trials":6312,"activeCount":99},[],{"trials":6314,"activeCount":99},[6315],{"nctId":6316,"briefTitle":6317,"status":105,"phases":6318,"primaryCompletion":6319,"completion":6319,"start":6320,"enrollment":6321,"conditions":6322,"interventions":6323},"NCT06033547","A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants",[89],"2025-07-25","2023-09-12",56,[15],[6309,6324],"Cabotegravir Formulation G",{"trials":6326,"activeCount":99},[],{"trials":6328,"activeCount":99},[],{"trials":6330,"activeCount":99},[],{"trials":6332,"activeCount":99},[],{"intervention":6324,"totalTrials":137,"cells":6334},{"EARLY_PHASE1":6335,"PHASE1":6337,"PHASE2":6343,"PHASE3":6345,"PHASE4":6347,"NA":6349},{"trials":6336,"activeCount":99},[],{"trials":6338,"activeCount":99},[6339],{"nctId":6316,"briefTitle":6317,"status":105,"phases":6340,"primaryCompletion":6319,"completion":6319,"start":6320,"enrollment":6321,"conditions":6341,"interventions":6342},[89],[15],[6309,6324],{"trials":6344,"activeCount":99},[],{"trials":6346,"activeCount":99},[],{"trials":6348,"activeCount":99},[],{"trials":6350,"activeCount":99},[],{"intervention":1023,"totalTrials":137,"cells":6352},{"EARLY_PHASE1":6353,"PHASE1":6355,"PHASE2":6361,"PHASE3":6363,"PHASE4":6365,"NA":6367},{"trials":6354,"activeCount":99},[],{"trials":6356,"activeCount":99},[6357],{"nctId":1016,"briefTitle":1017,"status":105,"phases":6358,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":760,"conditions":6359,"interventions":6360},[89],[18],[170,1023,1024],{"trials":6362,"activeCount":99},[],{"trials":6364,"activeCount":99},[],{"trials":6366,"activeCount":99},[],{"trials":6368,"activeCount":99},[],{"intervention":1024,"totalTrials":137,"cells":6370},{"EARLY_PHASE1":6371,"PHASE1":6373,"PHASE2":6379,"PHASE3":6381,"PHASE4":6383,"NA":6385},{"trials":6372,"activeCount":99},[],{"trials":6374,"activeCount":99},[6375],{"nctId":1016,"briefTitle":1017,"status":105,"phases":6376,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":760,"conditions":6377,"interventions":6378},[89],[18],[170,1023,1024],{"trials":6380,"activeCount":99},[],{"trials":6382,"activeCount":99},[],{"trials":6384,"activeCount":99},[],{"trials":6386,"activeCount":99},[],{"intervention":469,"totalTrials":137,"cells":6388},{"EARLY_PHASE1":6389,"PHASE1":6391,"PHASE2":6397,"PHASE3":6399,"PHASE4":6401,"NA":6403},{"trials":6390,"activeCount":99},[],{"trials":6392,"activeCount":99},[6393],{"nctId":461,"briefTitle":462,"status":105,"phases":6394,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":6395,"interventions":6396},[89],[18],[469,66],{"trials":6398,"activeCount":99},[],{"trials":6400,"activeCount":99},[],{"trials":6402,"activeCount":99},[],{"trials":6404,"activeCount":99},[],{"intervention":6406,"totalTrials":137,"cells":6407},"GSK1349572 formulation AP",{"EARLY_PHASE1":6408,"PHASE1":6410,"PHASE2":6420,"PHASE3":6422,"PHASE4":6424,"NA":6426},{"trials":6409,"activeCount":99},[],{"trials":6411,"activeCount":99},[6412],{"nctId":6413,"briefTitle":6414,"status":105,"phases":6415,"primaryCompletion":2260,"completion":2903,"start":2261,"enrollment":1219,"conditions":6416,"interventions":6417},"NCT01098513","GSK1349572 Relative Bioavailability Study",[89],[18],[6406,6418,6419],"GSK1349572 formulation AW","GSK1349572 formulation AX",{"trials":6421,"activeCount":99},[],{"trials":6423,"activeCount":99},[],{"trials":6425,"activeCount":99},[],{"trials":6427,"activeCount":99},[],{"intervention":6418,"totalTrials":137,"cells":6429},{"EARLY_PHASE1":6430,"PHASE1":6432,"PHASE2":6438,"PHASE3":6440,"PHASE4":6442,"NA":6444},{"trials":6431,"activeCount":99},[],{"trials":6433,"activeCount":99},[6434],{"nctId":6413,"briefTitle":6414,"status":105,"phases":6435,"primaryCompletion":2260,"completion":2903,"start":2261,"enrollment":1219,"conditions":6436,"interventions":6437},[89],[18],[6406,6418,6419],{"trials":6439,"activeCount":99},[],{"trials":6441,"activeCount":99},[],{"trials":6443,"activeCount":99},[],{"trials":6445,"activeCount":99},[],{"intervention":6419,"totalTrials":137,"cells":6447},{"EARLY_PHASE1":6448,"PHASE1":6450,"PHASE2":6456,"PHASE3":6458,"PHASE4":6460,"NA":6462},{"trials":6449,"activeCount":99},[],{"trials":6451,"activeCount":99},[6452],{"nctId":6413,"briefTitle":6414,"status":105,"phases":6453,"primaryCompletion":2260,"completion":2903,"start":2261,"enrollment":1219,"conditions":6454,"interventions":6455},[89],[18],[6406,6418,6419],{"trials":6457,"activeCount":99},[],{"trials":6459,"activeCount":99},[],{"trials":6461,"activeCount":99},[],{"trials":6463,"activeCount":99},[],{"intervention":4306,"totalTrials":137,"cells":6465},{"EARLY_PHASE1":6466,"PHASE1":6468,"PHASE2":6474,"PHASE3":6476,"PHASE4":6478,"NA":6480},{"trials":6467,"activeCount":99},[],{"trials":6469,"activeCount":99},[6470],{"nctId":4300,"briefTitle":4301,"status":105,"phases":6471,"primaryCompletion":2728,"completion":2728,"start":4303,"enrollment":110,"conditions":6472,"interventions":6473},[89],[18],[4293,4306],{"trials":6475,"activeCount":99},[],{"trials":6477,"activeCount":99},[],{"trials":6479,"activeCount":99},[],{"trials":6481,"activeCount":99},[],{"intervention":6483,"totalTrials":137,"cells":6484},"GSK1265744 injectable suspension",{"EARLY_PHASE1":6485,"PHASE1":6487,"PHASE2":6495,"PHASE3":6497,"PHASE4":6499,"NA":6501},{"trials":6486,"activeCount":99},[],{"trials":6488,"activeCount":99},[6489],{"nctId":6490,"briefTitle":6491,"status":105,"phases":6492,"primaryCompletion":2092,"completion":2092,"start":1919,"enrollment":751,"conditions":6493,"interventions":6494},"NCT01756131","A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects",[89],[30],[6483],{"trials":6496,"activeCount":99},[],{"trials":6498,"activeCount":99},[],{"trials":6500,"activeCount":99},[],{"trials":6502,"activeCount":99},[],{"intervention":6504,"totalTrials":137,"cells":6505},"GSK3640254 200 mg",{"EARLY_PHASE1":6506,"PHASE1":6508,"PHASE2":6526,"PHASE3":6528,"PHASE4":6530,"NA":6532},{"trials":6507,"activeCount":99},[],{"trials":6509,"activeCount":99},[6510],{"nctId":6511,"briefTitle":6512,"status":105,"phases":6513,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":1412,"conditions":6516,"interventions":6517},"NCT04425902","Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults",[89],"2021-03-10","2020-12-16",[15],[6504,6518,6519,6520,6521,6522,6523,6524,6525],"Caffeine 200 mg","Metoprolol 100 mg","Montelukast 10 mg","Flurbiprofen 100 mg","Omeprazole 40 mg","Midazolam 5 mg","Digoxin 0.25 mg","Pravastatin 40 mg",{"trials":6527,"activeCount":99},[],{"trials":6529,"activeCount":99},[],{"trials":6531,"activeCount":99},[],{"trials":6533,"activeCount":99},[],{"intervention":6518,"totalTrials":137,"cells":6535},{"EARLY_PHASE1":6536,"PHASE1":6538,"PHASE2":6544,"PHASE3":6546,"PHASE4":6548,"NA":6550},{"trials":6537,"activeCount":99},[],{"trials":6539,"activeCount":99},[6540],{"nctId":6511,"briefTitle":6512,"status":105,"phases":6541,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":1412,"conditions":6542,"interventions":6543},[89],[15],[6504,6518,6519,6520,6521,6522,6523,6524,6525],{"trials":6545,"activeCount":99},[],{"trials":6547,"activeCount":99},[],{"trials":6549,"activeCount":99},[],{"trials":6551,"activeCount":99},[],{"intervention":6519,"totalTrials":137,"cells":6553},{"EARLY_PHASE1":6554,"PHASE1":6556,"PHASE2":6562,"PHASE3":6564,"PHASE4":6566,"NA":6568},{"trials":6555,"activeCount":99},[],{"trials":6557,"activeCount":99},[6558],{"nctId":6511,"briefTitle":6512,"status":105,"phases":6559,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":1412,"conditions":6560,"interventions":6561},[89],[15],[6504,6518,6519,6520,6521,6522,6523,6524,6525],{"trials":6563,"activeCount":99},[],{"trials":6565,"activeCount":99},[],{"trials":6567,"activeCount":99},[],{"trials":6569,"activeCount":99},[],{"intervention":6520,"totalTrials":137,"cells":6571},{"EARLY_PHASE1":6572,"PHASE1":6574,"PHASE2":6580,"PHASE3":6582,"PHASE4":6584,"NA":6586},{"trials":6573,"activeCount":99},[],{"trials":6575,"activeCount":99},[6576],{"nctId":6511,"briefTitle":6512,"status":105,"phases":6577,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":1412,"conditions":6578,"interventions":6579},[89],[15],[6504,6518,6519,6520,6521,6522,6523,6524,6525],{"trials":6581,"activeCount":99},[],{"trials":6583,"activeCount":99},[],{"trials":6585,"activeCount":99},[],{"trials":6587,"activeCount":99},[],{"intervention":6521,"totalTrials":137,"cells":6589},{"EARLY_PHASE1":6590,"PHASE1":6592,"PHASE2":6598,"PHASE3":6600,"PHASE4":6602,"NA":6604},{"trials":6591,"activeCount":99},[],{"trials":6593,"activeCount":99},[6594],{"nctId":6511,"briefTitle":6512,"status":105,"phases":6595,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":1412,"conditions":6596,"interventions":6597},[89],[15],[6504,6518,6519,6520,6521,6522,6523,6524,6525],{"trials":6599,"activeCount":99},[],{"trials":6601,"activeCount":99},[],{"trials":6603,"activeCount":99},[],{"trials":6605,"activeCount":99},[],{"intervention":6522,"totalTrials":137,"cells":6607},{"EARLY_PHASE1":6608,"PHASE1":6610,"PHASE2":6616,"PHASE3":6618,"PHASE4":6620,"NA":6622},{"trials":6609,"activeCount":99},[],{"trials":6611,"activeCount":99},[6612],{"nctId":6511,"briefTitle":6512,"status":105,"phases":6613,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":1412,"conditions":6614,"interventions":6615},[89],[15],[6504,6518,6519,6520,6521,6522,6523,6524,6525],{"trials":6617,"activeCount":99},[],{"trials":6619,"activeCount":99},[],{"trials":6621,"activeCount":99},[],{"trials":6623,"activeCount":99},[],{"intervention":6523,"totalTrials":137,"cells":6625},{"EARLY_PHASE1":6626,"PHASE1":6628,"PHASE2":6634,"PHASE3":6636,"PHASE4":6638,"NA":6640},{"trials":6627,"activeCount":99},[],{"trials":6629,"activeCount":99},[6630],{"nctId":6511,"briefTitle":6512,"status":105,"phases":6631,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":1412,"conditions":6632,"interventions":6633},[89],[15],[6504,6518,6519,6520,6521,6522,6523,6524,6525],{"trials":6635,"activeCount":99},[],{"trials":6637,"activeCount":99},[],{"trials":6639,"activeCount":99},[],{"trials":6641,"activeCount":99},[],{"intervention":6524,"totalTrials":137,"cells":6643},{"EARLY_PHASE1":6644,"PHASE1":6646,"PHASE2":6652,"PHASE3":6654,"PHASE4":6656,"NA":6658},{"trials":6645,"activeCount":99},[],{"trials":6647,"activeCount":99},[6648],{"nctId":6511,"briefTitle":6512,"status":105,"phases":6649,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":1412,"conditions":6650,"interventions":6651},[89],[15],[6504,6518,6519,6520,6521,6522,6523,6524,6525],{"trials":6653,"activeCount":99},[],{"trials":6655,"activeCount":99},[],{"trials":6657,"activeCount":99},[],{"trials":6659,"activeCount":99},[],{"intervention":6525,"totalTrials":137,"cells":6661},{"EARLY_PHASE1":6662,"PHASE1":6664,"PHASE2":6670,"PHASE3":6672,"PHASE4":6674,"NA":6676},{"trials":6663,"activeCount":99},[],{"trials":6665,"activeCount":99},[6666],{"nctId":6511,"briefTitle":6512,"status":105,"phases":6667,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":1412,"conditions":6668,"interventions":6669},[89],[15],[6504,6518,6519,6520,6521,6522,6523,6524,6525],{"trials":6671,"activeCount":99},[],{"trials":6673,"activeCount":99},[],{"trials":6675,"activeCount":99},[],{"trials":6677,"activeCount":99},[],{"intervention":3963,"totalTrials":137,"cells":6679},{"EARLY_PHASE1":6680,"PHASE1":6682,"PHASE2":6688,"PHASE3":6690,"PHASE4":6692,"NA":6694},{"trials":6681,"activeCount":99},[],{"trials":6683,"activeCount":99},[6684],{"nctId":3956,"briefTitle":3957,"status":105,"phases":6685,"primaryCompletion":1029,"completion":3959,"start":3960,"enrollment":466,"conditions":6686,"interventions":6687},[89],[15],[3963,523],{"trials":6689,"activeCount":99},[],{"trials":6691,"activeCount":99},[],{"trials":6693,"activeCount":99},[],{"trials":6695,"activeCount":99},[],{"intervention":6697,"totalTrials":137,"cells":6698},"200mg [14C]- GSK2248761",{"EARLY_PHASE1":6699,"PHASE1":6701,"PHASE2":6711,"PHASE3":6713,"PHASE4":6715,"NA":6717},{"trials":6700,"activeCount":99},[],{"trials":6702,"activeCount":99},[6703],{"nctId":6704,"briefTitle":6705,"status":2201,"phases":6706,"primaryCompletion":6707,"completion":6707,"start":6708,"enrollment":99,"conditions":6709,"interventions":6710},"NCT01273103","A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects",[89],"2011-02","2011-01",[18],[6697],{"trials":6712,"activeCount":99},[],{"trials":6714,"activeCount":99},[],{"trials":6716,"activeCount":99},[],{"trials":6718,"activeCount":99},[],{"intervention":763,"totalTrials":137,"cells":6720},{"EARLY_PHASE1":6721,"PHASE1":6723,"PHASE2":6729,"PHASE3":6731,"PHASE4":6733,"NA":6735},{"trials":6722,"activeCount":99},[],{"trials":6724,"activeCount":99},[6725],{"nctId":755,"briefTitle":756,"status":105,"phases":6726,"primaryCompletion":758,"completion":758,"start":759,"enrollment":760,"conditions":6727,"interventions":6728},[89],[18],[42,479,763],{"trials":6730,"activeCount":99},[],{"trials":6732,"activeCount":99},[],{"trials":6734,"activeCount":99},[],{"trials":6736,"activeCount":99},[],{"intervention":6738,"totalTrials":137,"cells":6739},"GSK2248761 WBM",{"EARLY_PHASE1":6740,"PHASE1":6742,"PHASE2":6753,"PHASE3":6755,"PHASE4":6757,"NA":6759},{"trials":6741,"activeCount":99},[],{"trials":6743,"activeCount":99},[6744],{"nctId":6745,"briefTitle":6746,"status":105,"phases":6747,"primaryCompletion":6708,"completion":6708,"start":1919,"enrollment":1219,"conditions":6748,"interventions":6749},"NCT01209117","A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435",[89],[30,18],[6738,6750,6751,6752,6738],"GSK2248761 WBM Tablet Formulation 1","GSK2248761 WBM Tablet Formulation 2","GSK2248761 WBM Tablet Formulation 3",{"trials":6754,"activeCount":99},[],{"trials":6756,"activeCount":99},[],{"trials":6758,"activeCount":99},[],{"trials":6760,"activeCount":99},[],{"intervention":6750,"totalTrials":137,"cells":6762},{"EARLY_PHASE1":6763,"PHASE1":6765,"PHASE2":6771,"PHASE3":6773,"PHASE4":6775,"NA":6777},{"trials":6764,"activeCount":99},[],{"trials":6766,"activeCount":99},[6767],{"nctId":6745,"briefTitle":6746,"status":105,"phases":6768,"primaryCompletion":6708,"completion":6708,"start":1919,"enrollment":1219,"conditions":6769,"interventions":6770},[89],[30,18],[6738,6750,6751,6752,6738],{"trials":6772,"activeCount":99},[],{"trials":6774,"activeCount":99},[],{"trials":6776,"activeCount":99},[],{"trials":6778,"activeCount":99},[],{"intervention":6751,"totalTrials":137,"cells":6780},{"EARLY_PHASE1":6781,"PHASE1":6783,"PHASE2":6789,"PHASE3":6791,"PHASE4":6793,"NA":6795},{"trials":6782,"activeCount":99},[],{"trials":6784,"activeCount":99},[6785],{"nctId":6745,"briefTitle":6746,"status":105,"phases":6786,"primaryCompletion":6708,"completion":6708,"start":1919,"enrollment":1219,"conditions":6787,"interventions":6788},[89],[30,18],[6738,6750,6751,6752,6738],{"trials":6790,"activeCount":99},[],{"trials":6792,"activeCount":99},[],{"trials":6794,"activeCount":99},[],{"trials":6796,"activeCount":99},[],{"intervention":6752,"totalTrials":137,"cells":6798},{"EARLY_PHASE1":6799,"PHASE1":6801,"PHASE2":6807,"PHASE3":6809,"PHASE4":6811,"NA":6813},{"trials":6800,"activeCount":99},[],{"trials":6802,"activeCount":99},[6803],{"nctId":6745,"briefTitle":6746,"status":105,"phases":6804,"primaryCompletion":6708,"completion":6708,"start":1919,"enrollment":1219,"conditions":6805,"interventions":6806},[89],[30,18],[6738,6750,6751,6752,6738],{"trials":6808,"activeCount":99},[],{"trials":6810,"activeCount":99},[],{"trials":6812,"activeCount":99},[],{"trials":6814,"activeCount":99},[],{"intervention":3973,"totalTrials":137,"cells":6816},{"EARLY_PHASE1":6817,"PHASE1":6819,"PHASE2":6825,"PHASE3":6827,"PHASE4":6829,"NA":6831},{"trials":6818,"activeCount":99},[],{"trials":6820,"activeCount":99},[6821],{"nctId":3965,"briefTitle":3966,"status":105,"phases":6822,"primaryCompletion":3968,"completion":3968,"start":3969,"enrollment":31,"conditions":6823,"interventions":6824},[89],[15],[3972,3973,3974],{"trials":6826,"activeCount":99},[],{"trials":6828,"activeCount":99},[],{"trials":6830,"activeCount":99},[],{"trials":6832,"activeCount":99},[],{"intervention":3974,"totalTrials":137,"cells":6834},{"EARLY_PHASE1":6835,"PHASE1":6837,"PHASE2":6843,"PHASE3":6845,"PHASE4":6847,"NA":6849},{"trials":6836,"activeCount":99},[],{"trials":6838,"activeCount":99},[6839],{"nctId":3965,"briefTitle":3966,"status":105,"phases":6840,"primaryCompletion":3968,"completion":3968,"start":3969,"enrollment":31,"conditions":6841,"interventions":6842},[89],[15],[3972,3973,3974],{"trials":6844,"activeCount":99},[],{"trials":6846,"activeCount":99},[],{"trials":6848,"activeCount":99},[],{"trials":6850,"activeCount":99},[],{"intervention":5028,"totalTrials":137,"cells":6852},{"EARLY_PHASE1":6853,"PHASE1":6855,"PHASE2":6861,"PHASE3":6863,"PHASE4":6865,"NA":6867},{"trials":6854,"activeCount":99},[],{"trials":6856,"activeCount":99},[6857],{"nctId":5021,"briefTitle":5022,"status":105,"phases":6858,"primaryCompletion":5024,"completion":5024,"start":5025,"enrollment":1412,"conditions":6859,"interventions":6860},[89],[477],[5028,5029,498],{"trials":6862,"activeCount":99},[],{"trials":6864,"activeCount":99},[],{"trials":6866,"activeCount":99},[],{"trials":6868,"activeCount":99},[],{"intervention":5029,"totalTrials":137,"cells":6870},{"EARLY_PHASE1":6871,"PHASE1":6873,"PHASE2":6879,"PHASE3":6881,"PHASE4":6883,"NA":6885},{"trials":6872,"activeCount":99},[],{"trials":6874,"activeCount":99},[6875],{"nctId":5021,"briefTitle":5022,"status":105,"phases":6876,"primaryCompletion":5024,"completion":5024,"start":5025,"enrollment":1412,"conditions":6877,"interventions":6878},[89],[477],[5028,5029,498],{"trials":6880,"activeCount":99},[],{"trials":6882,"activeCount":99},[],{"trials":6884,"activeCount":99},[],{"trials":6886,"activeCount":99},[],{"intervention":6888,"totalTrials":137,"cells":6889},"JULUCA (Dolutegravir and Rilpivirine) 50mg\u002F25mg FDC",{"EARLY_PHASE1":6890,"PHASE1":6892,"PHASE2":6901,"PHASE3":6903,"PHASE4":6905,"NA":6907},{"trials":6891,"activeCount":99},[],{"trials":6893,"activeCount":99},[6894],{"nctId":6895,"briefTitle":6896,"status":105,"phases":6897,"primaryCompletion":6898,"completion":6898,"start":5557,"enrollment":466,"conditions":6899,"interventions":6900},"NCT03984838","Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)\u002F25 mg Tablets in Healthy Subjects of Japanese Descent",[89],"2019-08-13",[15],[6888],{"trials":6902,"activeCount":99},[],{"trials":6904,"activeCount":99},[],{"trials":6906,"activeCount":99},[],{"trials":6908,"activeCount":99},[],{"intervention":6910,"totalTrials":137,"cells":6911},"Treatment A",{"EARLY_PHASE1":6912,"PHASE1":6914,"PHASE2":6929,"PHASE3":6931,"PHASE4":6933,"NA":6935},{"trials":6913,"activeCount":99},[],{"trials":6915,"activeCount":99},[6916],{"nctId":6917,"briefTitle":6918,"status":105,"phases":6919,"primaryCompletion":6920,"completion":6920,"start":6921,"enrollment":722,"conditions":6922,"interventions":6923},"NCT03441984","To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG\u002F3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers",[89],"2018-04-28","2018-02-26",[15],[6910,6924,6925,6926,6927,6928],"Treatment B","Treatment C","Treatment D","Treatment E","Treatment F",{"trials":6930,"activeCount":99},[],{"trials":6932,"activeCount":99},[],{"trials":6934,"activeCount":99},[],{"trials":6936,"activeCount":99},[],{"intervention":6924,"totalTrials":137,"cells":6938},{"EARLY_PHASE1":6939,"PHASE1":6941,"PHASE2":6947,"PHASE3":6949,"PHASE4":6951,"NA":6953},{"trials":6940,"activeCount":99},[],{"trials":6942,"activeCount":99},[6943],{"nctId":6917,"briefTitle":6918,"status":105,"phases":6944,"primaryCompletion":6920,"completion":6920,"start":6921,"enrollment":722,"conditions":6945,"interventions":6946},[89],[15],[6910,6924,6925,6926,6927,6928],{"trials":6948,"activeCount":99},[],{"trials":6950,"activeCount":99},[],{"trials":6952,"activeCount":99},[],{"trials":6954,"activeCount":99},[],{"intervention":6925,"totalTrials":137,"cells":6956},{"EARLY_PHASE1":6957,"PHASE1":6959,"PHASE2":6965,"PHASE3":6967,"PHASE4":6969,"NA":6971},{"trials":6958,"activeCount":99},[],{"trials":6960,"activeCount":99},[6961],{"nctId":6917,"briefTitle":6918,"status":105,"phases":6962,"primaryCompletion":6920,"completion":6920,"start":6921,"enrollment":722,"conditions":6963,"interventions":6964},[89],[15],[6910,6924,6925,6926,6927,6928],{"trials":6966,"activeCount":99},[],{"trials":6968,"activeCount":99},[],{"trials":6970,"activeCount":99},[],{"trials":6972,"activeCount":99},[],{"intervention":6926,"totalTrials":137,"cells":6974},{"EARLY_PHASE1":6975,"PHASE1":6977,"PHASE2":6983,"PHASE3":6985,"PHASE4":6987,"NA":6989},{"trials":6976,"activeCount":99},[],{"trials":6978,"activeCount":99},[6979],{"nctId":6917,"briefTitle":6918,"status":105,"phases":6980,"primaryCompletion":6920,"completion":6920,"start":6921,"enrollment":722,"conditions":6981,"interventions":6982},[89],[15],[6910,6924,6925,6926,6927,6928],{"trials":6984,"activeCount":99},[],{"trials":6986,"activeCount":99},[],{"trials":6988,"activeCount":99},[],{"trials":6990,"activeCount":99},[],{"intervention":6927,"totalTrials":137,"cells":6992},{"EARLY_PHASE1":6993,"PHASE1":6995,"PHASE2":7001,"PHASE3":7003,"PHASE4":7005,"NA":7007},{"trials":6994,"activeCount":99},[],{"trials":6996,"activeCount":99},[6997],{"nctId":6917,"briefTitle":6918,"status":105,"phases":6998,"primaryCompletion":6920,"completion":6920,"start":6921,"enrollment":722,"conditions":6999,"interventions":7000},[89],[15],[6910,6924,6925,6926,6927,6928],{"trials":7002,"activeCount":99},[],{"trials":7004,"activeCount":99},[],{"trials":7006,"activeCount":99},[],{"trials":7008,"activeCount":99},[],{"intervention":6928,"totalTrials":137,"cells":7010},{"EARLY_PHASE1":7011,"PHASE1":7013,"PHASE2":7019,"PHASE3":7021,"PHASE4":7023,"NA":7025},{"trials":7012,"activeCount":99},[],{"trials":7014,"activeCount":99},[7015],{"nctId":6917,"briefTitle":6918,"status":105,"phases":7016,"primaryCompletion":6920,"completion":6920,"start":6921,"enrollment":722,"conditions":7017,"interventions":7018},[89],[15],[6910,6924,6925,6926,6927,6928],{"trials":7020,"activeCount":99},[],{"trials":7022,"activeCount":99},[],{"trials":7024,"activeCount":99},[],{"trials":7026,"activeCount":99},[],{"intervention":7028,"totalTrials":137,"cells":7029},"Fostemsavir 600 mg",{"EARLY_PHASE1":7030,"PHASE1":7032,"PHASE2":7043,"PHASE3":7045,"PHASE4":7047,"NA":7049},{"trials":7031,"activeCount":99},[],{"trials":7033,"activeCount":99},[7034],{"nctId":7035,"briefTitle":7036,"status":105,"phases":7037,"primaryCompletion":7038,"completion":7038,"start":7039,"enrollment":760,"conditions":7040,"interventions":7041},"NCT04757974","Low-dose Fostemsavir Extended Release Relative Bioavailability Study",[89],"2021-07-31","2021-03-05",[15],[7028,7042],"Fostemsavir 200 mg",{"trials":7044,"activeCount":99},[],{"trials":7046,"activeCount":99},[],{"trials":7048,"activeCount":99},[],{"trials":7050,"activeCount":99},[],{"intervention":7042,"totalTrials":137,"cells":7052},{"EARLY_PHASE1":7053,"PHASE1":7055,"PHASE2":7061,"PHASE3":7063,"PHASE4":7065,"NA":7067},{"trials":7054,"activeCount":99},[],{"trials":7056,"activeCount":99},[7057],{"nctId":7035,"briefTitle":7036,"status":105,"phases":7058,"primaryCompletion":7038,"completion":7038,"start":7039,"enrollment":760,"conditions":7059,"interventions":7060},[89],[15],[7028,7042],{"trials":7062,"activeCount":99},[],{"trials":7064,"activeCount":99},[],{"trials":7066,"activeCount":99},[],{"trials":7068,"activeCount":99},[],{"intervention":772,"totalTrials":137,"cells":7070},{"EARLY_PHASE1":7071,"PHASE1":7073,"PHASE2":7079,"PHASE3":7081,"PHASE4":7083,"NA":7085},{"trials":7072,"activeCount":99},[],{"trials":7074,"activeCount":99},[7075],{"nctId":765,"briefTitle":766,"status":105,"phases":7076,"primaryCompletion":768,"completion":768,"start":731,"enrollment":769,"conditions":7077,"interventions":7078},[89],[18],[42,772,773],{"trials":7080,"activeCount":99},[],{"trials":7082,"activeCount":99},[],{"trials":7084,"activeCount":99},[],{"trials":7086,"activeCount":99},[],{"intervention":773,"totalTrials":137,"cells":7088},{"EARLY_PHASE1":7089,"PHASE1":7091,"PHASE2":7097,"PHASE3":7099,"PHASE4":7101,"NA":7103},{"trials":7090,"activeCount":99},[],{"trials":7092,"activeCount":99},[7093],{"nctId":765,"briefTitle":766,"status":105,"phases":7094,"primaryCompletion":768,"completion":768,"start":731,"enrollment":769,"conditions":7095,"interventions":7096},[89],[18],[42,772,773],{"trials":7098,"activeCount":99},[],{"trials":7100,"activeCount":99},[],{"trials":7102,"activeCount":99},[],{"trials":7104,"activeCount":99},[],{"intervention":7106,"totalTrials":137,"cells":7107},"DTG\u002FABC\u002F3TC FDC DISPERSIBLE",{"EARLY_PHASE1":7108,"PHASE1":7110,"PHASE2":7122,"PHASE3":7124,"PHASE4":7126,"NA":7128},{"trials":7109,"activeCount":99},[],{"trials":7111,"activeCount":99},[7112],{"nctId":7113,"briefTitle":7114,"status":105,"phases":7115,"primaryCompletion":4179,"completion":7116,"start":7117,"enrollment":1412,"conditions":7118,"interventions":7119},"NCT02893488","Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir\u002FAbacavir\u002FLamivudine Dispersible Tablet",[89],"2016-11-25","2016-09-01",[18],[7106,7120,7121],"EPZICOM","TIVICAY",{"trials":7123,"activeCount":99},[],{"trials":7125,"activeCount":99},[],{"trials":7127,"activeCount":99},[],{"trials":7129,"activeCount":99},[],{"intervention":7120,"totalTrials":137,"cells":7131},{"EARLY_PHASE1":7132,"PHASE1":7134,"PHASE2":7140,"PHASE3":7142,"PHASE4":7144,"NA":7146},{"trials":7133,"activeCount":99},[],{"trials":7135,"activeCount":99},[7136],{"nctId":7113,"briefTitle":7114,"status":105,"phases":7137,"primaryCompletion":4179,"completion":7116,"start":7117,"enrollment":1412,"conditions":7138,"interventions":7139},[89],[18],[7106,7120,7121],{"trials":7141,"activeCount":99},[],{"trials":7143,"activeCount":99},[],{"trials":7145,"activeCount":99},[],{"trials":7147,"activeCount":99},[],{"intervention":7121,"totalTrials":137,"cells":7149},{"EARLY_PHASE1":7150,"PHASE1":7152,"PHASE2":7158,"PHASE3":7160,"PHASE4":7162,"NA":7164},{"trials":7151,"activeCount":99},[],{"trials":7153,"activeCount":99},[7154],{"nctId":7113,"briefTitle":7114,"status":105,"phases":7155,"primaryCompletion":4179,"completion":7116,"start":7117,"enrollment":1412,"conditions":7156,"interventions":7157},[89],[18],[7106,7120,7121],{"trials":7159,"activeCount":99},[],{"trials":7161,"activeCount":99},[],{"trials":7163,"activeCount":99},[],{"trials":7165,"activeCount":99},[],{"intervention":7167,"totalTrials":137,"cells":7168},"GSK1265744 10 mg oral solution",{"EARLY_PHASE1":7169,"PHASE1":7171,"PHASE2":7181,"PHASE3":7183,"PHASE4":7185,"NA":7187},{"trials":7170,"activeCount":99},[],{"trials":7172,"activeCount":99},[7173],{"nctId":7174,"briefTitle":7175,"status":105,"phases":7176,"primaryCompletion":2638,"completion":2638,"start":2617,"enrollment":7177,"conditions":7178,"interventions":7179},"NCT00812318","Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.",[89],45,[24,18],[7167,7180,7180],"GSK1265744 5 mg",{"trials":7182,"activeCount":99},[],{"trials":7184,"activeCount":99},[],{"trials":7186,"activeCount":99},[],{"trials":7188,"activeCount":99},[],{"intervention":7180,"totalTrials":137,"cells":7190},{"EARLY_PHASE1":7191,"PHASE1":7193,"PHASE2":7199,"PHASE3":7201,"PHASE4":7203,"NA":7205},{"trials":7192,"activeCount":99},[],{"trials":7194,"activeCount":99},[7195],{"nctId":7174,"briefTitle":7175,"status":105,"phases":7196,"primaryCompletion":2638,"completion":2638,"start":2617,"enrollment":7177,"conditions":7197,"interventions":7198},[89],[24,18],[7167,7180,7180],{"trials":7200,"activeCount":99},[],{"trials":7202,"activeCount":99},[],{"trials":7204,"activeCount":99},[],{"trials":7206,"activeCount":99},[],{"intervention":7208,"totalTrials":137,"cells":7209},"VH4004280 Formulation A",{"EARLY_PHASE1":7210,"PHASE1":7212,"PHASE2":7226,"PHASE3":7228,"PHASE4":7230,"NA":7232},{"trials":7211,"activeCount":99},[],{"trials":7213,"activeCount":99},[7214],{"nctId":7215,"briefTitle":7216,"status":105,"phases":7217,"primaryCompletion":7218,"completion":7218,"start":7219,"enrollment":4088,"conditions":7220,"interventions":7221},"NCT06168318","A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants",[89],"2024-06-03","2023-12-18",[15],[7208,7222,7223,7224,7225],"VH4004280 Formulation B","VH4004280 Formulation C","VH4004280 Formulation D","VH4004280 Formulation E",{"trials":7227,"activeCount":99},[],{"trials":7229,"activeCount":99},[],{"trials":7231,"activeCount":99},[],{"trials":7233,"activeCount":99},[],{"intervention":7222,"totalTrials":137,"cells":7235},{"EARLY_PHASE1":7236,"PHASE1":7238,"PHASE2":7244,"PHASE3":7246,"PHASE4":7248,"NA":7250},{"trials":7237,"activeCount":99},[],{"trials":7239,"activeCount":99},[7240],{"nctId":7215,"briefTitle":7216,"status":105,"phases":7241,"primaryCompletion":7218,"completion":7218,"start":7219,"enrollment":4088,"conditions":7242,"interventions":7243},[89],[15],[7208,7222,7223,7224,7225],{"trials":7245,"activeCount":99},[],{"trials":7247,"activeCount":99},[],{"trials":7249,"activeCount":99},[],{"trials":7251,"activeCount":99},[],{"intervention":7223,"totalTrials":137,"cells":7253},{"EARLY_PHASE1":7254,"PHASE1":7256,"PHASE2":7262,"PHASE3":7264,"PHASE4":7266,"NA":7268},{"trials":7255,"activeCount":99},[],{"trials":7257,"activeCount":99},[7258],{"nctId":7215,"briefTitle":7216,"status":105,"phases":7259,"primaryCompletion":7218,"completion":7218,"start":7219,"enrollment":4088,"conditions":7260,"interventions":7261},[89],[15],[7208,7222,7223,7224,7225],{"trials":7263,"activeCount":99},[],{"trials":7265,"activeCount":99},[],{"trials":7267,"activeCount":99},[],{"trials":7269,"activeCount":99},[],{"intervention":7224,"totalTrials":137,"cells":7271},{"EARLY_PHASE1":7272,"PHASE1":7274,"PHASE2":7280,"PHASE3":7282,"PHASE4":7284,"NA":7286},{"trials":7273,"activeCount":99},[],{"trials":7275,"activeCount":99},[7276],{"nctId":7215,"briefTitle":7216,"status":105,"phases":7277,"primaryCompletion":7218,"completion":7218,"start":7219,"enrollment":4088,"conditions":7278,"interventions":7279},[89],[15],[7208,7222,7223,7224,7225],{"trials":7281,"activeCount":99},[],{"trials":7283,"activeCount":99},[],{"trials":7285,"activeCount":99},[],{"trials":7287,"activeCount":99},[],{"intervention":7225,"totalTrials":137,"cells":7289},{"EARLY_PHASE1":7290,"PHASE1":7292,"PHASE2":7298,"PHASE3":7300,"PHASE4":7302,"NA":7304},{"trials":7291,"activeCount":99},[],{"trials":7293,"activeCount":99},[7294],{"nctId":7215,"briefTitle":7216,"status":105,"phases":7295,"primaryCompletion":7218,"completion":7218,"start":7219,"enrollment":4088,"conditions":7296,"interventions":7297},[89],[15],[7208,7222,7223,7224,7225],{"trials":7299,"activeCount":99},[],{"trials":7301,"activeCount":99},[],{"trials":7303,"activeCount":99},[],{"trials":7305,"activeCount":99},[],{"intervention":1042,"totalTrials":137,"cells":7307},{"EARLY_PHASE1":7308,"PHASE1":7310,"PHASE2":7316,"PHASE3":7318,"PHASE4":7320,"NA":7322},{"trials":7309,"activeCount":99},[],{"trials":7311,"activeCount":99},[7312],{"nctId":1035,"briefTitle":1036,"status":105,"phases":7313,"primaryCompletion":1038,"completion":1038,"start":1039,"enrollment":847,"conditions":7314,"interventions":7315},[89],[18,15],[170,235,1042],{"trials":7317,"activeCount":99},[],{"trials":7319,"activeCount":99},[],{"trials":7321,"activeCount":99},[],{"trials":7323,"activeCount":99},[],{"intervention":2605,"totalTrials":137,"cells":7325},{"EARLY_PHASE1":7326,"PHASE1":7328,"PHASE2":7334,"PHASE3":7336,"PHASE4":7338,"NA":7340},{"trials":7327,"activeCount":99},[],{"trials":7329,"activeCount":99},[7330],{"nctId":2600,"briefTitle":2601,"status":105,"phases":7331,"primaryCompletion":493,"completion":465,"start":583,"enrollment":691,"conditions":7332,"interventions":7333},[89],[18],[1922,2605,113],{"trials":7335,"activeCount":99},[],{"trials":7337,"activeCount":99},[],{"trials":7339,"activeCount":99},[],{"trials":7341,"activeCount":99},[],{"intervention":7343,"totalTrials":137,"cells":7344},"Cabotegravir tablet 30 mg once daily for 28 days.",{"EARLY_PHASE1":7345,"PHASE1":7347,"PHASE2":7357,"PHASE3":7359,"PHASE4":7361,"NA":7363},{"trials":7346,"activeCount":99},[],{"trials":7348,"activeCount":99},[7349],{"nctId":7350,"briefTitle":7351,"status":105,"phases":7352,"primaryCompletion":5230,"completion":5230,"start":7353,"enrollment":444,"conditions":7354,"interventions":7355},"NCT02478463","Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers",[89],"2017-02-27",[18,15],[7343,7356],"Cabotegravir injection 3 mL (200 mg\u002FmL) IM given once on Day 1.",{"trials":7358,"activeCount":99},[],{"trials":7360,"activeCount":99},[],{"trials":7362,"activeCount":99},[],{"trials":7364,"activeCount":99},[],{"intervention":7356,"totalTrials":137,"cells":7366},{"EARLY_PHASE1":7367,"PHASE1":7369,"PHASE2":7375,"PHASE3":7377,"PHASE4":7379,"NA":7381},{"trials":7368,"activeCount":99},[],{"trials":7370,"activeCount":99},[7371],{"nctId":7350,"briefTitle":7351,"status":105,"phases":7372,"primaryCompletion":5230,"completion":5230,"start":7353,"enrollment":444,"conditions":7373,"interventions":7374},[89],[18,15],[7343,7356],{"trials":7376,"activeCount":99},[],{"trials":7378,"activeCount":99},[],{"trials":7380,"activeCount":99},[],{"trials":7382,"activeCount":99},[],{"intervention":2734,"totalTrials":137,"cells":7384},{"EARLY_PHASE1":7385,"PHASE1":7387,"PHASE2":7393,"PHASE3":7395,"PHASE4":7397,"NA":7399},{"trials":7386,"activeCount":99},[],{"trials":7388,"activeCount":99},[7389],{"nctId":2725,"briefTitle":2726,"status":105,"phases":7390,"primaryCompletion":2728,"completion":2728,"start":2729,"enrollment":2730,"conditions":7391,"interventions":7392},[89],[18],[2718,2733,2734,2735,2736,2737,2738],{"trials":7394,"activeCount":99},[],{"trials":7396,"activeCount":99},[],{"trials":7398,"activeCount":99},[],{"trials":7400,"activeCount":99},[],{"intervention":2735,"totalTrials":137,"cells":7402},{"EARLY_PHASE1":7403,"PHASE1":7405,"PHASE2":7411,"PHASE3":7413,"PHASE4":7415,"NA":7417},{"trials":7404,"activeCount":99},[],{"trials":7406,"activeCount":99},[7407],{"nctId":2725,"briefTitle":2726,"status":105,"phases":7408,"primaryCompletion":2728,"completion":2728,"start":2729,"enrollment":2730,"conditions":7409,"interventions":7410},[89],[18],[2718,2733,2734,2735,2736,2737,2738],{"trials":7412,"activeCount":99},[],{"trials":7414,"activeCount":99},[],{"trials":7416,"activeCount":99},[],{"trials":7418,"activeCount":99},[],{"intervention":2736,"totalTrials":137,"cells":7420},{"EARLY_PHASE1":7421,"PHASE1":7423,"PHASE2":7429,"PHASE3":7431,"PHASE4":7433,"NA":7435},{"trials":7422,"activeCount":99},[],{"trials":7424,"activeCount":99},[7425],{"nctId":2725,"briefTitle":2726,"status":105,"phases":7426,"primaryCompletion":2728,"completion":2728,"start":2729,"enrollment":2730,"conditions":7427,"interventions":7428},[89],[18],[2718,2733,2734,2735,2736,2737,2738],{"trials":7430,"activeCount":99},[],{"trials":7432,"activeCount":99},[],{"trials":7434,"activeCount":99},[],{"trials":7436,"activeCount":99},[],{"intervention":2737,"totalTrials":137,"cells":7438},{"EARLY_PHASE1":7439,"PHASE1":7441,"PHASE2":7447,"PHASE3":7449,"PHASE4":7451,"NA":7453},{"trials":7440,"activeCount":99},[],{"trials":7442,"activeCount":99},[7443],{"nctId":2725,"briefTitle":2726,"status":105,"phases":7444,"primaryCompletion":2728,"completion":2728,"start":2729,"enrollment":2730,"conditions":7445,"interventions":7446},[89],[18],[2718,2733,2734,2735,2736,2737,2738],{"trials":7448,"activeCount":99},[],{"trials":7450,"activeCount":99},[],{"trials":7452,"activeCount":99},[],{"trials":7454,"activeCount":99},[],{"intervention":2738,"totalTrials":137,"cells":7456},{"EARLY_PHASE1":7457,"PHASE1":7459,"PHASE2":7465,"PHASE3":7467,"PHASE4":7469,"NA":7471},{"trials":7458,"activeCount":99},[],{"trials":7460,"activeCount":99},[7461],{"nctId":2725,"briefTitle":2726,"status":105,"phases":7462,"primaryCompletion":2728,"completion":2728,"start":2729,"enrollment":2730,"conditions":7463,"interventions":7464},[89],[18],[2718,2733,2734,2735,2736,2737,2738],{"trials":7466,"activeCount":99},[],{"trials":7468,"activeCount":99},[],{"trials":7470,"activeCount":99},[],{"trials":7472,"activeCount":99},[],{"intervention":4173,"totalTrials":137,"cells":7474},{"EARLY_PHASE1":7475,"PHASE1":7477,"PHASE2":7483,"PHASE3":7485,"PHASE4":7487,"NA":7489},{"trials":7476,"activeCount":99},[],{"trials":7478,"activeCount":99},[7479],{"nctId":4167,"briefTitle":4168,"status":105,"phases":7480,"primaryCompletion":3082,"completion":3082,"start":4170,"enrollment":2109,"conditions":7481,"interventions":7482},[89],[18],[2695,4173,4174,4174,4174],{"trials":7484,"activeCount":99},[],{"trials":7486,"activeCount":99},[],{"trials":7488,"activeCount":99},[],{"trials":7490,"activeCount":99},[],{"intervention":4174,"totalTrials":137,"cells":7492},{"EARLY_PHASE1":7493,"PHASE1":7495,"PHASE2":7501,"PHASE3":7503,"PHASE4":7505,"NA":7507},{"trials":7494,"activeCount":99},[],{"trials":7496,"activeCount":99},[7497],{"nctId":4167,"briefTitle":4168,"status":105,"phases":7498,"primaryCompletion":3082,"completion":3082,"start":4170,"enrollment":2109,"conditions":7499,"interventions":7500},[89],[18],[2695,4173,4174,4174,4174],{"trials":7502,"activeCount":99},[],{"trials":7504,"activeCount":99},[],{"trials":7506,"activeCount":99},[],{"trials":7508,"activeCount":99},[],{"intervention":1286,"totalTrials":137,"cells":7510},{"EARLY_PHASE1":7511,"PHASE1":7513,"PHASE2":7519,"PHASE3":7521,"PHASE4":7523,"NA":7525},{"trials":7512,"activeCount":99},[],{"trials":7514,"activeCount":99},[7515],{"nctId":1279,"briefTitle":1280,"status":105,"phases":7516,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":769,"conditions":7517,"interventions":7518},[89],[15],[425,1286],{"trials":7520,"activeCount":99},[],{"trials":7522,"activeCount":99},[],{"trials":7524,"activeCount":99},[],{"trials":7526,"activeCount":99},[],{"intervention":488,"totalTrials":137,"cells":7528},{"EARLY_PHASE1":7529,"PHASE1":7531,"PHASE2":7537,"PHASE3":7539,"PHASE4":7541,"NA":7543},{"trials":7530,"activeCount":99},[],{"trials":7532,"activeCount":99},[7533],{"nctId":481,"briefTitle":482,"status":105,"phases":7534,"primaryCompletion":484,"completion":484,"start":485,"enrollment":25,"conditions":7535,"interventions":7536},[89],[18],[66,488],{"trials":7538,"activeCount":99},[],{"trials":7540,"activeCount":99},[],{"trials":7542,"activeCount":99},[],{"trials":7544,"activeCount":99},[],{"intervention":7546,"totalTrials":137,"cells":7547},"GSK3640254 bis-hydrochloride salt",{"EARLY_PHASE1":7548,"PHASE1":7550,"PHASE2":7561,"PHASE3":7563,"PHASE4":7565,"NA":7567},{"trials":7549,"activeCount":99},[],{"trials":7551,"activeCount":99},[7552],{"nctId":7553,"briefTitle":7554,"status":105,"phases":7555,"primaryCompletion":7556,"completion":7556,"start":7557,"enrollment":456,"conditions":7558,"interventions":7559},"NCT03575962","A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254",[89],"2018-08-06","2018-06-18",[15],[7546,7560],"GSK3640254 Mesylate Salt",{"trials":7562,"activeCount":99},[],{"trials":7564,"activeCount":99},[],{"trials":7566,"activeCount":99},[],{"trials":7568,"activeCount":99},[],{"intervention":7560,"totalTrials":137,"cells":7570},{"EARLY_PHASE1":7571,"PHASE1":7573,"PHASE2":7579,"PHASE3":7581,"PHASE4":7583,"NA":7585},{"trials":7572,"activeCount":99},[],{"trials":7574,"activeCount":99},[7575],{"nctId":7553,"briefTitle":7554,"status":105,"phases":7576,"primaryCompletion":7556,"completion":7556,"start":7557,"enrollment":456,"conditions":7577,"interventions":7578},[89],[15],[7546,7560],{"trials":7580,"activeCount":99},[],{"trials":7582,"activeCount":99},[],{"trials":7584,"activeCount":99},[],{"trials":7586,"activeCount":99},[],{"intervention":7588,"totalTrials":137,"cells":7589},"Cabotegravir IR Formulation",{"EARLY_PHASE1":7590,"PHASE1":7592,"PHASE2":7603,"PHASE3":7605,"PHASE4":7607,"NA":7609},{"trials":7591,"activeCount":99},[],{"trials":7593,"activeCount":99},[7594],{"nctId":7595,"briefTitle":7596,"status":105,"phases":7597,"primaryCompletion":7598,"completion":7598,"start":7599,"enrollment":1219,"conditions":7600,"interventions":7601},"NCT05776108","A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation",[89],"2023-06-08","2023-03-23",[15],[7588,7602,7602],"Cabotegravir DT Formulation",{"trials":7604,"activeCount":99},[],{"trials":7606,"activeCount":99},[],{"trials":7608,"activeCount":99},[],{"trials":7610,"activeCount":99},[],{"intervention":7602,"totalTrials":137,"cells":7612},{"EARLY_PHASE1":7613,"PHASE1":7615,"PHASE2":7621,"PHASE3":7623,"PHASE4":7625,"NA":7627},{"trials":7614,"activeCount":99},[],{"trials":7616,"activeCount":99},[7617],{"nctId":7595,"briefTitle":7596,"status":105,"phases":7618,"primaryCompletion":7598,"completion":7598,"start":7599,"enrollment":1219,"conditions":7619,"interventions":7620},[89],[15],[7588,7602,7602],{"trials":7622,"activeCount":99},[],{"trials":7624,"activeCount":99},[],{"trials":7626,"activeCount":99},[],{"trials":7628,"activeCount":99},[],{"intervention":4138,"totalTrials":137,"cells":7630},{"EARLY_PHASE1":7631,"PHASE1":7633,"PHASE2":7639,"PHASE3":7641,"PHASE4":7643,"NA":7645},{"trials":7632,"activeCount":99},[],{"trials":7634,"activeCount":99},[7635],{"nctId":4131,"briefTitle":4132,"status":515,"phases":7636,"primaryCompletion":4134,"completion":4134,"start":4135,"enrollment":605,"conditions":7637,"interventions":7638},[89],[18,15],[4138,2264],{"trials":7640,"activeCount":99},[],{"trials":7642,"activeCount":99},[],{"trials":7644,"activeCount":99},[],{"trials":7646,"activeCount":99},[],{"intervention":791,"totalTrials":137,"cells":7648},{"EARLY_PHASE1":7649,"PHASE1":7651,"PHASE2":7657,"PHASE3":7659,"PHASE4":7661,"NA":7663},{"trials":7650,"activeCount":99},[],{"trials":7652,"activeCount":99},[7653],{"nctId":784,"briefTitle":785,"status":105,"phases":7654,"primaryCompletion":787,"completion":787,"start":788,"enrollment":760,"conditions":7655,"interventions":7656},[89],[18],[42,714,791],{"trials":7658,"activeCount":99},[],{"trials":7660,"activeCount":99},[],{"trials":7662,"activeCount":99},[],{"trials":7664,"activeCount":99},[],{"intervention":2078,"totalTrials":137,"cells":7666},{"EARLY_PHASE1":7667,"PHASE1":7669,"PHASE2":7675,"PHASE3":7677,"PHASE4":7679,"NA":7681},{"trials":7668,"activeCount":99},[],{"trials":7670,"activeCount":99},[7671],{"nctId":2072,"briefTitle":2073,"status":105,"phases":7672,"primaryCompletion":2075,"completion":2075,"start":454,"enrollment":1950,"conditions":7673,"interventions":7674},[89],[18],[2036,2078,2079,2079],{"trials":7676,"activeCount":99},[],{"trials":7678,"activeCount":99},[],{"trials":7680,"activeCount":99},[],{"trials":7682,"activeCount":99},[],{"intervention":2079,"totalTrials":137,"cells":7684},{"EARLY_PHASE1":7685,"PHASE1":7687,"PHASE2":7693,"PHASE3":7695,"PHASE4":7697,"NA":7699},{"trials":7686,"activeCount":99},[],{"trials":7688,"activeCount":99},[7689],{"nctId":2072,"briefTitle":2073,"status":105,"phases":7690,"primaryCompletion":2075,"completion":2075,"start":454,"enrollment":1950,"conditions":7691,"interventions":7692},[89],[18],[2036,2078,2079,2079],{"trials":7694,"activeCount":99},[],{"trials":7696,"activeCount":99},[],{"trials":7698,"activeCount":99},[],{"trials":7700,"activeCount":99},[],{"intervention":2265,"totalTrials":137,"cells":7702},{"EARLY_PHASE1":7703,"PHASE1":7705,"PHASE2":7711,"PHASE3":7713,"PHASE4":7715,"NA":7717},{"trials":7704,"activeCount":99},[],{"trials":7706,"activeCount":99},[7707],{"nctId":2257,"briefTitle":2258,"status":105,"phases":7708,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":110,"conditions":7709,"interventions":7710},[89],[18],[2250,2264,2265],{"trials":7712,"activeCount":99},[],{"trials":7714,"activeCount":99},[],{"trials":7716,"activeCount":99},[],{"trials":7718,"activeCount":99},[],{"intervention":7720,"totalTrials":137,"cells":7721},"TRIUMEQ",{"EARLY_PHASE1":7722,"PHASE1":7724,"PHASE2":7736,"PHASE3":7738,"PHASE4":7740,"NA":7742},{"trials":7723,"activeCount":99},[],{"trials":7725,"activeCount":99},[7726],{"nctId":7727,"briefTitle":7728,"status":105,"phases":7729,"primaryCompletion":7730,"completion":7730,"start":7731,"enrollment":7732,"conditions":7733,"interventions":7734},"NCT04827134","A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants",[89],"2021-07-23","2021-05-07",33,[15],[7720,7735],"DOVATO",{"trials":7737,"activeCount":99},[],{"trials":7739,"activeCount":99},[],{"trials":7741,"activeCount":99},[],{"trials":7743,"activeCount":99},[],{"intervention":7735,"totalTrials":137,"cells":7745},{"EARLY_PHASE1":7746,"PHASE1":7748,"PHASE2":7754,"PHASE3":7756,"PHASE4":7758,"NA":7760},{"trials":7747,"activeCount":99},[],{"trials":7749,"activeCount":99},[7750],{"nctId":7727,"briefTitle":7728,"status":105,"phases":7751,"primaryCompletion":7730,"completion":7730,"start":7731,"enrollment":7732,"conditions":7752,"interventions":7753},[89],[15],[7720,7735],{"trials":7755,"activeCount":99},[],{"trials":7757,"activeCount":99},[],{"trials":7759,"activeCount":99},[],{"trials":7761,"activeCount":99},[],{"intervention":5225,"totalTrials":137,"cells":7763},{"EARLY_PHASE1":7764,"PHASE1":7766,"PHASE2":7772,"PHASE3":7774,"PHASE4":7776,"NA":7778},{"trials":7765,"activeCount":99},[],{"trials":7767,"activeCount":99},[7768],{"nctId":5218,"briefTitle":5219,"status":105,"phases":7769,"primaryCompletion":5221,"completion":5221,"start":5222,"enrollment":110,"conditions":7770,"interventions":7771},[89],[18],[5225,5211],{"trials":7773,"activeCount":99},[],{"trials":7775,"activeCount":99},[],{"trials":7777,"activeCount":99},[],{"trials":7779,"activeCount":99},[],{"intervention":123,"totalTrials":137,"cells":7781},{"EARLY_PHASE1":7782,"PHASE1":7784,"PHASE2":7790,"PHASE3":7792,"PHASE4":7794,"NA":7796},{"trials":7783,"activeCount":99},[],{"trials":7785,"activeCount":99},[7786],{"nctId":115,"briefTitle":116,"status":105,"phases":7787,"primaryCompletion":118,"completion":118,"start":119,"enrollment":110,"conditions":7788,"interventions":7789},[89],[15],[56,122,123,124],{"trials":7791,"activeCount":99},[],{"trials":7793,"activeCount":99},[],{"trials":7795,"activeCount":99},[],{"trials":7797,"activeCount":99},[],{"intervention":124,"totalTrials":137,"cells":7799},{"EARLY_PHASE1":7800,"PHASE1":7802,"PHASE2":7808,"PHASE3":7810,"PHASE4":7812,"NA":7814},{"trials":7801,"activeCount":99},[],{"trials":7803,"activeCount":99},[7804],{"nctId":115,"briefTitle":116,"status":105,"phases":7805,"primaryCompletion":118,"completion":118,"start":119,"enrollment":110,"conditions":7806,"interventions":7807},[89],[15],[56,122,123,124],{"trials":7809,"activeCount":99},[],{"trials":7811,"activeCount":99},[],{"trials":7813,"activeCount":99},[],{"trials":7815,"activeCount":99},[],{"intervention":497,"totalTrials":137,"cells":7817},{"EARLY_PHASE1":7818,"PHASE1":7820,"PHASE2":7826,"PHASE3":7828,"PHASE4":7830,"NA":7832},{"trials":7819,"activeCount":99},[],{"trials":7821,"activeCount":99},[7822],{"nctId":490,"briefTitle":491,"status":105,"phases":7823,"primaryCompletion":474,"completion":474,"start":493,"enrollment":494,"conditions":7824,"interventions":7825},[89],[477],[66,497,498],{"trials":7827,"activeCount":99},[],{"trials":7829,"activeCount":99},[],{"trials":7831,"activeCount":99},[],{"trials":7833,"activeCount":99},[],{"intervention":5235,"totalTrials":137,"cells":7835},{"EARLY_PHASE1":7836,"PHASE1":7838,"PHASE2":7844,"PHASE3":7846,"PHASE4":7848,"NA":7850},{"trials":7837,"activeCount":99},[],{"trials":7839,"activeCount":99},[7840],{"nctId":5227,"briefTitle":5228,"status":105,"phases":7841,"primaryCompletion":5230,"completion":5230,"start":5231,"enrollment":8,"conditions":7842,"interventions":7843},[89],[15],[5234,5235,5236],{"trials":7845,"activeCount":99},[],{"trials":7847,"activeCount":99},[],{"trials":7849,"activeCount":99},[],{"trials":7851,"activeCount":99},[],{"intervention":5236,"totalTrials":137,"cells":7853},{"EARLY_PHASE1":7854,"PHASE1":7856,"PHASE2":7862,"PHASE3":7864,"PHASE4":7866,"NA":7868},{"trials":7855,"activeCount":99},[],{"trials":7857,"activeCount":99},[7858],{"nctId":5227,"briefTitle":5228,"status":105,"phases":7859,"primaryCompletion":5230,"completion":5230,"start":5231,"enrollment":8,"conditions":7860,"interventions":7861},[89],[15],[5234,5235,5236],{"trials":7863,"activeCount":99},[],{"trials":7865,"activeCount":99},[],{"trials":7867,"activeCount":99},[],{"trials":7869,"activeCount":99},[],{"intervention":1052,"totalTrials":137,"cells":7871},{"EARLY_PHASE1":7872,"PHASE1":7874,"PHASE2":7880,"PHASE3":7882,"PHASE4":7884,"NA":7886},{"trials":7873,"activeCount":99},[],{"trials":7875,"activeCount":99},[7876],{"nctId":1044,"briefTitle":1045,"status":105,"phases":7877,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":1049,"conditions":7878,"interventions":7879},[89],[15],[523,170,1052],{"trials":7881,"activeCount":99},[],{"trials":7883,"activeCount":99},[],{"trials":7885,"activeCount":99},[],{"trials":7887,"activeCount":99},[],{"intervention":2095,"totalTrials":137,"cells":7889},{"EARLY_PHASE1":7890,"PHASE1":7892,"PHASE2":7898,"PHASE3":7900,"PHASE4":7902,"NA":7904},{"trials":7891,"activeCount":99},[],{"trials":7893,"activeCount":99},[7894],{"nctId":2088,"briefTitle":2089,"status":105,"phases":7895,"primaryCompletion":2091,"completion":2091,"start":2092,"enrollment":1219,"conditions":7896,"interventions":7897},[89],[18],[2036,2095,2096],{"trials":7899,"activeCount":99},[],{"trials":7901,"activeCount":99},[],{"trials":7903,"activeCount":99},[],{"trials":7905,"activeCount":99},[],{"intervention":2096,"totalTrials":137,"cells":7907},{"EARLY_PHASE1":7908,"PHASE1":7910,"PHASE2":7916,"PHASE3":7918,"PHASE4":7920,"NA":7922},{"trials":7909,"activeCount":99},[],{"trials":7911,"activeCount":99},[7912],{"nctId":2088,"briefTitle":2089,"status":105,"phases":7913,"primaryCompletion":2091,"completion":2091,"start":2092,"enrollment":1219,"conditions":7914,"interventions":7915},[89],[18],[2036,2095,2096],{"trials":7917,"activeCount":99},[],{"trials":7919,"activeCount":99},[],{"trials":7921,"activeCount":99},[],{"trials":7923,"activeCount":99},[],{"intervention":508,"totalTrials":137,"cells":7925},{"EARLY_PHASE1":7926,"PHASE1":7928,"PHASE2":7934,"PHASE3":7936,"PHASE4":7938,"NA":7940},{"trials":7927,"activeCount":99},[],{"trials":7929,"activeCount":99},[7930],{"nctId":500,"briefTitle":501,"status":105,"phases":7931,"primaryCompletion":503,"completion":503,"start":504,"enrollment":505,"conditions":7932,"interventions":7933},[89],[18],[66,333,508,509],{"trials":7935,"activeCount":99},[],{"trials":7937,"activeCount":99},[],{"trials":7939,"activeCount":99},[],{"trials":7941,"activeCount":99},[],{"intervention":509,"totalTrials":137,"cells":7943},{"EARLY_PHASE1":7944,"PHASE1":7946,"PHASE2":7952,"PHASE3":7954,"PHASE4":7956,"NA":7958},{"trials":7945,"activeCount":99},[],{"trials":7947,"activeCount":99},[7948],{"nctId":500,"briefTitle":501,"status":105,"phases":7949,"primaryCompletion":503,"completion":503,"start":504,"enrollment":505,"conditions":7950,"interventions":7951},[89],[18],[66,333,508,509],{"trials":7953,"activeCount":99},[],{"trials":7955,"activeCount":99},[],{"trials":7957,"activeCount":99},[],{"trials":7959,"activeCount":99},[],{"intervention":2181,"totalTrials":137,"cells":7961},{"EARLY_PHASE1":7962,"PHASE1":7964,"PHASE2":7970,"PHASE3":7972,"PHASE4":7974,"NA":7976},{"trials":7963,"activeCount":99},[],{"trials":7965,"activeCount":99},[7966],{"nctId":2173,"briefTitle":2174,"status":105,"phases":7967,"primaryCompletion":2176,"completion":2176,"start":2177,"enrollment":2178,"conditions":7968,"interventions":7969},[89],[15],[523,2181,715],{"trials":7971,"activeCount":99},[],{"trials":7973,"activeCount":99},[],{"trials":7975,"activeCount":99},[],{"trials":7977,"activeCount":99},[],{"intervention":7979,"totalTrials":137,"cells":7980},"Part A, C and D: VH3739937 500 mg",{"EARLY_PHASE1":7981,"PHASE1":7983,"PHASE2":8001,"PHASE3":8003,"PHASE4":8005,"NA":8007},{"trials":7982,"activeCount":99},[],{"trials":7984,"activeCount":99},[7985],{"nctId":7986,"briefTitle":7987,"status":2201,"phases":7988,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":99,"conditions":7991,"interventions":7992},"NCT06533280","VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)",[89],"2024-08-14","2024-08-02",[15],[7979,7993,7994,7995,7996,7997,7998,7999,8000],"Part A: VH3739937 100 mg","Part A and C: Placebo","Part B: Treatment A","Part B: Treatment B","Part B: Treatment C","Part B: Treatment D","Part B: Treatment E","Part D: Probe cocktail",{"trials":8002,"activeCount":99},[],{"trials":8004,"activeCount":99},[],{"trials":8006,"activeCount":99},[],{"trials":8008,"activeCount":99},[],{"intervention":7993,"totalTrials":137,"cells":8010},{"EARLY_PHASE1":8011,"PHASE1":8013,"PHASE2":8019,"PHASE3":8021,"PHASE4":8023,"NA":8025},{"trials":8012,"activeCount":99},[],{"trials":8014,"activeCount":99},[8015],{"nctId":7986,"briefTitle":7987,"status":2201,"phases":8016,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":99,"conditions":8017,"interventions":8018},[89],[15],[7979,7993,7994,7995,7996,7997,7998,7999,8000],{"trials":8020,"activeCount":99},[],{"trials":8022,"activeCount":99},[],{"trials":8024,"activeCount":99},[],{"trials":8026,"activeCount":99},[],{"intervention":7994,"totalTrials":137,"cells":8028},{"EARLY_PHASE1":8029,"PHASE1":8031,"PHASE2":8037,"PHASE3":8039,"PHASE4":8041,"NA":8043},{"trials":8030,"activeCount":99},[],{"trials":8032,"activeCount":99},[8033],{"nctId":7986,"briefTitle":7987,"status":2201,"phases":8034,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":99,"conditions":8035,"interventions":8036},[89],[15],[7979,7993,7994,7995,7996,7997,7998,7999,8000],{"trials":8038,"activeCount":99},[],{"trials":8040,"activeCount":99},[],{"trials":8042,"activeCount":99},[],{"trials":8044,"activeCount":99},[],{"intervention":7995,"totalTrials":137,"cells":8046},{"EARLY_PHASE1":8047,"PHASE1":8049,"PHASE2":8055,"PHASE3":8057,"PHASE4":8059,"NA":8061},{"trials":8048,"activeCount":99},[],{"trials":8050,"activeCount":99},[8051],{"nctId":7986,"briefTitle":7987,"status":2201,"phases":8052,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":99,"conditions":8053,"interventions":8054},[89],[15],[7979,7993,7994,7995,7996,7997,7998,7999,8000],{"trials":8056,"activeCount":99},[],{"trials":8058,"activeCount":99},[],{"trials":8060,"activeCount":99},[],{"trials":8062,"activeCount":99},[],{"intervention":7996,"totalTrials":137,"cells":8064},{"EARLY_PHASE1":8065,"PHASE1":8067,"PHASE2":8073,"PHASE3":8075,"PHASE4":8077,"NA":8079},{"trials":8066,"activeCount":99},[],{"trials":8068,"activeCount":99},[8069],{"nctId":7986,"briefTitle":7987,"status":2201,"phases":8070,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":99,"conditions":8071,"interventions":8072},[89],[15],[7979,7993,7994,7995,7996,7997,7998,7999,8000],{"trials":8074,"activeCount":99},[],{"trials":8076,"activeCount":99},[],{"trials":8078,"activeCount":99},[],{"trials":8080,"activeCount":99},[],{"intervention":7997,"totalTrials":137,"cells":8082},{"EARLY_PHASE1":8083,"PHASE1":8085,"PHASE2":8091,"PHASE3":8093,"PHASE4":8095,"NA":8097},{"trials":8084,"activeCount":99},[],{"trials":8086,"activeCount":99},[8087],{"nctId":7986,"briefTitle":7987,"status":2201,"phases":8088,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":99,"conditions":8089,"interventions":8090},[89],[15],[7979,7993,7994,7995,7996,7997,7998,7999,8000],{"trials":8092,"activeCount":99},[],{"trials":8094,"activeCount":99},[],{"trials":8096,"activeCount":99},[],{"trials":8098,"activeCount":99},[],{"intervention":7998,"totalTrials":137,"cells":8100},{"EARLY_PHASE1":8101,"PHASE1":8103,"PHASE2":8109,"PHASE3":8111,"PHASE4":8113,"NA":8115},{"trials":8102,"activeCount":99},[],{"trials":8104,"activeCount":99},[8105],{"nctId":7986,"briefTitle":7987,"status":2201,"phases":8106,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":99,"conditions":8107,"interventions":8108},[89],[15],[7979,7993,7994,7995,7996,7997,7998,7999,8000],{"trials":8110,"activeCount":99},[],{"trials":8112,"activeCount":99},[],{"trials":8114,"activeCount":99},[],{"trials":8116,"activeCount":99},[],{"intervention":7999,"totalTrials":137,"cells":8118},{"EARLY_PHASE1":8119,"PHASE1":8121,"PHASE2":8127,"PHASE3":8129,"PHASE4":8131,"NA":8133},{"trials":8120,"activeCount":99},[],{"trials":8122,"activeCount":99},[8123],{"nctId":7986,"briefTitle":7987,"status":2201,"phases":8124,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":99,"conditions":8125,"interventions":8126},[89],[15],[7979,7993,7994,7995,7996,7997,7998,7999,8000],{"trials":8128,"activeCount":99},[],{"trials":8130,"activeCount":99},[],{"trials":8132,"activeCount":99},[],{"trials":8134,"activeCount":99},[],{"intervention":8000,"totalTrials":137,"cells":8136},{"EARLY_PHASE1":8137,"PHASE1":8139,"PHASE2":8145,"PHASE3":8147,"PHASE4":8149,"NA":8151},{"trials":8138,"activeCount":99},[],{"trials":8140,"activeCount":99},[8141],{"nctId":7986,"briefTitle":7987,"status":2201,"phases":8142,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":99,"conditions":8143,"interventions":8144},[89],[15],[7979,7993,7994,7995,7996,7997,7998,7999,8000],{"trials":8146,"activeCount":99},[],{"trials":8148,"activeCount":99},[],{"trials":8150,"activeCount":99},[],{"trials":8152,"activeCount":99},[],{"intervention":4091,"totalTrials":137,"cells":8154},{"EARLY_PHASE1":8155,"PHASE1":8157,"PHASE2":8163,"PHASE3":8165,"PHASE4":8167,"NA":8169},{"trials":8156,"activeCount":99},[],{"trials":8158,"activeCount":99},[8159],{"nctId":4083,"briefTitle":4084,"status":105,"phases":8160,"primaryCompletion":4086,"completion":4086,"start":4087,"enrollment":4088,"conditions":8161,"interventions":8162},[89],[18],[411,4091],{"trials":8164,"activeCount":99},[],{"trials":8166,"activeCount":99},[],{"trials":8168,"activeCount":99},[],{"trials":8170,"activeCount":99},[],{"intervention":8172,"totalTrials":137,"cells":8173},"Cabotegravir 30 mg",{"EARLY_PHASE1":8174,"PHASE1":8176,"PHASE2":8185,"PHASE3":8187,"PHASE4":8189,"NA":8191},{"trials":8175,"activeCount":99},[],{"trials":8177,"activeCount":99},[8178],{"nctId":8179,"briefTitle":8180,"status":105,"phases":8181,"primaryCompletion":8182,"completion":8182,"start":2075,"enrollment":1219,"conditions":8183,"interventions":8184},"NCT02799264","A Study to Evaluate the Effect of High Fat Meal on Cabotegravir",[89],"2016-08",[18],[8172],{"trials":8186,"activeCount":99},[],{"trials":8188,"activeCount":99},[],{"trials":8190,"activeCount":99},[],{"trials":8192,"activeCount":99},[],{"intervention":8194,"totalTrials":137,"cells":8195},"GSK3739937",{"EARLY_PHASE1":8196,"PHASE1":8198,"PHASE2":8208,"PHASE3":8210,"PHASE4":8212,"NA":8214},{"trials":8197,"activeCount":99},[],{"trials":8199,"activeCount":99},[8200],{"nctId":8201,"briefTitle":8202,"status":105,"phases":8203,"primaryCompletion":8204,"completion":8204,"start":1582,"enrollment":8205,"conditions":8206,"interventions":8207},"NCT04493684","GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers",[89],"2021-08-30",91,[15],[8194,8194],{"trials":8209,"activeCount":99},[],{"trials":8211,"activeCount":99},[],{"trials":8213,"activeCount":99},[],{"trials":8215,"activeCount":99},[],{"intervention":1061,"totalTrials":137,"cells":8217},{"EARLY_PHASE1":8218,"PHASE1":8220,"PHASE2":8226,"PHASE3":8228,"PHASE4":8230,"NA":8232},{"trials":8219,"activeCount":99},[],{"trials":8221,"activeCount":99},[8222],{"nctId":1054,"briefTitle":1055,"status":105,"phases":8223,"primaryCompletion":1057,"completion":1057,"start":1058,"enrollment":466,"conditions":8224,"interventions":8225},[89],[18],[170,1061],{"trials":8227,"activeCount":99},[],{"trials":8229,"activeCount":99},[],{"trials":8231,"activeCount":99},[],{"trials":8233,"activeCount":99},[],{"intervention":8235,"totalTrials":137,"cells":8236},"Conventional dolutegravir 10 mg",{"EARLY_PHASE1":8237,"PHASE1":8239,"PHASE2":8252,"PHASE3":8254,"PHASE4":8256,"NA":8258},{"trials":8238,"activeCount":99},[],{"trials":8240,"activeCount":99},[8241],{"nctId":8242,"briefTitle":8243,"status":105,"phases":8244,"primaryCompletion":8245,"completion":8245,"start":8246,"enrollment":805,"conditions":8247,"interventions":8248},"NCT03095638","Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir",[89],"2017-06-23","2017-05-03",[15],[8235,8249,8250,8251],"Conventional dolutegravir 50 mg","Dispersible dolutegravir 5 mg","Conventional dolutegravir 25 mg",{"trials":8253,"activeCount":99},[],{"trials":8255,"activeCount":99},[],{"trials":8257,"activeCount":99},[],{"trials":8259,"activeCount":99},[],{"intervention":8249,"totalTrials":137,"cells":8261},{"EARLY_PHASE1":8262,"PHASE1":8264,"PHASE2":8270,"PHASE3":8272,"PHASE4":8274,"NA":8276},{"trials":8263,"activeCount":99},[],{"trials":8265,"activeCount":99},[8266],{"nctId":8242,"briefTitle":8243,"status":105,"phases":8267,"primaryCompletion":8245,"completion":8245,"start":8246,"enrollment":805,"conditions":8268,"interventions":8269},[89],[15],[8235,8249,8250,8251],{"trials":8271,"activeCount":99},[],{"trials":8273,"activeCount":99},[],{"trials":8275,"activeCount":99},[],{"trials":8277,"activeCount":99},[],{"intervention":8250,"totalTrials":137,"cells":8279},{"EARLY_PHASE1":8280,"PHASE1":8282,"PHASE2":8288,"PHASE3":8290,"PHASE4":8292,"NA":8294},{"trials":8281,"activeCount":99},[],{"trials":8283,"activeCount":99},[8284],{"nctId":8242,"briefTitle":8243,"status":105,"phases":8285,"primaryCompletion":8245,"completion":8245,"start":8246,"enrollment":805,"conditions":8286,"interventions":8287},[89],[15],[8235,8249,8250,8251],{"trials":8289,"activeCount":99},[],{"trials":8291,"activeCount":99},[],{"trials":8293,"activeCount":99},[],{"trials":8295,"activeCount":99},[],{"intervention":8251,"totalTrials":137,"cells":8297},{"EARLY_PHASE1":8298,"PHASE1":8300,"PHASE2":8306,"PHASE3":8308,"PHASE4":8310,"NA":8312},{"trials":8299,"activeCount":99},[],{"trials":8301,"activeCount":99},[8302],{"nctId":8242,"briefTitle":8243,"status":105,"phases":8303,"primaryCompletion":8245,"completion":8245,"start":8246,"enrollment":805,"conditions":8304,"interventions":8305},[89],[15],[8235,8249,8250,8251],{"trials":8307,"activeCount":99},[],{"trials":8309,"activeCount":99},[],{"trials":8311,"activeCount":99},[],{"trials":8313,"activeCount":99},[],{"intervention":735,"totalTrials":769,"cells":8315},{"EARLY_PHASE1":8316,"PHASE1":8318,"PHASE2":8358,"PHASE3":8391,"PHASE4":8434,"NA":8462},{"trials":8317,"activeCount":99},[],{"trials":8319,"activeCount":99},[8320,8327,8331,8335,8339,8343,8350,8354],{"nctId":8321,"briefTitle":8322,"status":515,"phases":8323,"primaryCompletion":1993,"completion":1993,"start":8324,"enrollment":466,"conditions":8325,"interventions":8326},"NCT00496782","Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay",[89],"2007-07",[15],[2210],{"nctId":5630,"briefTitle":5631,"status":105,"phases":8328,"primaryCompletion":2066,"completion":2066,"start":5633,"enrollment":456,"conditions":8329,"interventions":8330},[89],[33],[735,5623,5636],{"nctId":6087,"briefTitle":6088,"status":105,"phases":8332,"primaryCompletion":6090,"completion":6090,"start":6091,"enrollment":4071,"conditions":8333,"interventions":8334},[89],[2058],[735,735,6080],{"nctId":2894,"briefTitle":2895,"status":105,"phases":8336,"primaryCompletion":2047,"completion":2047,"start":2610,"enrollment":494,"conditions":8337,"interventions":8338},[89],[33],[735,2887,2899,735,2887,2899],{"nctId":727,"briefTitle":728,"status":105,"phases":8340,"primaryCompletion":730,"completion":730,"start":731,"enrollment":732,"conditions":8341,"interventions":8342},[89],[18],[42,735],{"nctId":8344,"briefTitle":8345,"status":105,"phases":8346,"primaryCompletion":1936,"completion":1936,"start":8347,"enrollment":25,"conditions":8348,"interventions":8349},"NCT00821535","Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers",[89],"2009-02",[2030],[2210],{"nctId":5086,"briefTitle":5087,"status":105,"phases":8351,"primaryCompletion":2261,"completion":2261,"start":5089,"enrollment":25,"conditions":8352,"interventions":8353},[89],[33,15],[1277,1277,735],{"nctId":2901,"briefTitle":2895,"status":515,"phases":8355,"primaryCompletion":2004,"completion":2004,"start":2903,"enrollment":456,"conditions":8356,"interventions":8357},[89],[33],[735,2887,2899,735,2887,2899],{"trials":8359,"activeCount":99},[8360,8367,8374,8383],{"nctId":8361,"briefTitle":8362,"status":105,"phases":8363,"primaryCompletion":3220,"completion":3220,"start":8364,"enrollment":1049,"conditions":8365,"interventions":8366},"NCT00643643","Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus",[90],"2002-10",[15],[735,735,735,735],{"nctId":8368,"briefTitle":8369,"status":105,"phases":8370,"completion":8371,"start":2152,"enrollment":5258,"conditions":8372,"interventions":8373},"NCT00634959","Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus",[90],"2003-12",[27],[735,735,735,735],{"nctId":8375,"briefTitle":8376,"status":1093,"phases":8377,"primaryCompletion":2770,"completion":8378,"start":8379,"enrollment":8380,"conditions":8381,"interventions":8382},"NCT00791700","An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children",[90],"2023-06-30","2009-04-22",103,[2207],[735],{"nctId":8384,"briefTitle":8385,"status":105,"phases":8386,"primaryCompletion":2903,"completion":2055,"start":2204,"enrollment":8387,"conditions":8388,"interventions":8390},"NCT00827112","A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients",[90],129,[8389],"Human Immunodeficiency Virus-1",[2210,2210],{"trials":8392,"activeCount":99},[8393,8402,8406,8410,8418,8422,8430],{"nctId":8394,"briefTitle":8395,"status":105,"phases":8396,"primaryCompletion":8397,"completion":1919,"start":8324,"enrollment":8398,"conditions":8399,"interventions":8401},"NCT00478231","Multicenter, Safety Study Of Maraviroc",[91],"2010-08",209,[8400,24],"Acquired Immunodeficiency Syndrome",[735],{"nctId":3239,"briefTitle":3240,"status":515,"phases":8403,"primaryCompletion":3242,"completion":1057,"start":485,"enrollment":3243,"conditions":8404,"interventions":8405},[91],[3245],[735,3228,3247],{"nctId":2859,"briefTitle":2860,"status":105,"phases":8407,"primaryCompletion":2862,"completion":1937,"start":2863,"enrollment":2864,"conditions":8408,"interventions":8409},[90,91],[15],[2848,2210,2848,2210,2848],{"nctId":8411,"briefTitle":8412,"status":2201,"phases":8413,"primaryCompletion":8414,"completion":8414,"start":2638,"enrollment":99,"conditions":8415,"interventions":8417},"NCT00719823","Maraviroc Compassionate Use",[91],"2010-05",[8416],"Human Immunodeficiency Virus Type 1",[735],{"nctId":2868,"briefTitle":2869,"status":105,"phases":8419,"primaryCompletion":2871,"completion":2610,"start":2802,"enrollment":2872,"conditions":8420,"interventions":8421},[90,91],[15],[735,2875,735,2875,2875],{"nctId":8423,"briefTitle":8424,"status":105,"phases":8425,"primaryCompletion":2260,"completion":2260,"start":8426,"enrollment":8427,"conditions":8428,"interventions":8429},"NCT00426660","Expanded Access Program for Maraviroc At Multiple Centers",[91],"2007-02",1047,[15],[2210],{"nctId":2877,"briefTitle":2869,"status":105,"phases":8431,"primaryCompletion":2871,"completion":2610,"start":2863,"enrollment":2879,"conditions":8432,"interventions":8433},[90,91],[15],[735,2848,2848,2848],{"trials":8435,"activeCount":99},[8436,8440,8444,8448,8458],{"nctId":2296,"briefTitle":2297,"status":105,"phases":8437,"primaryCompletion":2299,"completion":2299,"start":2300,"enrollment":2056,"conditions":8438,"interventions":8439},[92],[33],[735,735,2250,2250],{"nctId":2410,"briefTitle":2411,"status":105,"phases":8441,"primaryCompletion":2413,"completion":2413,"start":2414,"enrollment":2056,"conditions":8442,"interventions":8443},[92],[35],[735,2397,735],{"nctId":2024,"briefTitle":2025,"status":105,"phases":8445,"primaryCompletion":2027,"completion":2027,"start":2028,"enrollment":1950,"conditions":8446,"interventions":8447},[92],[2030],[735,735,413,2032,735,413,2032,735,413,2032,735,735,735],{"nctId":8449,"briefTitle":8450,"status":105,"phases":8451,"primaryCompletion":8452,"completion":8453,"start":8454,"enrollment":1583,"conditions":8455,"interventions":8457},"NCT01327547","A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And\u002FOr Hepatitis B",[92],"2013-04-23","2015-03-24","2011-05-18",[8456],"HIV Coinfection",[735],{"nctId":2199,"briefTitle":2200,"status":2201,"phases":8459,"primaryCompletion":2203,"completion":2203,"start":2204,"enrollment":99,"conditions":8460,"interventions":8461},[92],[2206,2207,2208],[2210,2211],{"trials":8463,"activeCount":99},[8464,8472],{"nctId":8465,"briefTitle":8466,"status":105,"phases":8467,"primaryCompletion":484,"completion":484,"start":8468,"enrollment":8469,"conditions":8470,"interventions":8471},"NCT00850395","Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection",[],"2009-07",79,[3245],[2210],{"nctId":8473,"briefTitle":8474,"status":8475,"phases":8476,"primaryCompletion":2055,"completion":2055,"start":2647,"conditions":8477,"interventions":8478},"NCT00801515","A Compassionate Access Protocol For Those Patients Who Have Completed A4001029","NO_LONGER_AVAILABLE",[],[27],[735],{"intervention":8480,"totalTrials":137,"cells":8481},"HAART Treatment",{"EARLY_PHASE1":8482,"PHASE1":8484,"PHASE2":8486,"PHASE3":8488,"PHASE4":8490,"NA":8492},{"trials":8483,"activeCount":99},[],{"trials":8485,"activeCount":99},[],{"trials":8487,"activeCount":99},[],{"trials":8489,"activeCount":99},[],{"trials":8491,"activeCount":99},[],{"trials":8493,"activeCount":99},[8494],{"nctId":8495,"briefTitle":8496,"status":105,"phases":8497,"primaryCompletion":8498,"completion":8498,"start":2204,"enrollment":99,"conditions":8499,"interventions":8502},"NCT01054638","HIV Treatment and CVD Events",[],"2010-12",[24,8500,18,8501],"Cardiovascular Disease","Acute Myocardial Infarction",[8480],{"intervention":8504,"totalTrials":137,"cells":8505},"Open Label Treatment Access: Maraviroc",{"EARLY_PHASE1":8506,"PHASE1":8508,"PHASE2":8510,"PHASE3":8512,"PHASE4":8514,"NA":8516},{"trials":8507,"activeCount":99},[],{"trials":8509,"activeCount":99},[],{"trials":8511,"activeCount":99},[],{"trials":8513,"activeCount":99},[],{"trials":8515,"activeCount":99},[],{"trials":8517,"activeCount":99},[8518],{"nctId":8519,"briefTitle":8520,"status":8475,"phases":8521,"conditions":8522,"interventions":8524},"NCT00992654","A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India",[],[8523],"Human Immunodeficiency Virus (HIV)",[8504],{"intervention":8526,"totalTrials":137,"cells":8527},"ZIAGEN®",{"EARLY_PHASE1":8528,"PHASE1":8530,"PHASE2":8532,"PHASE3":8534,"PHASE4":8536,"NA":8538},{"trials":8529,"activeCount":99},[],{"trials":8531,"activeCount":99},[],{"trials":8533,"activeCount":99},[],{"trials":8535,"activeCount":99},[],{"trials":8537,"activeCount":99},[],{"trials":8539,"activeCount":99},[8540],{"nctId":8541,"briefTitle":8542,"status":105,"phases":8543,"primaryCompletion":8544,"completion":8545,"start":8546,"enrollment":8547,"conditions":8548,"interventions":8549},"NCT01205243","ZIAGEN® Post-marketing Surveillance",[],"2015-02-01","2015-02-05","2010-11-01",671,[21],[8526],{"intervention":8551,"totalTrials":137,"cells":8552},"Exposure to licensed dose of FPV",{"EARLY_PHASE1":8553,"PHASE1":8555,"PHASE2":8557,"PHASE3":8559,"PHASE4":8561,"NA":8563},{"trials":8554,"activeCount":99},[],{"trials":8556,"activeCount":99},[],{"trials":8558,"activeCount":99},[],{"trials":8560,"activeCount":99},[],{"trials":8562,"activeCount":99},[],{"trials":8564,"activeCount":99},[8565],{"nctId":8566,"briefTitle":8567,"status":105,"phases":8568,"primaryCompletion":485,"completion":485,"start":1993,"enrollment":137,"conditions":8569,"interventions":8570},"NCT01077635","PENTA Fosamprenavir Study",[],[18],[8551],{"intervention":8572,"totalTrials":137,"cells":8573},"Continued Access Arm",{"EARLY_PHASE1":8574,"PHASE1":8576,"PHASE2":8578,"PHASE3":8580,"PHASE4":8582,"NA":8584},{"trials":8575,"activeCount":99},[],{"trials":8577,"activeCount":99},[],{"trials":8579,"activeCount":99},[],{"trials":8581,"activeCount":99},[],{"trials":8583,"activeCount":99},[],{"trials":8585,"activeCount":99},[8586],{"nctId":8587,"briefTitle":8588,"status":8475,"phases":8589,"conditions":8590,"interventions":8591},"NCT01776996","An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc",[],[18],[8572],{"intervention":8593,"totalTrials":137,"cells":8594},"cabotegravir, CAB",{"EARLY_PHASE1":8595,"PHASE1":8597,"PHASE2":8599,"PHASE3":8601,"PHASE4":8603,"NA":8605},{"trials":8596,"activeCount":99},[],{"trials":8598,"activeCount":99},[],{"trials":8600,"activeCount":99},[],{"trials":8602,"activeCount":99},[],{"trials":8604,"activeCount":99},[],{"trials":8606,"activeCount":99},[8607],{"nctId":8608,"briefTitle":8609,"status":675,"phases":8610,"conditions":8611,"interventions":8612},"NCT03462810","GSK1265744 (Cabotegravir, CAB) for Named Patient\u002FCompassionate Use in HIV",[],[18],[8593],{"intervention":8614,"totalTrials":137,"cells":8615},"Any Antiretroviral (ARV) Drug Exposure",{"EARLY_PHASE1":8616,"PHASE1":8618,"PHASE2":8620,"PHASE3":8622,"PHASE4":8624,"NA":8626},{"trials":8617,"activeCount":99},[],{"trials":8619,"activeCount":99},[],{"trials":8621,"activeCount":99},[],{"trials":8623,"activeCount":99},[],{"trials":8625,"activeCount":99},[],{"trials":8627,"activeCount":99},[8628],{"nctId":8629,"briefTitle":8630,"status":105,"phases":8631,"primaryCompletion":493,"completion":493,"start":8632,"enrollment":137,"conditions":8633,"interventions":8635},"NCT01077557","Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status",[],"2006-11",[8634,18],"Fracture",[8614],{"intervention":8637,"totalTrials":137,"cells":8638},"JULUCA",{"EARLY_PHASE1":8639,"PHASE1":8641,"PHASE2":8643,"PHASE3":8645,"PHASE4":8647,"NA":8649},{"trials":8640,"activeCount":99},[],{"trials":8642,"activeCount":99},[],{"trials":8644,"activeCount":99},[],{"trials":8646,"activeCount":99},[],{"trials":8648,"activeCount":99},[],{"trials":8650,"activeCount":99},[8651],{"nctId":8652,"briefTitle":8653,"status":105,"phases":8654,"primaryCompletion":8655,"completion":8655,"start":8656,"enrollment":8398,"conditions":8657,"interventions":8658},"NCT03518060","Dolutegravir\u002FRilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1",[],"2023-05-14","2018-06-25",[15],[8637],{"intervention":8660,"totalTrials":137,"cells":8661},"CELSENTRI®",{"EARLY_PHASE1":8662,"PHASE1":8664,"PHASE2":8666,"PHASE3":8668,"PHASE4":8670,"NA":8672},{"trials":8663,"activeCount":99},[],{"trials":8665,"activeCount":99},[],{"trials":8667,"activeCount":99},[],{"trials":8669,"activeCount":99},[],{"trials":8671,"activeCount":99},[],{"trials":8673,"activeCount":99},[8674],{"nctId":8675,"briefTitle":8676,"status":105,"phases":8677,"primaryCompletion":8678,"completion":8678,"start":8679,"enrollment":8680,"conditions":8681,"interventions":8683},"NCT00864474","Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)",[],"2018-12-24","2010-03-31",68,[8682],"CCR5-tropic HIV-1 Infection",[8660],{"intervention":8685,"totalTrials":137,"cells":8686},"DTG based ARV regimen with ABC",{"EARLY_PHASE1":8687,"PHASE1":8689,"PHASE2":8691,"PHASE3":8693,"PHASE4":8695,"NA":8697},{"trials":8688,"activeCount":99},[],{"trials":8690,"activeCount":99},[],{"trials":8692,"activeCount":99},[],{"trials":8694,"activeCount":99},[],{"trials":8696,"activeCount":99},[],{"trials":8698,"activeCount":99},[8699],{"nctId":8700,"briefTitle":8701,"status":105,"phases":8702,"primaryCompletion":8703,"completion":8703,"start":8704,"enrollment":137,"conditions":8705,"interventions":8706},"NCT03327740","PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)",[],"2019-12-31","2014-09-30",[21],[8685,8707,8708,8709,8710],"DTG based ARV regimen without ABC","RAL or EGV based ARV regimens with ABC","RAL or EGV based regimens without ABC","Any other DTG based ARV regimen as monotherapy",{"intervention":8707,"totalTrials":137,"cells":8712},{"EARLY_PHASE1":8713,"PHASE1":8715,"PHASE2":8717,"PHASE3":8719,"PHASE4":8721,"NA":8723},{"trials":8714,"activeCount":99},[],{"trials":8716,"activeCount":99},[],{"trials":8718,"activeCount":99},[],{"trials":8720,"activeCount":99},[],{"trials":8722,"activeCount":99},[],{"trials":8724,"activeCount":99},[8725],{"nctId":8700,"briefTitle":8701,"status":105,"phases":8726,"primaryCompletion":8703,"completion":8703,"start":8704,"enrollment":137,"conditions":8727,"interventions":8728},[],[21],[8685,8707,8708,8709,8710],{"intervention":8708,"totalTrials":137,"cells":8730},{"EARLY_PHASE1":8731,"PHASE1":8733,"PHASE2":8735,"PHASE3":8737,"PHASE4":8739,"NA":8741},{"trials":8732,"activeCount":99},[],{"trials":8734,"activeCount":99},[],{"trials":8736,"activeCount":99},[],{"trials":8738,"activeCount":99},[],{"trials":8740,"activeCount":99},[],{"trials":8742,"activeCount":99},[8743],{"nctId":8700,"briefTitle":8701,"status":105,"phases":8744,"primaryCompletion":8703,"completion":8703,"start":8704,"enrollment":137,"conditions":8745,"interventions":8746},[],[21],[8685,8707,8708,8709,8710],{"intervention":8709,"totalTrials":137,"cells":8748},{"EARLY_PHASE1":8749,"PHASE1":8751,"PHASE2":8753,"PHASE3":8755,"PHASE4":8757,"NA":8759},{"trials":8750,"activeCount":99},[],{"trials":8752,"activeCount":99},[],{"trials":8754,"activeCount":99},[],{"trials":8756,"activeCount":99},[],{"trials":8758,"activeCount":99},[],{"trials":8760,"activeCount":99},[8761],{"nctId":8700,"briefTitle":8701,"status":105,"phases":8762,"primaryCompletion":8703,"completion":8703,"start":8704,"enrollment":137,"conditions":8763,"interventions":8764},[],[21],[8685,8707,8708,8709,8710],{"intervention":8710,"totalTrials":137,"cells":8766},{"EARLY_PHASE1":8767,"PHASE1":8769,"PHASE2":8771,"PHASE3":8773,"PHASE4":8775,"NA":8777},{"trials":8768,"activeCount":99},[],{"trials":8770,"activeCount":99},[],{"trials":8772,"activeCount":99},[],{"trials":8774,"activeCount":99},[],{"trials":8776,"activeCount":99},[],{"trials":8778,"activeCount":99},[8779],{"nctId":8700,"briefTitle":8701,"status":105,"phases":8780,"primaryCompletion":8703,"completion":8703,"start":8704,"enrollment":137,"conditions":8781,"interventions":8782},[],[21],[8685,8707,8708,8709,8710],{"intervention":8784,"totalTrials":137,"cells":8785},"Dolutegravir\u002FAbacavir\u002FLamivudin",{"EARLY_PHASE1":8786,"PHASE1":8788,"PHASE2":8790,"PHASE3":8792,"PHASE4":8794,"NA":8796},{"trials":8787,"activeCount":99},[],{"trials":8789,"activeCount":99},[],{"trials":8791,"activeCount":99},[],{"trials":8793,"activeCount":99},[],{"trials":8795,"activeCount":99},[],{"trials":8797,"activeCount":99},[8798],{"nctId":8799,"briefTitle":8800,"status":105,"phases":8801,"primaryCompletion":8802,"completion":8802,"start":8803,"enrollment":8804,"conditions":8805,"interventions":8806},"NCT02342769","Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany",[],"2018-10-28","2015-02-19",403,[15],[8784],{"intervention":8808,"totalTrials":137,"cells":8809},"Maraviroc along with an optimized background antiretroviral drug regimen",{"EARLY_PHASE1":8810,"PHASE1":8812,"PHASE2":8814,"PHASE3":8816,"PHASE4":8818,"NA":8820},{"trials":8811,"activeCount":99},[],{"trials":8813,"activeCount":99},[],{"trials":8815,"activeCount":99},[],{"trials":8817,"activeCount":99},[],{"trials":8819,"activeCount":99},[],{"trials":8821,"activeCount":99},[8822],{"nctId":8823,"briefTitle":8824,"status":105,"phases":8825,"primaryCompletion":8826,"completion":8826,"start":8827,"enrollment":8828,"conditions":8829,"interventions":8830},"NCT00665561","Prospective Observational Epidemiologic Study of Maraviroc's Safety",[],"2019-02-14","2008-03-31",2500,[2207],[8808,8831],"Optimized background antiretroviral drug regimen without maraviroc",{"intervention":8831,"totalTrials":137,"cells":8833},{"EARLY_PHASE1":8834,"PHASE1":8836,"PHASE2":8838,"PHASE3":8840,"PHASE4":8842,"NA":8844},{"trials":8835,"activeCount":99},[],{"trials":8837,"activeCount":99},[],{"trials":8839,"activeCount":99},[],{"trials":8841,"activeCount":99},[],{"trials":8843,"activeCount":99},[],{"trials":8845,"activeCount":99},[8846],{"nctId":8823,"briefTitle":8824,"status":105,"phases":8847,"primaryCompletion":8826,"completion":8826,"start":8827,"enrollment":8828,"conditions":8848,"interventions":8849},[],[2207],[8808,8831]]